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Let me tell you the secret that has led me to my goal. 
My strength lies solely in my tenacity. 
 
- Louis Pasteur -
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Abstract 
Peptides represent a promising format for the development of therapeutics since 
they combine the advantages of proteins and small molecules. Several techniques based 
on rational design or in vitro evolution can be used to develop peptides as therapeutics. 
A limitation of peptides is a rapid clearance from the blood circulation when applied in-
travenously, preventing their application in therapies that require prolonged drug expo-
sure. Several methods have been tested to extend the in vivo half-life of peptides, in-
cluding fusion to long-lived serum proteins, PEGylation and conjugation to non-covalent 
albumin-binding ligands. 
A particularly attractive approach is a “piggy back” strategy in which peptides bind 
via a ligand to albumin without increasing significantly their small size. Acylation with fatty 
acids is the most successful strategy for delaying peptide clearance. The attachment of 
either myristic or palmitic acid to insulin and GLP-1 led to the approval of three acylated 
peptide drugs as daily injectable. Nevertheless, acylated conjugates generally present 
low solubility and weak affinity for albumin. Peptides have been explored as an alterna-
tive, as their format offers multiple approaches for affinity maturation as well as an easier 
synthesis of the conjugates. However, the albumin-binding peptides developed so far do 
not overcome the disadvantages faced with fatty acids. 
The first aim of my project was the development of an albumin-binding tag that 
combines the favorable properties of both fatty acids and peptides, and overcomes at 
the same time their limitations. This tag was engineered in order to have i) a high affinity 
for human albumin, ii) a high solubility in physiological solutions, and iii) an efficient syn-
thesis in conjunction with therapeutic peptides. Towards this goal, I created a chimeric 
format consisting of a fatty acid combined with a short linear peptide. After iterative 
rounds of affinity screening, an evolved peptide-fatty acid tag able to bind human, rat 
and rabbit albumin with Kd values of 39, 220 and 320 nM, respectively, was obtained. 
This makes it the best albumin-binding tag among all of the peptide- or fatty acid-based 
ligands that have been developed. This tag can be easily synthesized in conjugation with 
peptides on standard automated synthesizers. Finally, it exhibits a high solubility due to 
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four negatively charged amino acids in the peptide sequence, despite the presence of a 
16-carbon palmitic hydrophobic tail. 
The second aim of my project was the application of this tag to three bioactive 
bicyclic peptides, previously developed in the laboratory, in order to improve their in vivo 
half-lives. I demonstrated that the conjugation has, overall, a mild impact on peptides’ 
binding affinity towards their targets and human albumin, and increases their proteolytic 
stability. Pharmacokinetic experiments showed that the tag extends the elimination half-
life of bicyclic peptides in rats and rabbits approximately 25-fold to over seven and five 
hours, respectively. Tag conjugation to a bicyclic peptide targeting coagulation factor XII 
led to an efficient inhibition of coagulation in rabbits up to eight hours, suggesting a po-
tential application in humans as anti-thrombotic drug. These results indicated that the 
tag will efficiently prolong the exposure of target proteins to bioactive peptides in humans 
due to its higher affinity for human albumin than that of rat and rabbit. 
Keywords: peptide, half-life extension, human albumin, non-covalent binding, 
affinity, solubility, synthesis, fatty acid, tag, bioactive conjugates 
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Sommario 
I peptidi hanno un formato promettente per la creazione di farmaci in quanto com-
binano molti vantaggi tipici delle proteine e dei classici farmaci chimici. Diverse tecnolo-
gie basate sullo sviluppo razionale o sull’evoluzione in vitro delle proprietà dei peptidi 
possono essere utilizzate per il loro sviluppo come farmaci. Tuttavia, un limite dei peptidi 
è la loro rapida eliminazione dalla circolazione sanguigna quando sono somministrati per 
via endovenosa, e ciò ne impedisce l’applicazione in terapie che richiedono una prolun-
gata esposizione al farmaco. Diversi metodi sono stati testati per aumentare l’emivita dei 
peptidi in vivo, come ad esempio la fusione con proteine del siero, la modifica con poli-
meri idrofilici (PEG) e la coniugazione a molecole che legano l’albumina. 
Un approccio particolarmente interessante si basa su una strategia "piggy back" 
in cui i peptidi legano l’albumina attraverso un ligando dell’albumina stessa, senza che 
ciò aumenti in modo significativo le loro piccole dimensioni. La modifica con gli acidi 
grassi è la strategia di maggior successo per ritardare l’eliminazione dei peptidi dal san-
gue. L'aggiunta di uno acido miristico o palmitico a polipeptidi come insulina e GLP-1 ha 
portato all'approvazione di tre peptidici acilati che possono essere iniettati una sola volta 
al giorno. Tuttavia, molti coniugati acilati generalmente hanno una bassa solubilità e una 
debole affinità di legame per l'albumina. I peptidi sono stati studiati come alternativa in 
quanto presentano una struttura che offre molteplici approcci per la maturazione dell’af-
finità di legame e permette una sintesi potenzialmente più semplice dei coniugati. Tutta-
via, i peptidi sviluppati finora non hanno risolto i problemi degli acidi grassi. 
Il primo scopo del mio progetto è stato lo sviluppo di un nuovo ligando dell’albumina 
che combini le migliori proprietà di acidi grassi e peptidi, superando nel contempo i loro 
limiti. Tale ligando è stato progettato in modo da avere i) un’elevata affinità di legame 
per l'albumina umana ii) un’elevata solubilità in soluzioni fisiologiche, e iii) un’efficiente 
sintesi in combinazione con i peptidi terapeutici. Con questo obiettivo, ho creato una 
chimera composta da un acido grasso legato ad un breve peptide lineare. Ripetute fasi 
di screening basate sull’affinità di legame della chimera per l’albumina hanno portato alla 
creazione di un elaborato tag acil-peptidico in grado di legare l’albumina umana, di ratto 
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e di coniglio con Kd uguali rispettivamente a 39, 220 e 320 nM. Al momento, questo tag 
risulta essere il miglior ligando dell’albumina tra tutti quelli sviluppati basandosi su formati 
peptidici e/o con acidi grassi. Questo tag può essere facilmente e direttamente sintetiz-
zato in combinazione con peptidi terapeutici utilizzando sintetizzatori automatizzati. In-
fine, nonostante l’acido palmitico abbia una coda idrofobica di 16 carboni, il tag presenta 
una elevata solubilità grazie all’inserimento di quattro amminoacidi carichi negativa-
mente nella sequenza del peptide.  
Il secondo scopo del mio progetto è stata la coniugazione del ligando creato a tre 
peptidi biciclici bioattivi, precedentemente sviluppati in laboratorio, con il fine di miglio-
rarne l’emivita in vivo. Ho dimostrato che la coniugazione ha, nel complesso, un lieve 
impatto sull’affinità di legame sia nei confronti del target dei peptidi biciclici che verso 
l’albumina umana, e ne aumenta la stabilità alla degradazione proteolitica. Esperimenti 
di farmacocinetica hanno dimostrato che il tag estende l'emivita dei peptidi biciclici in 
ratto e coniglio di circa 25 volte, raggiungendo rispettivamente valori di sette e cinque 
ore. La coniugazione del tag ad un peptide biciclico attivo contro il fattore di coagulazione 
XII ha portato ad un’inibizione efficace della coagulazione in coniglio fino ad otto ore, 
suggerendone un potenziale applicazione come farmaco anti-trombotico. Questi risultati 
indicano che il tag potrà efficientemente prolungare l’azione di peptidi attivi contro pro-
teine di interesse farmacologico, grazie alla sua maggiore affinità di legame per l'albu-
mina umana rispetto a quella di ratto e coniglio. 
Parole chiave: peptide, estensione dell’emivita plasmatica, albumina 
umana, legame non covalente, affinità di legame, solubilità, sintesi, acidi grassi, 
tag, coniugati bioattivi 
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chart.html#prop
 xi 
List of abbreviations 
ABD Albumin-Binding Domain 
 
i.v. intravenous 
Ac Acetyl Ka Association constant 
aPTT 
activated Partial 
Thromboplastin Time 
Kd Dissociation constant 
Boc Tert-butyloxycarbonyl Ki Inhibition constant 
Da Dalton KM Michaelis-Menten constant 
Dde 1-(4,4-dimethyl-2,6-dioxycyclo-hex-1-ylidene)theyl LC-MS 
Liquid Chromatography 
Mass Spectrometry 
DNA DeoxyriboNucleic Acid mRNA messenger RiboNucleic Acid 
ELISA Enzyme-Linked ImmunoSorbent Assay MW Molecular Weight 
EMA European Medicines Agency NMR Nuclear Magnetic Resonance 
ESI-MS 
ElectroSpray Ionization 
Mass Spectrometry 
or oral 
Fc region Fragment crystallizable region PBS Phosphate Buffered Saline 
FcRn Neonatal Fc receptor PDB Protein Data Bank 
FDA Food and Drug Administration PEG PolyEthylene Glycol 
Fmoc Fluorenylmethyloxycarbonyl PK Plasma Kallikrein 
FXIIa Activated coagulation factor XII RP-HPLC Reverse Phase High-Perfor-mance Liquid Chromatography 
(F) Fluorescein rt room temperature 
GLP-1 Glucagon-Like Peptide-1 SPPS Solid Phase Peptide Synthesis 
IC50 
Half maximal 
inhibitory concentration 
s.c. subcutaneous 
IgG Gamma Immunoglobulin Trt Triphenylmethyl 
IgBD IgG-Binding Domain UFLC Ultra Fast Liquid Chromatography 
ITC Isothermal Titration Calorimetry uPA 
Urokinase-type Plasminogen 
Activator 
i.m. intramuscolar USD United States Dollar 
Abbreviation of reagents, proteins and solvents used are listed in chapter 5 "Material and methods"

 1 
  
1. Introduction 
NOTE: sub-section 1.1.2 of the introduction was adapted with permission from the review 
“Cyclic peptide therapeutics: past, present and future”, in which I am one of the authors 
with Deyle, K. and Heinis, C. Article published in Current Opinion in Chemical Biology 
(DOI: 10.1016/j.cbpa.2017.02.006). Reprinting license nr. 4057571248016. Copyright © 
2017 Elsevier Ltd. All rights reserved. 
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 1.1 Development of peptide therapeutics 
 Around one hundred linear and cyclic peptide drugs are currently used as thera-
peutics for the treatment of cancer, infective diseases, metabolic disorders, cardiovas-
cular diseases and many other pathologies, and there are many other peptides currently 
in clinical trials.1–3 Some of these peptide therapeutics recently reached the status of 
blockbusters, with annual sales higher than one billion USD. Examples include the insu-
lin derivatives glargine (Lantus, Sanofi) and lispro (Humalog, Eli Lilly), and the GLP-1 
analogues liraglutide (Victoza, Novo Nordisk) and exenatide (Byetta, Astrazeneca) for 
diabetes, glatiramer (Copaxone, Teva) for multiple sclerosis, teripatide (Forteo, Eli Lilly) 
for osteoporosis, octreotide (Sandostatin, Novartis) for acromegaly and daptomycin (Cu-
bicin, Merck) for bacterial infections.4 
Because a universal definition of a peptide-based drug is not-existent, in this thesis 
I arbitrarily define peptides as all of the molecules that contain at least three amino acids 
linked by two peptide bonds. All peptides of up to approximately 50-amino acids, insulin 
included, were placed into this class of therapeutics, applying the cut-off which is typically 
imposed as the boundary between peptides and proteins.5,6 
 The majority of the approved peptides are based on naturally evolved compounds 
that were initially isolated from different biological sources (humans, animals, bacteria 
and plants), and were chemically modified into analogues with improved potency, stabil-
ity, safety, and activity against clinically validated targets.7 Improvements in the charac-
terization of protein structures as well as a better understanding of physiological proc-
esses in the human body and related pathologies directed new research fields (e.g. mo-
lecular biology, biotechnologies, and -omics) towards the identification of a great number 
of new biological targets against which peptides could play a crucial role.3 
As a consequence, several de novo technologies that allow the combinatorial pro-
duction and screening of millions of different peptide variants have been developed. In 
parallel, innovative solution- and solid-phase synthetic approaches and purification strat-
egies have enabled the generation of complex peptides, encouraging the development 
of novel peptide-based drugs targeting diseases lacking clinical treatments.1,5,6 
  
Chapter 1 - Introduction 
4 
1.1.1 Properties of peptide therapeutics 
Peptides have typically a molecular size between 0.5 and 5 kDa. They fill the gap 
between proteins and small molecules, and they combine several favorable properties 
of both formats (Fig. 1).1,3,8,9 As proteins and antibodies, peptides exhibit high target se-
lectivity and potency, thus reducing the risk of off-target side-effects. The improved bind-
ing properties are generally related to their larger surface of interaction with the target, 
which allows specific contacts and structural rearrangements. Similarly, peptide back-
bone also contains natural amino acid building blocks that undergo physiological catab-
olism without hepatic or renal accumulation of harmful metabolites. This property, com-
bined with a small size, strongly decreases the chance of immunogenic reactions and 
toxicity.3,8,9 
 
Figure 1. Peptides combine the advantages of biologics, namely high selectivity and potency, with those of 
small molecules, including stability, bioavailability, non-immunogenicity, and low manufacturing cost. Re-
printed with permission from 9, copyright © 2014 American Chemical Society. 
As small molecules, peptides can be chemically synthesized and modified (e.g. 
backbone cyclization, unnatural amino acid substitution, fluorophore labeling) in large 
scales with a much lower cost of production compared to biologicals. The small size 
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allows a deeper penetration into tissues, and could additionally enhance the cell mem-
brane permeability. Analogously to small molecules, peptides can be lyophilized and 
have a long shelf-life thanks to a high stability at room temperature, and are thus easier 
to handle for clinicians and patients.1,3,9 
According to their structure, peptide therapeutics can be classified as linear or cy-
clic. In the last decades, peptide macrocycles demonstrated strong advantages over their 
linear counterparts.10,11 Differently from the linear format, cyclic peptides are character-
ized by a limited conformational flexibility that confers a higher binding affinity by reduc-
ing the entropic penalty upon binding, allowing therapeutic effects at lower drug concen-
trations. The cyclic format might also present multiple structures that adopt shapes which 
fit into binding pockets with great selectivity. Furthermore, cyclization increases peptide 
metabolic stability by both limiting the backbone accessibility to endopeptidases and pro-
tecting the termini from exopeptidases. This preserves them from fast degradation in the 
systemic circulation, a limitation commonly faced by many linear peptides. Peptide cy-
clization can be achieved by applying several methodologies such as head-to-tail, head-
to-side chain, side chain-to-tail, or side chain-to-side chain (Fig. 2). The chemistry re-
quired for macrocyclization includes the formation of cyclic structure through disulfide 
bridges or different redox stable bonds, such as lactams, thioethers and other options.9,12  
 
Figure 2. The four conventional synthetic approaches used for peptide macrocyclization: head-to-tail, head-
to-side chain, side chain-to-tail or side chain-to-side chain. Adapted with permission from 12, reprinting li-
cense nr. 4047091488316, copyright © 2011 Nature Publishing Group. 
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1.1.2 Cyclic peptide therapeutics 
As discussed in the previous sub-section, cyclic peptides are potentially a success-
ful format since they possess several favorable properties that are ideal for the develop-
ment of therapeutics. Examples of widely applied cyclic peptide drugs are the hormones 
or hormone analogues oxytocin, octreotide and vasopressin, the antibiotics vancomycin, 
daptomycin and polymyxin B or the immunosuppressant cyclosporine.3,10 We actually 
counted that more than 40 cyclic peptide drugs entered in the market so far and, over 
the last decade, an average of one new entity has been added per year. Although many 
of these cyclic peptides are derivatives of naturally occurring compounds, there are 
clearly new opportunities for the in vitro development of novel peptides.13  
In this sub-section, the first part (1.1.2.1) provides a look into the past by discussing 
the cyclic peptide therapeutics that have reached the market in the last ten years and 
details the techniques that were used to develop them. This part highlights that nearly all 
of these drugs are based on natural products or derivatives thereof. In a second part 
(1.1.2.2), we look at the present by discussing cyclic peptides that are currently under-
going clinical studies. This overview shows that there are several original cyclic peptide 
drug candidates developed de novo by rational design or in vitro evolution instead of 
through the modification of natural products. In a third part (1.1.2.3), we look to the future 
by discussing the most promising new cyclic formats and predict the technologies that 
will comprise the next generation of cyclic peptide therapeutics.  
1.1.2.1 Peptide macrocycle drugs approved in the last ten years  
In the last ten years, 2006-2015, the FDA and EMA have approved nine cyclic 
peptide drugs, which account for 3% of the new drugs that entered the market in this 
time period (Tab. 1, Fig. 3).14–23  Four of these cyclic peptides, telavancin, dalbavancin, 
oritavancin and anidulafungin, are employed in bacterial and fungal infections. Three 
peptides, lanreotide, romidepsin, and pasireotide are oncology drugs, and one, linaclo-
tide, is specific for gastrointestinal disorders. The last drug, peginesatide, was developed 
for the treatment of anemia during dialysis but was withdrawn soon after its approval due 
to safety concerns.  
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Table 1. Cyclic peptide drugs approved in the last ten years by the FDA and/or EMA. 
Yeara Generic name Indication Mode of action 
MW 
(Da) 
Route of ad-
ministrationb Company 
2006 anidulafungin fungal infections 
fungal 1,3-
?-D-glucan 
synthase 
inhibitor 
1140 i.v. infusion Vicuron / Pfizer 
2007 lanreotide 
acromegaly and 
neuroendocrine 
tumors 
growth hor-
mone re-
lease inhib-
itor 
1156 s.c., i.m. Ipsen 
2009 telavancin 
complicated skin 
and skin struc-
ture infections 
(CSSSIs) and 
nosocomial 
pneumonia 
bacterial 
cell-wall 
synthesis 
inhibitor 
1756 i.v. infusion Theravance 
2009 romidepsin 
cutaneous T-cell 
lymphoma 
(CTCL) and pe-
ripheral T-cell 
lymphomas 
(PTCLs) 
histone 
deacety-
lase inhibi-
tor 
541 i.v. infusion 
Gloucester 
Pharmaceu-
ticals / 
Celgene 
2012 peginesatide 
anemia associ-
ated with chronic 
kidney disease 
erythropoi-
esis stimu-
lating agent 
4415 i.v., s.c. Affymax / Takeda 
2012 linaclotide 
constipation-pre-
dominant irrita-
ble bowel syn-
drome (IBS-C) 
and chronic idio-
pathic constipa-
tion (CIC) 
guanylate 
cyclase 2C 
receptor 
activator 
1527 or 
Forest Labs 
/ Ironwood 
Pharmaceu-
ticals 
2012 pasireotide 
Cushing’s dis-
ease, acromeg-
aly and neuroen-
docrine tumors 
growth hor-
mone re-
lease inhib-
itor 
1047 s.c., i.m. Novartis 
2014 dalbavancin 
complicated skin 
and skin struc-
ture infections 
(CSSSIs) 
bacterial 
cell-wall 
synthesis 
inhibitor 
1817 i.v. infusion 
Durata 
Therapeu-
tics / Teva 
2014 oritavancin 
complicated skin 
and skin struc-
ture infections 
(CSSSIs) 
bacterial 
cell-wall 
synthesis 
inhibitor 
1793 i.v. infusion 
The Medi-
cines Com-
pany 
(a) Year of first approval by FDA or EMA for at least one of the indicated diseases. (b) Administration route: 
i.v., intravenous; s.c., subcutaneous; i.m., intramuscular; or, oral. 
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Figure 3. Cyclic peptide drugs approved in the last ten years by the FDA and/or EMA. For peginesatide, the 
40 kDa PEG is not shown. 
The three antibacterials on this list, telavancin, dalbavancin and oritavancin, are 
semi-synthetic cyclic lipoglycopeptides.24 They belong to the same drug class as the 
established antibiotics vancomycin and teicoplanin, which all contain a common hep-
tapeptidic core with five fixed residues that serves as the main binding site for the D-Ala-
D-Ala target. Binding of these drugs to their target blocks the transpeptidation of peptido-
glycan precursors in the bacterial cell wall.25 These three new antibiotics all contain a 
lipophilic side chain that is thought to increase the dwell time near the target by anchoring 
them to the cell membrane and/or destabilize the bacterial membrane. Interactions of 
the hydrophobic tails with cell membranes and plasma proteins also prolong the plasma 
half-life. These three drugs are used for the treatment of complicated skin and skin struc-
ture infections and nosocomial pneumonia. Small variations in their structures cause 
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subtle differences in their pharmacological effects by fine-tuning their activities towards 
different bacterial strains or differing pharmacokinetic properties. 
The cyclic peptide anidulafungin is a member of the class of echinocandin antifun-
gals to which caspofungin and micafungin, approved in 2001 and 2005, also belong.26 
All three drugs share a similar peptide core formed by six amino acids, two of which are 
Pro derivatives and two are Thr or Thr derivatives. Anidulafungin, derived from echi-
nocandin B, is a natural fermentation product of Aspergillus nidulans wherein the lineoyl 
side-chain tail is replaced by a lipophilic alkoxytriphenyl group. Like caspofungin and 
micafungin, anidulafungin inhibits the 1,3-?-D-glucan synthase responsible for fungal cell 
wall synthesis. Anidulafungin has a high affinity for human plasma proteins and a slow 
degradation time, giving it a half-life in the body of around 24 hours, doubling that of 
caspofungin and micafungin. 
The oncology drugs lanreotide and pasireotide are analogues of the successful 
cyclic peptide drug octreotide, which itself is an analogue of the endogenous cyclic pep-
tide hormone somatostatin.27 Somatostatin blocks the release of hormones such as the 
growth hormone by inhibiting G-protein-coupled somatostatin receptors. These new mi-
metics, which have a substantially longer plasma half-life than somatostatin, are used to 
treat acromegaly and endocrine tumors. Lanreotide, like octreotide, is a disulfide cyclized 
octapeptide wherein four amino acids are identical and the other four are closely related. 
The two drugs also have similar pharmacologic properties. Pasireotide’s structure was 
reduced to a hexapeptide cyclized through an amide bond and its sequence conserves 
only the D-Trp-Lys core of somatostatin.28 Pasireotide differs from octreotide and lanre-
otide in its substantially higher affinity for certain receptor subtypes, making it more suit-
able for treating Cushing’s disease and acromegaly in patients unresponsive to the other 
agents. 
 The third oncology drug, romidepsin is a natural product isolated from gram-neg-
ative Chromabacterium violaceum, approved for the treatment of T-cell lymphomas.29 It 
is a depsipeptide composed of five backbone-cyclized residues and a disulfide bond that 
creates a bicyclic structure. The disulfide-cyclized romidepsin is a pro-drug that is signif-
icantly more stable in plasma than the active drug. Once inside the cell, it is reduced to 
its active form wherein a free thiol group chelates the zinc ion in the active site of intra-
cellular histone deacetylase (HDAC) enzymes. The drug inhibits the removal of acetyl 
groups from Lys residues of N-terminal histone tails, maintaining a more open and tran-
scriptionally active chromatin state which alters gene expression. Romidepsin is the sec-
ond HDAC inhibitor that entered the market after the small molecule drug vorinostat. 
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Linaclotide is a 14-amino acid cyclic peptide derived from heat-stable enterotoxins, 
cyclic peptides produced by various E.coli strains which are a frequent cause of diar-
rhea.30 The drug provides well-tolerated relief in patients with chronic constipation and 
irritable bowel syndrome. Linaclotide contains three disulfide bonds that constrain the 
conformation of the peptide, providing high proteolytic stability. The drug acts by binding 
to guanylate cyclase C on the surface of intestinal epithelial cells.31 Activation of the 
cyclase triggers a signaling pathway that leads to chloride and fluid secretions into the 
lumen, increasing colonic transit. The location of this target in the intestine allows for 
linaclotide to be orally administered while not orally available, as the drug does not have 
to pass through the gastrointestinal lining.32 
The final cyclic peptide approved in the last ten years is peginesatide, an agonist 
of the erythropoietin receptor developed for severe anemia in which erythropoietin can-
not be used.33 This cyclic peptide was discovered through phage display panning against 
the erythropoietin receptor.34,35 It was then chemically dimerized with a polyethylene gly-
col (PEG), increasing the affinity, potency and circulation time in blood. It was voluntarily 
withdrawn from the market, however, one year after its approval due to safety concerns 
not experienced during the clinical trials. Unlike all the other previously approved cyclic 
peptide drugs, peginesatide was the first to be developed de novo. 
Taken together, eight of the newly approved nine drugs have a mechanism of ac-
tion similar to established drugs and only one, linaclotide, is a first-in-class drug. Besides 
being highly innovative and serving a large group of patients, linaclotide is also a highlight 
in terms of sales. It generated revenues of 460 million USD, improving upon the already 
impressive sales of 140 and 300 million USD in the two first years after approval, and it 
is likely to become a blockbuster drug within the next five years.36 Lanreotide and ro-
midepsin are the other two drugs approved in the last ten years to have noteworthy sales, 
earning 440 and 70 million USD last year, respectively. 
1.1.2.2 Peptide macrocycles in clinical development 
Our database and literature search has identified over 20 cyclic peptides that are 
currently undergoing clinical evaluation. These molecules have been developed for a 
highly diverse set of medical conditions, including several types of cancer, various infec-
tious diseases, endocrine/metabolic disorders, hematological diseases and cardiovas-
cular disorders. The majority of these cyclic peptides, similar to those already approved, 
are derivatives of natural products from microorganisms or human hormones. Interest-
ingly, several of the cyclic peptides in clinical trials were developed de novo using newer 
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methods based on either rational design strategies or in vitro evolution (Tab. 2). We focus 
in this part on five of these peptides in order to shine a light on the new and innovative 
techniques for developing cyclic peptide therapeutics.  
Table 2. Cyclic peptides developed by de novo design or in vitro evolution that are currently under clinical 
evaluation. 
Phasea Name Indication Mode of action Discovery plat-form Company 
2 POL7080 
pseudomonas ae-
ruginosa infec-
tions, gram-nega-
tive infections 
LptD protein homo-
log inhibitor, inhibits 
outer-membrane bi-
ogenesis 
iterative modifica-
tion and screening 
of peptide libraries 
using cationic anti-
microbial peptide 
protegrin I as start-
ing point 
Polyphor 
2 POL6326 
metastatic breast 
cancer, acute myo-
cardial infarction, 
hematopoietic 
stem cell mobiliza-
tion from donors 
chemokine receptor 
CXCR4 antagonist 
prevents the binding 
of stromal derived 
factor-1 (SDF-1) to 
mobilize stem cells 
designed protein 
epitope mimetic 
(PEM) based on 
natural CXCR4 in-
hibitor T22 
Polyphor 
2 APL-2 
age related macu-
lar degeneration, 
paroxysmal noctur-
nal hemoglobinuria 
complement factor 
C3 inhibitor, blocks 
complement activa-
tion, PEGylated 
phage display 
screening of cyclic 
peptide library 
Apellis 
1/2 ALRN-6924 
acute myeloid leu-
kemia, hematologi-
cal leukemia he-
matological malig-
nancies, myelodys-
plastic syndromes, 
solid tumors 
inhibitor of p53-
MDM2/MDMX inter-
action, restores p53-
mediated apoptotic 
activity in tumors 
peptide isolated by 
phage display and 
modified into sta-
pled peptide 
Aileron 
1 RA101495 paroxysmal noctur-nal hemoglobinuria 
complement factor 
C5 inhibitor, blocks 
complement in-
duced hemolysis 
mRNA display 
screening of cyclic 
peptide libraries 
containing unnatural 
amino acids 
Ra Pharma 
(a) For cyclic peptides tested for multiple indications, the most advanced clinical phase is indicated.  
POL7080 is a Pseudomonas aeruginosa-specific antibacterial cyclic peptide with 
a new mode of action developed through multiple iterative rounds of peptide library syn-
thesis and screening for enhanced antibacterial activity.37 The starting point of this evo-
lution process was protegrin I, a ?-hairpin peptide having broad antibiotic properties 
through membrane lytic activity. After stabilizing its secondary structure by a D-Pro-L-
Pro ?-turn motif, the basis of Polyphor’s proprietary PEM technology 38, and several 
rounds of optimization by amino acid substitution, the new 14-amino acid peptide showed 
reduced cell lysis but high activity and selectivity towards Pseudomonas aeruginosa. 
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Analysis of the potent antibiotic revealed binding to the membrane protein LptD, involved 
in membrane biogenesis, and therefore demonstrated a new mode of action from the 
precursor. A phase 1 trial established the clinical safety and tolerability of POL7080, and 
this antibiotic is currently under phase 2 trial evaluation for the treatment of Pseudomo-
nas aeruginosa infections. 
POL6326 is a bicyclic peptide inhibitor of the chemokine receptor CXCR4. Block-
age of CXCR4 avoids the interaction with the ligand SDF-1 (stromal cell-derived factor 
1), which induces hematopoietic stem cell (HSC) detachment from the bone marrow into 
the circulating blood.39 The mobilization of hematopoietic stem cells is of interest for stem 
cell transplantation, tissue regeneration and chemotherapy. POL6326 was developed 
using a combination of rational design and iterative optimization by peptide sequence 
variation and activity testing. In a first step, an analogue of the natural peptide polyphe-
musin II inhibiting CXCR4 was mounted onto the PEM technology D-Pro-L-Pro template 
to stabilize its ?-strand conformation.38 In a second step, the potency and various other 
properties of the receptor antagonist were optimized through several rounds of sequence 
modification, providing a final amino acid sequence for POL6326 that differs greatly from 
the starting polyphemusin II. A phase 1 trial for HSC mobilization was completed, and 
phase 2 trials have been initiated. 
APL-2 is a PEGylated cyclic peptide inhibitor of C3, a central protein in the com-
plement cascade. Excessive or uncontrolled activation of the complement system plays 
a role in a range of autoimmune and inflammatory diseases. APL-2 binds to a site on C3 
that prevents binding of convertases and thus conversion to C3b. It is based on 
compstatin, a disulfide cyclized 13-amino acid peptide derived from a 27-mer peptide 
isolated by phage selection against C3b.40 The addition of a PEG moiety to APL-2 pre-
vents fast renal clearance and enables C3 inhibition for several days per injection. APL-
2 is currently in phase 2 trial testing for age-related macular degeneration (AMD) and in 
phase 1 trial for paroxysmal nocturnal hemoglobinuria (PNH). For these two indications, 
the drug is applied by intravitreal and subcutaneous administration, respectively. A non-
PEGylated form of the peptide, APL-1 is in development for inhalation treatment of 
chronic obstructive pulmonary disease (COPD). 
ALRN-6924 is a dual inhibitor of MDM2 and MDMX based on a stapled peptide 
that interrupts p53 suppression and restores normal p53-mediated apoptosis activity in 
tumor cells.41 Stapled peptides stabilize ?-helices through hydrocarbon linkers that 
bridge two amino acid side chains on the same face of a helix. In addition to forming a 
stable cyclic peptide, this process can facilitate peptide cell penetration. ALRN-6924 was 
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developed by optimizing the stapled peptide ATSP-7041 which in turn was obtained by 
stapling the phage display peptide pDI with an 11 carbon linker through ring-closing me-
tathesis. This final stapled peptide mimics an ?-helix of p53 that binds to the same region 
of MDM2/MDMX. ALRN-6924 is currently undergoing testing in a phase 1/2 trial in pa-
tients with advanced solid tumors or lymphomas expressing wild-type p53 protein, and 
in a phase 1 trial in patients with acute myeloid leukemia or advanced myelodysplastic 
syndrome. 
RA101495 is a cyclic peptide that binds and allosterically inhibits the cleavage of 
the complement factor C5 into C5a and C5b.42 The peptide was developed by screening 
mRNA display combinatorial libraries of cyclic peptides based on a combination of natu-
ral and unnatural amino acids.43 Inhibition of C5 activation is of interest for the treatment 
of complement disorders such as PNH, refractory generalized myasthenia gravis and 
lupus nephritis. A C5 inhibitor based on a monoclonal antibody, eculizumab, is success-
fully used for the treatment of PNH and for atypical hemolytic uremic syndrome (aHUS), 
though it is administered intravenously. The peptide-based inhibitor RA101495 was de-
veloped for subcutaneous injection in order to enable more convenient self-administra-
tion. A phase 1 trial with RA101495 has been completed successfully. 
A look at the techniques used to develop these clinical candidates shows that all 
depended heavily on peptide library screening. In the case of the two peptides POL7080 
and POL6326, natural peptides served as starting points but were extensively modified 
over several rounds of amino acid substitution and activity testing. As described above, 
POL7080 was so changed in its sequence that a new mechanism of action had evolved. 
The development of ALRN-6924 was encouraged by successes with stapled peptides 
that were rationally designed from the ?-helices of p53 located at the p53-MDM2/MDMX 
binding interface. The template that was eventually used for the development of ALRN-
6924 was derived from a phage display peptide library. Finally, the drug candidates APL-
2 and RA101495 were developed by in vitro evolution through large random peptide 
library screening using either phage display or mRNA display. These and other powerful 
in vitro evolution techniques are now being broadly applied to develop ligands for a wide 
range of targets. It can be expected that many more de novo cyclic peptides with activi-
ties for interesting or previously unexplored targets will be fished out of random libraries 
by phage or mRNA display, and will soon be evaluated in clinical studies. 
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1.1.2.3 Future challenges and potential solutions 
Several important challenges remain in the development of cyclic peptide thera-
peutics, the two most important ones being oral availability and cell permeability. Inno-
vative approaches applied in recent years address one or both of these challenges, in-
cluding the use of cell penetrating peptides 44, the stabilization of peptides in ?-helical 
conformations with hydrocarbon linkers 45, or the in vitro evolution of N-methylated pep-
tides.46 In order to develop cyclic peptides with a good oral availability and that able to 
efficiently enter cells by passive diffusion, it might be necessary to consider molecules 
with smaller molecular weights and fewer peptide bonds. One could imagine that future 
macrocycles will contain only one or a few amino acids with an additional polyketide type 
component in the backbone. A good role model is the orally available and cell permeable 
drug tacrolimus which contains a backbone based on one amino acid and a polyketide 
chain wherein the amino acid forms key interactions with the target. To develop such 
chimeric peptide/polyketide macrocycle ligands, it will be crucial to create efficient chem-
istries and strategies that allow the synthesis and screening of large combinatorial librar-
ies. 
1.1.3 In vitro evolution of peptides 
In vitro evolution methodologies are artificial reproductions of spontaneous genetic 
mutations and functional natural selection, core of the Darwinian process, accelerated in 
time and limited in space. These techniques allow the generation and screening of an 
enormous number of variants, while maintaining the linkage between genotype and phe-
notype, in order to rapidly evolve them towards the desired applications.47  
Phage display was the first established technology based on an in vitro display 
system, developed by G.P. Smith in 1985.48 Briefly, DNA coding for randomized combi-
natorial libraries of peptides, proteins or antibodies is cloned in the genome of bacterio-
phages. As result, each phage expresses on its surface a single variant fused to a coat 
protein (phenotype), while the corresponding nucleic acid sequence is inside the phage 
particle (genotype). Heterogenous mixtures of phage-encoded libraries are screened in 
a biopanning process to isolate ligands carrying the desired binding properties. Phage 
clones are incubated with targets, non-binding sequences are removed by multiple wash-
ing steps, while the binders are fished out by various elution methods. This cycle of af-
finity selection is repeated two to three times, enriching the phage population for binding 
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variants while eliminating the unspecific background. The specific amino acid sequences 
are retrievable by sequencing the genome of the isolated phages (Fig. 4).49  
The most commonly used phage strains are the M13, f1 and fd, characterized by 
a genome expressing five different virion proteins. Combinatorial libraries are commonly 
displayed on the five copies of the pIII coat protein.50 This multivalency introduces an 
avidity effect that might be suitable for initial screenings, when peptide leads have to be 
captured from a naïve library. A monovalent display is often preferred in the following 
steps of affinity maturation since avidity effects could skew the binding results towards 
less desirable clones.51 
 
Figure 4. Phage display selection of combinatorial peptide libraries (corresponding DNA and amino acid 
sequence shown in blue) displayed on the coat protein pIII (corresponding DNA and amino acid sequence 
shown in red) of a filamentous phage. Libraries are subjected to two or three rounds of incubation with the 
immobilized target, washing of unspecific binders, elution of specific binders, and reamplification in bacteria 
for the next round. The amino acid sequences of the peptides are identified by DNA sequencing. 
Other display methodologies feasible for in vitro evolution of peptides are yeast52 
and bacterial53 display. Similarly to phage display, they are cell-based techniques that 
consist in the display of libraries on the cell surface, allowing the direct determination of 
the binding using cell-flow cytometry. However, they also suffer from reduced library 
sizes (typically 1010 clones) due to a low efficiency of DNA transformation, and from chal-
lenging incorporation of unnatural amino acids during the screening.54 Recently, a new 
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cell-based system which could introduce unnatural residues in the sequence has been 
described, however it was limited to a single amino acid addition.55 
In order to screen larger peptide libraries for in vitro evolution, new cell-free sys-
tems have been developed and are currently widely applied, such as mRNA56 and ribo-
some57 display. In both methods, screening variants are directly linked to their encoding 
sequence via puromycin or the ribosome, respectively.  Their main advantages over cell-
based display are the creation of library consisting of up to 1015 variants, and a more 
efficient inclusion of unnatural residues.54,58  
So far, two peptides developed by phage display have been approved as drugs, 
the linear romiplostim (Nplate, Amgen) and the cyclic peginesatide (Hematide, Affi-
max/Takeda), in addition to several monoclonal antibodies and proteins like the block-
buster adalimumab (Humira, Abbott).50,59 In contrast, no peptides generated with one of 
the other mentioned technologies have yet reached the market. This proves that phage 
display, despite some limitations, is a powerful technique for the generation and screen-
ing of large combinatorial libraries, and led to the development of specific ligands.60 In 
particular, it allowed for the isolation of bioactive sequences unrelated to the natural 
binding partner. In future, it might also permit the development of peptides with entirely 
novel functions, enhancing the hope that new binders can be found for proteins with 
unknown natural ligands.50,59 Because of the simplicity of its protocol, the high versatility 
of applications and manipulations, and the easy generation or commercial availability of 
different peptide libraries, phage display is still the most common system used for in vitro 
evolution.61  
1.1.4 Phage selection of cyclic peptides  
Since the introduction of phage display for the screening of peptides in the early 
1990s, cyclic peptides appear to be the preferred format. Peptides having two Cys resi-
dues were often enriched over linear peptides, suggesting their selection as disulfide 
monocyclized structures.62 As a consequence, new generations of phage libraries, con-
sisting of two fixed Cys residues flanking a central random sequence, resulted in cyclic 
peptide binders presenting on average 100 to 1000-fold higher binding affinity respect to 
linear peptides selected against the same target.63,64 Better biochemical properties of 
cyclic peptides stimulated a stronger interest towards the extensive creation of even 
larger libraries with this format, resulting in the isolation of many cyclic ligands (Fig. 
5a).60,65,66 
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Figure 5. Encoded cyclic peptide libraries. (a) Cyclization of a phage-encoded peptide by oxidation of two 
Cys to form a disulfide bond. (b) Cyclization of phage-encoded peptides by chemically linking the amino 
groups of the N-terminus and a Lys residue with disuccinimidyl glutarate. (c) Cyclization of mRNA-encoded 
peptides by spontaneous reaction of a chloroacetamide group in an unnatural amino acid with a Cys to form 
a thioether bond. (d) Oxidative cyclization of peptides containing benzylamine and 5-hydroxytryptophane. 
(e) Peptide cyclization by Michael addition of a Cys side chain to dehydrobutyrine. Dehydrobutyrine is ob-
tained by heat-induced isomerization of vinylglycine. Newly generated stereogenic centers are indicated by 
asterisks. (f) Cyclization of mRNA-encoded peptides by linking two Cys with the thiol-reactive reagent ?,?’-
dibromo-m-xylene. (g) Cyclization of an mRNA-encoded peptide library by Michael addition of a Cys residue 
to dehydroalanine. The latter amino acid is generated by oxidative transformation of 4-selenalysine. The 
newly generated stereogenic center is indicated by an asterisk. Reprinted with permission from 60, reprinting 
license nr. 4047111125961, copyright © 2015 Elsevier Ltd. 
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The only example of an approved peptide drug selected as monocycle is 
peginesatide, previously introduced in the sub-section 1.1.2. The initial peginesatide pre-
cursor was identified after two consecutive phage panels against the human erythropoi-
etin receptor, starting from a peptide library having the CX8C format. The sequence of 
the selected peptide was used as template for the generation of two different phagemid 
libraries: the first one with randomized residues, and the second one with three extra 
random residues at both termini. The new libraries led to the isolation of a nanomolar 
peptide binder able to stimulate the erythropoiesis. Further analysis permitted a shorten-
ing of the peptide sequence while retaining its activity. The chemical dimerization of two 
identical peptide molecules achieved an even stronger effect in vivo.34,35 The final struc-
ture of peginesatide was based on two identical 21-mer cyclic peptides connected 
through a linker, which was composed of an iminodiacetic acid and ?-Ala, to two 20 kDa 
PEG units. PEGylation led to three to four weeks of sustained effect in humans, thus 
making it suitable for monthly dosing.67 Unfortunately, this drug was recalled from the 
market due to lethal problems.33  
Development of non-reducible cyclic bonds have been recently achieved by new 
chemical cyclization methods applied in different in vitro techniques in place of the more 
traditional disulfide bridges (Fig. 5b-g). Thanks to the different geometries that a peptide 
can undergo when differently cyclized, the diversity of phage libraries was further en-
larged through these methods, thus generating ligands with higher affinity and stability.60 
1.1.5 Bicyclic peptides 
Towards the development of cyclic peptides with even more constrained struc-
tures, and thus better affinity, stability and specificity, Heinis et al. developed a new meth-
odology for the in vitro evolution of bicyclic peptides on phage.68 As the name suggests, 
the new molecular format is based on two macrocyclic peptide rings, chemically cyclized 
around a reactive organic core. In general, bicyclic peptides present all of the properties 
previously described for cyclic peptides, with some other key advantages. 
Unlike monocyclic peptides, both rings of this format can bind the target, partially 
mimicking the complementary determining regions (CDRs) of antibodies. The wider con-
tact region and a higher number of non-covalent interactions are important for both bind-
ing affinity and selectivity.60 A better specificity could permit the development of drugs 
with less side effects on paralogous species.69 The bicyclic format has finally a more 
compact conformation that shows a much higher potency and stability to proteolytic 
cleavage compared to the linear and monocyclic counterparts.68,70,71 
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The bicyclic configuration can be obtained by quantitative and selective chemical 
cyclization of linear peptides containing three Cys residues with a small trivalent thiol-
reactive molecule, applying a strategy previously developed to mimic non-linear epitopes 
of antibodies.72 Heinis et al. efficiently combined the mild reaction required for this pep-
tide cyclization with the enormous variability of phage-encoded combinatorial libraries 
(up to 109 variants). The initial bicyclic format was composed of two rings with six variable 
positions flanked by Cys residues at both ends and one in the middle (ACX6CX6CG, two 
loops of six residues, named 6x6) modified with a reactive molecule called 1,3,5-tris-
(bromomethyl)benzene (TBMB) (Fig. 6). This molecule was chosen since it allowed a 
symmetric rotational arrangement of the peptide structure and thus the formation of a 
single product.68 
 
Figure 6. Phage display selection of combinatorial bicyclic peptide libraries (corresponding DNA and amino 
acid sequence of the N-terminal and C-terminal loops shown in blue and green, respectively) displayed on 
the coat protein pIII of a filamentous phage. Linear peptide libraries are chemically modified with the cycliza-
tion molecule TBMB. Libraries are subjected to two or three rounds of incubation with the immobilized target, 
washing of unspecific binders, elution of specific binders, and reamplification in bacteria for the next round. 
The amino acid sequences of the peptides are identified by DNA sequencing. 
A high diversity in combinatorial peptide libraries is a critical parameter for the de-
velopment of ligands. In addition to variation in the amino acid sequence, the diversity of 
the bicyclic format was further expanded by changing size and geometry of the two loops. 
This was done varying both the number of amino acids in each ring and the thiol-reactive 
molecules used for the chemical cyclization.73  
As a proof of concept, Rentero et al. generated fourteen new libraries having dif-
ferent ring size formats (ACXmCXnCG, with "m" and "n" representing the number of ran-
dom amino acids ranging between three and six) (Fig. 7). They screened them against 
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the same target and showed consensus sequences specific for each new combination, 
quite different from those previously isolated with the initial 6x6 format.74 This demon-
strated that bicyclic peptides with variable ring sizes could allocate in different manners 
into protein binding pockets, and this advantage was later efficiently exploited for the 
selection of ligands against orthologous targets.69  
 
Figure 7. Bicyclic peptide phage libraries with different ring sizes. (a) Chemical structure of a representative 
bicyclic peptide with green rings of 3 and 4 amino acids. For size comparison, the peptide rings with 3, 4, 5 
and 6 variable amino acids are shown as grey circles. (b) Overview of the libraries. Indicated on the axes 
are the number of variable amino acids in the two rings of the bicyclic peptides. Libraries that were cloned 
in that work are indicated with different colored dots. The 6x6 library indicated with a red dot was cloned 
previously. Reprinted with permission from 74, reprinting license nr. 4047120151435, copyright © 2012 Royal 
Society of Chemistry. 
In parallel, structurally different thiol-reactive molecules were tested for the cycliza-
tion of the same peptide format. Since the first molecule used (TBMB) is rather small, 
hydrophobic, and did not contribute to the binding, two new reagents were developed to 
obtain different geometrical conformations of bicyclic peptides. These were based on 
either bromoacetamide (TBAB) or acrylamide (TATA) moieties, and they were compati-
ble with the conditions previously set up for cyclization on phage.75 In addition, they both 
contain more sophisticated chemical structures, which allowed for extra interactions be-
tween the molecule and the peptide sequence (Fig. 8). Both NMR and crystal structure 
experiments confirmed that the new reagents brought about conformational changes in 
the peptide and participated in the binding interactions with the target.75 When applied 
on phage, they led to the isolation of specific consensus motives, further increasing the 
number of possible bicyclic formats.76,77 Combination of these new molecules with differ-
ent chemical structures triplicated the diversity of each phage library. Recently the library 
variability was further expanded using sequences carrying four Cys residues, each of 
them being cyclized into three possible isomers by oxidation.78 Moreover, structural and 
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in silico analyses of bicyclic peptides demonstrated that this format is suitable for the 
synthetic incorporation of unnatural amino acids, a different way to increase peptide di-
versity and affinity after phage selection.79 
 
Figure 8. Structurally diverse small molecules for the phage selection of bicyclic peptides. (a) The structures 
of previously developed and structurally characterized bicyclic peptides were not directed by the central 
chemical molecule (illustrated by a gray ball; left). Small molecules with polar groups (illustrated as a red 
ball) form H-bond interactions (black dashed lines) with the peptide loops and serve as nucleating scaffolds 
(right). (b) Structures of the small molecules, each containing three thiol-reactive groups, before and after 
reaction. Potential H-bond donors and acceptors are indicated by red arrows. Computed distance ranges 
between the sulfur atoms of the cyclized peptides are indicated. Reprinted with permission from 76, reprinting 
license nr. 4047120502109, copyright © 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. 
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1.1.6 Examples of bicyclic peptides 
So far, several potent and specific bicyclic peptides with high binding affinity and 
potency have been isolated against a variety of disease-related protein targets, such as 
the following human serine proteases plasma kallikrein (PK)68,69, urokinase-type plas-
minogen activator (uPA)70, and coagulation factor XII (FXIIa).80,81  
1.1.6.1 Plasma kallikrein inhibitor 
Human plasma kallikrein (PK) is a serine protease that is involved in several pro-
teolytic cascades such as the intrinsic coagulation pathway and the kallikrein-kininogen 
system.82 Its inhibition would be beneficial for different diseases, since an increase in its 
activity causes an excessive activation of both coagulation factor XII and bradykinin, as-
sociated with a higher risk of thrombosis and inflammation, respectively.82 A PK inhibitor 
called ecallantide (Kalbitor, Dyax Corporation), a phage selected polypeptide of 60 amino 
acid, has already been approved for the treatment of a PK-related inflammatory disease 
called hereditary angioedema (HAE).83 Since a smaller inhibitor would be preferred, PK 
immediately emerged as an optimal target for the isolation of bicyclic peptides. The first 
generation of phage-encoded libraries developed by Heinis et al. was subjected to se-
lection and further affinity maturation against immobilized PK, leading to the isolation of 
a potent 6x6 bicyclic peptide inhibitor, called PK15 (Ki = 1.5 nM) (Fig. 9). This peptide 
did not show any inhibition of the target activity when not cyclized with TBMB, confirming 
that the bicyclic structure was critical for the binding. In addition, it was characterized by 
a high specificity with reduced inhibition of other serine proteases.68 
However, PK15 was not able to inhibit the orthologous PK from other species such 
as mouse and rat, preventing the possibility to test its activity in vivo. In order to solve 
this limitation, Baeriswyl et al. performed a new selection using a second generation of 
peptide libraries with smaller loop sizes (3x3 and 5x5, cyclized with TBMB), and suc-
ceeded in isolating several bicyclic peptides with inhibitory activities in the pico- or low 
nanomolar range for human PK, and in the medium nanomolar range for the orthologous 
proteins. Among them, the best inhibitor, called PK128, was almost inactive against pa-
ralogous proteases while it exhibited high potency against human and orthologous mon-
key and rat PK (Ki = 0.3, 0.4, and 11 nM, respectively).69 
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Figure 9. Inhibition of human plasma kallikrein by different bicyclic peptides and NMR solution structure of 
PK15. (a) The inhibitory activity is expressed as the fractional activity at varying inhibitor concentrations. 
Clones PK2, PK4, PK6, PK13 and PK15 were isolated in phage selections using two different libraries. (b) 
The peptide loops of conjugate PK15 are shown in yellow (loop 1) and orange (loop 2). The mesitylene core, 
the three Cys residues and the terminal Ala (N-terminus) and Gly (C-terminus) are shown in gray. The back-
bone atoms of the peptide are represented as a cartoon, and the side chains of the amino acids are repre-
sented as sticks. Reprinted with permission from 68, reprinting license nr. 4047121037044, copyright © 2009 
Nature Publishing Group. 
1.1.6.2 Urokinase-type plasminogen activator inhibitor 
Human urokinase-type plasminogen activator (uPA) is a serine protease overex-
pressed in cancer and involved in tumor growth and metastasis. When released from 
tumor cells, this protease converts the inactive plasminogen to plasmin, which is respon-
sible for the degradation of the extracellular matrix and, as consequence, cancer cell 
invasion. The inhibition of uPA would be beneficial as initial therapy for limiting metasta-
ses.84 Using the 6x6 phage library and the TBMB cyclization reagent, Angelini et al. could 
isolate a potent and highly specific competitive inhibitor of uPA, called UK18 (Ki = 53 
nM). Co-crystallization of UK18 with its target showed a large contact surface and gave 
extra insights about the binding mechanism of the bicyclic peptide (Fig. 10).70 In particu-
lar, this analysis allowed the specific replacement of a Gly residue with several D-amino 
acids, which resulted in improvements of peptide’s affinity and stability.79 Angelini et al. 
confirmed what was already observed with PK15: the constrained bicyclic format of UK18 
had an advantage in terms of both potency and stability over its monocyclic and linear 
analogues.70,71 
The first pharmacokinetic studies with UK18 showed a rapid peptide clearance 
upon i.v. injection in mice, with a half-life of only 30 minutes.71 In order to increase the 
circulation time in blood, UK18 was both recombinantly fused to a Fc region and chemi-
cally conjugated to an albumin-binding peptide. These strategies prolonged sensitively 
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the half-life of the bicyclic peptide to at least one day in mice.71,85 However, these options 
were not attractive in terms of production, and their application was thus discontinued. 
 
Figure 10. Inhibitory activity and specificity of UK18. Crystal structure of uPA in complex with the bicyclic 
peptide UK18. (a) Residual activities of uPA incubated with bicyclic UK18 or the linear or monocyclic deriv-
ative. (b) The residual activities of uPA and a range of homologous trypsin-like serine proteases were meas-
ured at different concentrations of bicyclic peptide UK18. (c) Surface representation of human uPA (gray) in 
complex with UK18 (peptide ribbon in blue, mesitylene scaffold in red). (d) Schematic representation of 
molecular interactions between uPA and UK18. Residues of uPA are labeled according to the chymotrypsin 
numbering system. Potential intermolecular (red) and intramolecular (blue) hydrogen bonds are shown as 
dashed lines. Bent gray lines indicate residues of UK18 in close contact with uPA (distances shorter than 
4.0 Å that are not hydrogen bonds). Adapted with permission from 70, copyright © 2012 American Chemical 
Society. 
1.1.6.3 Coagulation factor XII inhibitor 
Activated human coagulation factor XII (FXIIa) is the initial serine protease of a 
plasma cascade which has several implications in inflammatory, coagulative and immu-
nologic processes.86 This protease circulates in the blood as inactive zymogen and it is 
converted to the active form by auto-proteolysis when exposed to negatively charged 
surfaces. Activated FXIIa cleaves both factor XI, initiating the intrinsic coagulation path-
way, and plasma kallikrein, activating the kallikrein-kinin system, which further back-ac-
tivates FXIIa and amplifies the cascade.87 Although the physiology of FXIIa has not yet 
been clarified, its role in coagulation and/or inflammation related diseases, such as 
thrombosis and hereditary angioedema, has already been extensively documented.83,88 
In addition, surgeries in which the blood makes contacts with medical devices, such as 
coronary pulmonary bypass (CPB) and extracorporeal membrane oxygenation (ECMO), 
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can activate FXII and trigger coagulation, with potential life-threating consequences. Cur-
rently, heparin is widely used in these situations. However, this drug has itself serious 
well-known side effects, such as an excessive bleeding, which were stimuli for the dis-
covery of substituents with safer anti-thrombotic effects.89 
For this reason, FXIIa was considered an important target for the development of 
new inhibitors. Two phage display screenings were performed against this protein using 
different libraries of bicyclic peptides. The first selection was performed using a 4x4 li-
brary cyclized with TBMB and resulted in weak inhibitors of FXIIa (Ki = 1.2 ?M).80 In the 
second screening, variations in both peptide library size (3x3, 4x4 and 6x6) and cycliza-
tion reagents (TBMB and TATA) were introduced. The phage selection, followed by an 
affinity maturation step, yielded a medium nanomolar inhibitor, called FXII618. This bi-
cyclic peptide was cyclized with TATA and inhibited FXIIa with a Ki value of 22 nM. Fur-
ther characterizations showed a much higher selectivity towards the target protease and 
a better efficiency in the inhibition of the intrinsic coagulation pathway compared to a 
known FXIIa inhibitor, called corn trypsin inhibitor (CTI) (Fig. 11).81 However, the bicyclic 
peptide could be applied exclusively as reagent for coagulation assays in clinical labor-
atories due to a low stability towards serum proteases and a fast elimination half-life.  
 
Figure 11. Comparison of FXII618 and CTI. (a) Specificity profile and inhibitory activity of CTI (left panel) 
and FXII618 (right panel). The residual activity of several trypsin-like serine proteases is shown. (b) Com-
parison of aPTT in citrated platelet poor plasma in the presence of the same quantities of FXII618 and CTI. 
Adapted with permission from 81, copyright © 2015 American Chemical Society. 
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These drawbacks hampered the application of FXII618 in anti-thrombotic therapies 
where the inhibitor needs to block FXIIa, and prevents the activation of the intrinsic co-
agulation pathway, over an extended period of time. In order to overcome this limitation, 
several variants of this bicyclic peptide have been recently developed in our laboratory, 
introducing D- or unnatural amino acid substitutions. These new bicyclic peptides 
showed strong improvements in terms of inhibitory activity, target selectivity and plasma 
stability (Fig. 12).90,91 The combination of these results and further optimizations led to 
the design of a potent picomolar FXII inhibitor with even better biochemical properties. 
However, pharmacokinetic studies in rabbits confirmed that the the plasma half-life of 
this new inhibitor is still too short to exert efficiently its activity in vivo (unpublished data).  
 
Figure 12. Optimization of FXII618. Adapted with permission from 91, copyright © 2017 American Chemical 
Society 
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1.2 - Strategies for prolonging the plasma 
half-life of peptides 
The recent success of peptides as a new class of therapeutics is mainly related to 
their appealing advantages over other drug formats, as described in the first section. 
However, this should not hide the limitations which affect peptide ADME (absorption, 
distribution, metabolism and excretion) profiles. The main drawbacks that impact on their 
in vivo pharmacological efficacy are briefly presented in the following paragraphs.1,92,93  
First, peptides can undergo enzymatic proteolysis in blood, which is responsible 
for their short metabolic half-life.1 Several chemical modifications were efficiently devel-
oped to prevent this degradative pathway, such as the previously mentioned cyclization 
of peptide backbone11; the stabilization of ?-helical conformation with hydrocarbon link-
ers45 or D-Pro-L-Pro ?-turn motives38; the substitution of natural amino acids and amide 
bonds susceptible to cleavage by unnatural derivatives and isosteric bonds creating pep-
tidomimetic sequences; and the protective effect of the conjugation to hydrophilic poly-
mers, fatty acids or carbohydrates (Fig. 13).1,9 
 
Figure 13. Modification approaches explored for enhancing the pharmacological properties of peptides. Re-
printed with permission from 9, copyright © 2014 American Chemical Society. 
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Second, peptides have limited membrane permeability, and therefore their applica-
bility is restricted to extracellular targets.92 Innovative solutions were applied to facilitate 
their entrance into cells, such as conjugation to cell penetrating peptides44 and stapled 
formats45. Despite these numerous efforts, cyclosporine is the only approved peptide that 
is cell permeable46, and few promising candidates are currently in clinical trials.41,94  
Third, peptides have typically a poor oral availability due to a low stability in the 
digestive system as well as low absorption by intestinal epithelium.92 This limitation has 
been partially challenged through the generation of N-methylated peptides46,95. Few pep-
tides are reported as orally available or orally administered, though they exert their ac-
tivity on a target located in the intestine.96  
Finally, another shortcoming for peptides to overcome is their negative pharmaco-
kinetic profile generally characterized by short systemic half-lives, and associated with a 
fast clearance from the circulation by the kidneys.93 As a direct consequence, peptides 
that act as antagonists are not available in the body for a period of time sufficient to exert 
their therapeutic effect. Thus, they require high dosages and frequent injections, affect-
ing the patient's compliance to the treatments.93 This last criticism is the main problem 
discussed, addressed and solved in the research project presented in this thesis. 
1.2.1 The physiology of renal clearance 
Kidneys have an essential physiological role in our body. They are involved in sev-
eral key processes such as the maintenance of water, acid-base and electrolytes home-
ostasis; control of blood pressure; production of vitamin D, glucose and erythropoietin; 
and the removal of metabolic products and chemicals from the blood.97 Each kidney is 
divided into approximately one million small units called nephrons, each consisting of a 
glomerulus that contains a three-layered barrier essential for blood filtration, and a tubule 
that transforms the filtrate coming out from glomerulus in urine. Glomerular epithelium 
has pores with a diameter of around 8 nm and cells (podocytes) rich in negatively 
charged proteoglycans. Thus, the glomerular filtration barrier acts mainly according to 
size and electrical charge of the molecules entering the kidneys. All the molecules and 
small proteins below the molecular size and dimension of albumin (66.5 kDa and 8x8x3 
nm, respectively) are rapidly cleared.98 In addition, molecules having a net negative 
charge are retained in the blood circulation more easily than cationic ones because of a 
strong repulsion mediated by the negatively charged podocytes in the kidney. As ex-
pected, peptides with a molecular weight of 5 kDa are completely filtered out within 
minutes, showing a filterability value of 1.0, which is the same of water.97 
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Based on this fact, one way to keep peptides in the circulation for a longer time is 
to hamper the renal filtration by increasing their hydrodynamic volume, without affecting 
the biological activity. Such an effect can be achieved by covalent genetic fusion or 
chemical conjugation of peptides to large endogenous or exogenous molecules, and it 
would be even better if these molecules are negatively charged.93 Another solution is a 
non-covalent binding to serum proteins of either peptides themselves or via the linkage 
to natural ligands or drugs (e.g. fatty acids and ibuprofen) that prolong their half-life by 
interacting tightly with these proteins (Fig. 14).93 Strategies developed to counteract the 
elimination of peptides will be discussed in detail in the following sub-sections. 
 
Figure 14. Overview of half-life extension strategies. Reprinted with permission from 93, copyright © 2016 
Taylor & Francis. 
1.2.2 Attachment to synthetic or natural polymeric units 
1.2.2.1 Polyethylene glycol 
The hydrodynamic volume of peptides and small proteins can be increased by 
conjugation to large hydrophilic polymers of natural or chemical derivation (Tab. 3).93,99 
The most common and successful polymer currently used and approved by FDA is the 
well-known polyethylene glycol [PEG; X-(CH2CH2O)n-CH2CH2-OH, with X representing 
either a hydroxy (OH-) or methoxy (CH3O-) group], based on repeated units of ethylene 
oxide. The variable number of these units determines the molecular weight and the ar-
chitecture of the PEG type, and allowed to create a range of polymers with masses from 
5 to 50 kDa. Even though the effective size of the conjugates could be smaller than the 
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clearance threshold, single or multiple PEG monomers attached to a molecule of interest 
can coordinate several water molecules, thus increasing the overall hydrodynamic vol-
ume and avoiding kidney’s filtration (Fig. 15).100 Moreover, PEGylation is a well-estab-
lished strategy to improve peptides’ proteolytic stability as well as their solubility in both 
aqueous and organic solutions. Finally, PEGylation has been shown to reduce the risk 
of eliciting protein immunogenicity.101  
The first PEGylated derivatives were developed in the late 1970s by Davis and co-
workers, and according to the chemistry used for the conjugation, they were classified in 
two generations.102,103 In the first-generation, the PEG polymers had low molecular 
weight and this often resulted in diol contamination. Their conjugation suffered from weak 
bond stability and poor site specificity since it occurred randomly with different reactive 
groups present in the peptide or protein sequence, mainly N?-amine of Lys side chains 
or the N-terminus. Some examples of reactive moieties attached to PEG for conjugation 
are propionaldehydes and succinimidyl esters, which form imine and amide bond, re-
spectively.102,103 Despite the difficulty in the characterization of the isomers in the heter-
ogeneous mixtures of products and the low reproducibility of these chemical approaches 
among different batches, several first-generation PEGylated proteins were approved. 
These include conjugates of adenosine deaminase (Pegademase, Adagen, Enzon), as-
paraginase (Pegaspargase, Oncaspar, Enzon) and interferon ?2b (Peginterferon, 
PegIntron, Schering-Plough).103 
Some of these limitations were overcome in the second-generation of PEG poly-
mers by introducing both chemical groups that react with specific residues and function-
alized PEG units that produce larger, degradable, releasable, bifunctional or branched 
structures.102,103 One example is represented by PEG units activated with maleimide or 
haloacetamide moieties that can selectively react with the thiol of a Cys residue.102,103 
Among all the second-generation PEGylated proteins approved using these new chem-
ical options, only two drugs are site-specifically modified. These are the granulocyte col-
ony-stimulating factor (Pegfilgastrim, Neulasta, Amgen), which has a PEG at the N-ter-
minus, and a fragment of anti-tumor necrosis factor (TNF)-??monoclonal antibody (Cer-
tolizumab pegol, Cimzia, UCB), which has an added PEG on the thiol group of a C-
terminal Cys residue.104 
Chapter 1 - Introduction 
31 
 
Figure 15. A comparison of uricase and PEG-uricase model adapted from 105. Reprinted from “Evolution 
and evolvability” (https://commons.wikimedia.org/wiki/File:PegUricase.png), this figure is available under the 
terms of CC-BY 4.0 license (https://creativecommons.org/licenses/by/4.0/), via Wikimedia Commons. 
Though PEGylation has been widely applied in the last decades and is considered 
safe, some problems emerged from its use. These include an undesired interaction of 
PEG with blood components, production of anti-PEG antibodies, allergic reactions and 
hypersensitivity, cytoplasmic vacuolation in kidneys, concerns about long-term effects of 
accumulation in the kidney and liver, possible degradation and toxicity of PEG monomers 
and side-products formed during storage and production.101,106 In addition, PEG-conju-
gation reduces the pharmacodynamic properties when compared to the original non-
PEGylated proteins, mostly because of the steric hindrance of the large PEG units.107 
This last point strongly affects the rate of successful attempts to PEGylate peptides 
due to the few available sites that can be modified without reducing or abolishing pep-
tide’s activity. This challenge has limited a number of potential applications, and only one 
PEGylated peptide has reached the market, most likely due to the distance between the 
PEGylation site and the pharmacologically active part.108 In addition to the preiously de-
scribed peginesatide33,67 (sub-section 1.1.4), another promising PEGylated peptide was 
the insulin derivative lispro, modified with a PEG unit on the LysB28 side-chain. The 
resulting peglispro (Eli Lilly) showed up to 30-fold improved circulating time in a phase 1 
trial109, compared to insulin itself, which has a half-life of few minutes or hours upon i.v. 
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and s.c. injection, respectively.110,111 In addition, peglispro showed a preferential hepatic 
effect, which might result in a better control of glucose release from liver with lower risk 
of hypoglycemia, thus allowing a safer mode of action.112 However, the clinical trials also 
revealed an increase in the concentration of liver enzymes which was asked to be clari-
fied before approvals. Even if the company initially wanted to investigate this side effect, 
postponing the final submission, the costs of new trials were considered too high and the 
clinical development discontinued.112 
Another example is an integrin-binding peptide, called HM-3, modified with differ-
ent PEG units. The best combination showed a six-fold prolonged half-life in rats and a 
promising activity in mice, but it has not been tested yet in humans.113,114 Despite these 
high number of studies, the development of PEGylated peptides requires further efforts 
to gain an efficient engineering of the conjugation sites. This is crucial for finding a proper 
balance between drug properties and cost of productions. New methodologies have al-
ready been employed for peptide modification and described in literature.115 However, 
any new PEGylated peptide has reached the clinical stage yet.108 
1.2.2.2 Natural polymers 
In order to circumvent the previously mentioned drawbacks of PEGylation, safer 
and less expensive alternatives for peptide’s modification were recently investigated. 
These substituents are newly designed synthetic PEG analogues and natural polymers 
made of glycans or polypeptides.93,99 
Naturally occurring post-translational N- and O-glycosylations usually have a pos-
itive impact on the half-life and activity of proteins. Similarly, peptides can be modified 
with carbohydrates by introducing glycosylation sites in the sequence. N-glycosylation 
often occurs on Asn residue presented in the motif NXS/TX (with X any amino acid ex-
cluded Pro).93 Addition of two extra glycosylation sites in the sequence of the recombi-
nant human erythropoietin led to Darbepoetin alfa (Aranesp, Amgen), an EPO analogue 
currently used in patients with anemia caused by renal insufficiency or chemotherapy.67 
Compared to the original protein, Darbopoietin has a half-life in human that is three and 
five-fold longer when injected i.v. or s.c., respectively.116 
In contrast, O-glycosylations of Ser or Thr residues are not associated with a spe-
cific consensus sequence. This modification is usually introduced by fusing peptides with 
natural O-glycosylated substrate sites, such as the carboxy-terminal peptide of the cho-
rionic gonadotropin ?-chain (CTP).117 As demonstrated by the approved follicle-stimulat-
ing hormone (FSH) conjugated to CTP (corifollitropin-???????????? ???????????????????????
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a O-glycosylated region almost tripled the half-life of the initial protein upon s.c. admin-
istration in human.118,119 Although successful for several protein-based drugs, only few 
peptides modified with glycans were generated due to difficulties in preparation, and 
none of them is in clinical use.120 
Other emerging strategies include conjugation of polypeptides to polysaccharidic 
polymers such as dextran, polysialic acid (PSA), hyaluronic acid (HA), and hydroxy-ethyl-
starch (HES) (Fig 16). All of them have the advantage of being natural or semisynthetic 
constituents of human metabolic products, and thus have the potential to be poorly im-
munogenic. Some of them are even already claimed as safe products since they are 
applied in cosmetics and in hospital as plasma volume expanders or for other applica-
tions. Moreover, they have a high hydrodynamic volume and they are often negatively 
charged, which both are key properties for prolonging the half-life. 99 
 
Figure 16. Structures of (a) dextran, (b) HES, (c) PSA and (d) HA. Adapted with permission from 99, reprint-
ing license nr. 4047140757234, copyright © 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.  
Dextran is a polymer of D-glucose that it is naturally processed by dextranases 
(Fig. 16a).99 As an example of its half-life extending ability, the peptide hormone soma-
tostatin conjugated to dextran showed similar activity to the analogue octreotide, but ex-
hibited a 75-fold increased half-life in a phase 1 trial.121  
Polysialic acid is a group of different polysaccharides, and the most used is the 
colominic acid (CA) (Fig. 16c). This plays an important role in cell adhesion and synaptic 
plasticity, and it is fully degraded without toxicity.99 Several polysialylated proteins, both 
enzymes and antibody fragments, are currently in pre-clinical and clinical stage, and pol-
ysialyated peptides are expected to enter soon. As example, insulin derivatives modified 
ba
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with two different CA polymers gave a two to three-fold prolonged reduction in glucose 
levels than the native peptide in mice.122 
Hyaluronic acid is a linear polymer composed of 20-25 thousand of negatively 
charged dimeric units of D-glucuronic acid and N-acetyl-D-glucosamine (Fig. 16d).99 This 
polymer is widely present in human skin, eyes, and connective tissues. It is highly bio-
compatible since it is metabolized by enzymes called hyaluronidases. Several peptides 
modified with HA showed a prolonged half-life and a negligible reduction of their activity. 
For example, HA was applied to exendin-4 (synthetic form: Exenatide, Byetta, Astra-
zeneca), which is a peptide analogue of GLP-1 that shares with it activity and 50% se-
quence identity. Due to a low proteolytic stability towards dipeptidyl peptidase-4 (DPP-
4), the half-life of GLP-1 is less than two minutes and 1.5 hours upon i.v. and s.c. injec-
tion, respectively.123 In contrast, the exendin-4 had a corresponding half-life of 30 
minutes and 2.5 hours, respectively.124,125 Several copies of exendin-4 were linked to HA, 
resulting in a conjugate with a 24-fold higher in vitro serum stability and relevant glucose 
lowering-effect in mice.126 
Finally, hydroxy-ethyl-starch is a semisynthetic derivative resulting from the hy-
droxyethylation of the vegetal compound amylopectin (Fig. 16b).99 Used as plasma vol-
ume substituent, it is degraded by ?-amylase without any reported immunogenic effect. 
However, some drawbacks already experienced with PEG conjugation were observed.99 
A promising example of HESylated peptide is a dimeric erythropoietin mimetic peptide, 
named AGEM400, which displayed an in vitro activity superior or equal to EPO and re-
lated drugs, and is expected to have a longer half-life when tested in vivo.127  
Peptides can be also recombinantly fused to long unstructured amino acid specific 
sequences. These hybrid systems, called recombinant PEG mimetics, have the same 
properties as both polymers and fusion proteins. Non repeated series of amino acids 
form a fully biodegradable and defined platform that increases peptides’ solubility, sta-
bility and hydrodynamic volume.117 The most innovative technology, with a couple of 
products in clinical trials, is XTENylation. XTEN is a polypeptide sequence up to 864 
amino acids composed of only six specific residues (Ala, Asp, Gly, Pro, Ser, and Thr).128 
The first XTEN product was developed by Schellenberger et al. and it consisted in the 
genetic fusion of exendin-4 at the C-terminus of the XTEN polypeptide (VRS-859). Pre-
clinical studies in mice, rats and monkeys, showed a 65 to 125-fold increase of exendin-
4 half-life (Fig. 17a).129 This XTENylated version of exendin-4 just finished a phase 1 trial 
for type 2 diabetes, resulting in high safety and tolerability, and a 50-fold extended half-
life.128 At a first glance, the XTEN system could appear limited to peptides composed of 
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only natural amino acids, without allowing multiple copies and chemical modifications of 
the peptide of interest. However, the introduction of specific reactive moieties on the 
XTEN sequence, like Cys or alkyne residues, overcomes this limitation and offers new 
options for site-directed conjugation of peptides and small molecules (Fig. 17b).130 More-
over, this approach requires few to no modification and purification steps, overcoming 
some of the disadvantages of PEGylation such as cost and time of production.117 Since 
its first application, several other peptides were linked to XTEN showing improvements 
in plasma half-life.128  
 
Figure 17. XTENylation of biologically active molecules. (a) Genetic fusion: a single polypeptide includes 
both the therapeutic and bulking moieties. (b) Chemical conjugation: XTEN is first expressed and purified as 
an intermediate and then conjugated to biologically active payloads. Reprinted (open access) from 128, this 
article is available under the terms of CC-BY 4.0 license (https://creativecommons.org/licenses/by/4.0/). 
Another recombinant PEG mimetic strategy is ELPylation that exploits the re-
peated sequence VPGXP (with X any amino acid excluded Pro), found in human elastin 
and degraded by elastases. Examples of three ELPylated peptides are GLP-1 (Glymera, 
PB1023), insulin (Insumera, PE0139), and vasoactive intestinal peptide (Vasomera, 
PB1046) derivatives. All of them are in phase 2 trial and required one injection per week. 
More similar to XTENylation is PASylation, a strategy developed by Skerra and co-work-
ers. The PAS polypeptide contains only three amino acids (Pro, Ala, Ser) and exhibits a 
strong positive effect on the half-life. Minor applications include HAPylation, consisting 
of repeated Gly4-Ser units, and gelatin-like-protein (GLP) polymers. Several PAS, HAP 
and GLP derivatives are currently in pre-clinical stage with promising results.117   
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Table 3. Peptide conjugation to polymers. 
Cargo Polymeric conjugate 
Factor Ref. 
Type t1/2 Type t1/2 
erythopoethin mi-
metic peptide 
(peginesatide) 
n.a. 
two PEG units 
of 20 kDa 
19-30 hrs (i.v.)a 
35-68 hrs (s.c.)a 
- a 33 67 
insulin 
(peglispro) 
4-6 min (i.v.)a 
2.3 hrs (s.c.)a 
one PEG unit 
of 20 kDa?
2.3 hrs (i.v.)a 
24-46 hrs (s.c.)a 
28a 
10-20a 
109 
110 
111 
integrin-binding 
peptide (HM-3) 
28 min (i.v.)b 
one PEG unit 
of 10 kDa 
162 min (i.v.)b 6b 113 
somatostatin 
(sms-D70) 
1.5 hrs (s.c.)a 
for octreotide 
70 kDa of dextran 112 hrs (s.c.)a 75a 121 
insulin 
(-) 3 hrs (s.c.)*
c 
22 and 39 kDa of 
colominic acid 
6-9 hrs (s.c.)*c 2-3*c 122 
exendin-4 
(-) 1 d (s.c.)*
c 
100 kDa of hyalu-
ronic acid 
3 d (s.c.)*c 3*c 126 
erythopoethin mi-
metic peptide 
(AGEM400) 
n.a. 
130 kDa of hy-
droxy-ethyl-starch 
n.a. - 127 
exendin-4 
(VRS-859) 2.5 hrs (s.c.)
a 864 amino acids 
for XTEN 
128 hrs (s.c.)a 51a 125 128 
Half-life (or activity when marked with an asterisk) and factor of improvement were measured for human (a), 
rat (b) and mouse (c) species. n.a. = not available. 
1.2.3 Fusion or conjugation to serum proteins 
Blood is composed of blood cells (45%) and plasma (55%). Plasma is an aqueous 
solution containing 92% water, 7% blood plasma proteins and 1% of other small mole-
cules, such as glucose, amino acids, fatty acids, and waste products. Plasma depleted 
of clotting proteins is called serum. Plasma proteins have several different functions, 
including the transport of lipids, hormones, vitamins and minerals in the circulatory sys-
tem as well as the regulation of cellular activity and the immune system. The three most 
abundant plasma proteins are albumin (54-60%), globulins (35-38%) and fibrinogen (4-
7%). The remaining proteins act as enzymes, complement components, protease inhib-
itors or kinin precursors. All plasma proteins are synthesized in the liver except for the 
gamma immunoglobulins (IgGs).131 
Albumin and IgGs are characterized by a nominal plasma half-life of 19 and 21 
days in humans, respectively.117 The long circulating time in the blood is related to their 
molecular weight, which prevents fast renal clearance. In addition to this, their half-life is 
much longer than other plasma proteins thanks to a recycling process mediated by bind-
ing to the neonatal Fc receptor (FcRn).117 In transgenic mice without FcRn, IgG and al-
bumin have a half-life similar to other non filtered proteins with the same or even higher 
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molecular weight, suggesting a similar degradative pathway.132 The FcRn is a major his-
tocompatibility complex (MHC) class I-related receptor, widely expressed in the body, 
and it exerts its function mainly during pregnancy translocating IgGs from the mother to 
the fetus. However, it also binds IgGs and albumin in a pH-dependent manner as soon 
as these proteins are internalized by pinocytosis into vesicles. In acidic condition (pH < 
6.5), IgGs and albumin bind strongly to the FcRn receptor, while all the other free proteins 
are directed to lysosomal degradation. Once the receptor is recycled back to the cell 
surface, the external neutral pH (pH > 7) causes the release of these proteins in the 
bloodstream (Fig. 18). This mechanism of recycling is valid only for IgG isotypes 1, 2 and 
4, and albumin.132 The FcRn receptor is characterized by two different regions for the 
binding of these two proteins, and this allows for an efficient recycle with a specific ratio 
albumin : IgG = 700 : 1.117  
      
Figure 18. FcRn recycling mechanism. Fc-fusion protein drugs or albumin-fusion protein drugs bind to FcRn 
on the endothelium. Receptor-bound proteins are internalized into endocytic vesicles. Endosomes are acid-
ified and undergo sorting of FcRn. Non-receptor-bound proteins are degraded in the lysosomal compartment 
and receptor-bound proteins are recycled back to the cell membrane. The protein therapeutic is subse-
quently released back into the blood. Reprinted with permission from 133, reprinting license nr. 
4047141451047, copyright © 2014 Nature Publishing Group. 
Because of their long half-life, both IgGs and albumin have been extensively used 
in the last decades to improve the pharmacokinetics of peptides and small proteins 
through a covalent linkage. Moreover, recent analyses proved that IgG and albumin mu-
tants with improved binding affinity for the FcRn receptor are characterized by further 
prolonged half-life compared to their native counterparts.134 These optimizations have 
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already been proven on therapeutic IgGs and recombinant variants of albumin, translat-
ing into potential benefits also for the molecules covalently bound to them.135–137 
The following parts will present some applications of two covalent half-life exten-
sion platforms for peptides and small proteins, namely IgGs and transferrin (Tab. 4). 
Properties of albumin as covalently bound carrier will be detailed in a dedicated section.  
1.2.3.1 Gamma immunoglobulin 
Gamma immunoglobulins are the most represented type of antibodies in the 
plasma. Three out of four subclasses have a half-life of around 21 days in humans thanks 
to their size and FcRn-mediated recycling.138 The IgG sites responsible for the binding 
to the receptor are the CH2 and CH3 domains of the 50 kDa Fc region. As consequence, 
several Fc fusion proteins have been developed since 1980s for half-life extension using 
this region as platform for the incorporation of proteins and peptides.117 Several studies 
demonostrated that the biological activity of the Fc fusion proteins can be modulated i) 
dimerizing the sequence or the Fc region for avidity effects, ii) inserting specific linker 
sequences, or iii) changing the orientation of the fused molecules.139 The first Fc-fusion 
protein to enter in the market was etanercept (Embrel, Amgen), used for the treatment 
of rheumatoid arthritis. Etanercept is composed of the extracellular region of the TNF 
receptor 2 fused to a Fc domain. This molecule binds with high affinity the natural ligand, 
TNF-?, blocking the activation of its receptor in chronic inflammatory diseases.117  
In the following decades, at least ten other Fc-fusion proteins were approved by 
the FDA, and many others are in clinical trials, showing half-lives ranging from five to 13 
days.139 Among them, only two are peptide-Fc proteins (“peptibodies”) (Fig. 19): romip-
lostim (Nplate, Amgen) and dulaglutide (Trulicity, Eli Lilly), approved for the treatment of 
immune chronic thrombocytopenia and type 2 diabetes, respectively.93,117 Romiplostim 
is composed of two tandem copies of a linear thrombopoietin mimetic peptide recombi-
nantly fused to the C-terminus of an IgG1 Fc fragment using a Gly linker. This peptide 
was initially developed and further optimized by phage display selection, and it showed 
an IC50 value of 500 pM when tested as dimer.140,141 Dulaglutide is an optimized analogue 
of GLP-1 expressed to the N-terminus an IgG4 Fc region. The peptide has been engi-
neered to improve the stability against DPP-4. Further modifications were introduced on 
the Fc region to reduce its affinity for the FcRn and module the effector properties.142 
Both peptibodies have half-lives of approximately three to five days when s.c. injected in 
human, allowing a single administration per week. 
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Figure 19. Comparison of the structure of (left) IgG antibodies, (center) a small therapeutic peptide, and 
(right) a peptibody. Reprinted (open access) from 139, copyright © 2013 Wiley Periodicals, Inc. and the Amer-
ican Pharmacists Association. 
Other peptibodies have reached different preclinical and clinical stages with op-
posing results.139 The most advanced is blisibimod (AMG-623), a B cell-activating factor 
(BAFF) antagonist in phase 3 trial for the treatment of systemic lupus erymatosus.143 It 
is composed of two equally active parts, each carrying four BAFF-binding peptides, fused 
to an IgG1 Fc fragment. The BAFF-binding peptide was selected by phage display and 
cross reacts with both soluble and cell surface BAFF with extremely high affinity (1 pM), 
interrupting its interaction with the three natural receptors.144 The BAFF-peptibody has a 
half-life in human of eight to ten days, shorter than the other anti-BAFF antibodies, but 
in contrast it can be efficiently expressed in bacteria.145 
Another peptibody is trebananib (AMG-386), in which the active peptide was iso-
lated by phage display as inhibitor of angiopoietin-1 and -2, and it blocks their interactions 
with the natural receptor Tie2.146,147 As romiplostim, trebananib presents two tandem 
copies of the peptide fused to an IgG1 Fc fragment and showed a half-life of three to six 
days in human.148 Because of its potent anticancer activity it reached phase 3 trial. How-
ever, these studies were discontinued in 2014 from Amgen without further information.149 
Two other promising peptibodies were developed and entered in clinical trials, but 
no data has recently been reported. The first product was a GLP-1 analogue, named 
CNTO-736, with a significantly prolonged half-life and in vivo efficacy in mice.150,151 The 
second peptibody was CNTO-528, an erythropoietin mimetic peptide discovered from 
phage peptide libraries.152 The peptide was again fused to an IgG1 Fc fragment as either 
a single or a double copy (CNTO-528 and CNTO-530, respectively), and displayed a 
much better activity and half-life than erythropoietin.153,154 In a phase 1 trial, CNTO-528 
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showed a dose-dependent half-life ranging from 1.5 to 7.5 days.153 Preclinical studies 
with CNTO-530 gave similar results in mice.154 
In our laboratory, Angelini et al. developed a peptibody composed of the bicyclic 
peptide UK18 fused to a Fc fragment in the linear format and the cyclized in situ, skipping 
the individual steps of peptide production, cyclization, purification, activation and chemi-
cal conjugation.85 They initially fused UK18 on both Fc monomers, replacing the hinge 
region with a short Gly-Ser linker, and they cyclized the peptide with TBMB (Fig. 20a). 
However, they experienced the formation of different dimers due to a cross-reaction be-
tween the two displayed peptides, and this resulted in a 60-fold reduction in the inhibitory 
activity. Thus, they extended the short Gly-Ser linker testing hinge regions of different 
lengths and they expressed UK18 only on one of the Fc monomers (Fig. 20b). This new 
format proved that the inhibition potency was strictly related to the linker size since longer 
hinge regions had Ki values in the same order of magnitude as the peptide alone.85 The 
half-life of the best heterodimeric peptibody was tested in mice upon intravenous injec-
tion and resulted to be approximately 1.5 days, 72-fold longer than the bicyclic peptide 
alone.71,85 The ELISA assay used for the quantification demonstrated that the peptide 
was fully stable. These results proved that Fc fusion of peptides that need to be chemi-
cally cyclized can be efficiently achieved if appropriate optimizations are introduced in 
the system.85 
 
Figure 20. Chemical macrocyclization of UK18-Fc fusion protein. (a) Schematic representation of UK18-Fc 
homodimer and cyclization reaction of the peptide with TBMB. Two of the nine possible regioisomers are 
shown, including the desired one (lower drawing). (b) Schematic representation of UK18-Fc heterodimer 
and cyclization reaction based of the peptide with TBMB. Only the desired isomer can be obtained. Linkers 
with different lengths were inserted between the peptide and the Fc fragment, using the amino acid sequence 
of the human IgG1 hinge region wherein Cys were replaced by Ser. Adapted with permission from 85, copy-
right © 2012 American Chemical Society.  
In addition to recombinant expression, peptibodies can be created through a chem-
ical conjugation of peptides to both Lys and Cys residues present or recombinantly 
added in the hinge part of the Fc region.139 Mezo et al. demonstrated the feasibility of 
this approach with the atrial natriuretic peptide (ANP). ANP is a natural peptide hormone 
involved in the control of pressure and fluid in the body, characterized by a short half-
life. The peptide was modified with terminal thioester moieties and coupled by native 
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chemical ligation to an IgG1 Fc fragment bearing two free N-terminal Cys residues (Fig. 
21). Similar to other peptibodies previously reviewed, the variation of linker length be-
tween peptide and Fc region resulted in molecules with altered in vitro activity. The de-
veloped monomeric and dimeric conjugates improved the half-life of ANP more than 30-
fold in rats. Nevertheless, the degradation of the linear peptide was much faster than the 
effective half-life of the Fc fragment to which it was conjugated, confirming the superior 
stability of cyclic peptides over linear ones.155  
 
Figure 21. Schematic representation of the semisynthetic method used to generate the ANP-Fc fusion pro-
teins. Reprinted with permission from 155, copyright © 2012 American Chemical Society. 
Despite the high success, the Fc fusion protein strategy still has several limitations 
which makes it less attractive117,138, such as: 
i) difficulties in recombinantly introducing multiple unnatural amino acids in pep-
tide active moieties or for site specific conjugation; 
ii) low protein yield due to the complex production and purification steps, further 
reduced with homo or bispecific dimers, as shown in one of the reported ex-
amples (few milligrams of pure heterodimer product before cyclization)85; 
iii) low tissue penetration for targeting solid tumors due to a relatively large size; 
iv) high cost of production and issues in storage and/or handling; 
v) recombinant engineering often required to remove unwanted ancillary activa-
tions of the immune system when targeting soluble proteins, or to restore the 
proper sites of glycosylation. 
1.2.3.2 Transferrin 
In addition to IgGs and albumin, transferrin has also been exploited as carrier pro-
tein, sharing with them many of the properties and problems. Transferrin is an iron trans-
porter with a molecular weight of 80 kDa that is present in the serum at a relatively high 
concentration. Transferrin has a half-life of between 14-17 days for the aglycosylated 
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form, and 7-10 days for the glycosylated one. Similarly to the two other long-lived serum 
proteins, its half-life is related to a specific receptor-mediated mechanism.93 
As model peptides widely used in almost all of the half-life extension platforms, the 
previously described GLP-1 and exendin-4 were fused to transferrin, leading to the gen-
eration of different conjugates with retained in vivo activity as well as much longer half-
lives in different animal models.156,157 Insulin was also recently fused to transferrin as 
pro-drug and it showed a 15-fold longer half-life in mice and a better activity than the 
approved insulin glargine.158 In addition, transferrin was investigated for its efficient tar-
geting of tumor cells, its potential drug delivery through the blood–brain barrier of chemo-
therapeutics, and potential oral delivery of biologicals.159 The last application has a par-
ticular interest and it has been already investigated. A still functional and intact transfer-
rin-insulin conjugate was detected in rat serum four hours after its oral administration, 
demonstrating the ability of transferrin to pass through the gastrointestinal tract.158 
Table 4. Peptide fusion or conjugation to serum proteins. 
Cargo Serum protein 
Factor Ref. 
Type ?1/2 Type ?1/2 
thrombopoietin 
mimetic peptide 
(romiplostin) 
n.a. 
Fc fusion 
3.5 d (s.c.)a - a 140 
GLP-1 analogue 
(dulaglutide) 1-1.5 hrs (s.c.)
a 4.7 d (s.c.)a 75-113a 
123 
142 
BAFF-binding 
peptide 
(AMG-623) 
n.a. 8-10 d (s.c.)a - a 145 
angiopoietin1- and 
-2 binding peptide 
(AMG-623) 
n.a. 3-6 d (i.v.)a - a 148 
GLP-1 analogue 
(CNTO-736) n.a. 
15-20 hrs (i.v.)b - b 151 
erythopoethin mi-
metic peptide 
(CNTO-528) 
n.a. 1.5-7.5 d (i.v.)a - a 153 
erythopoethin mi-
metic peptide 
(CNTO-530) 
n.a. 40 hrs (s.c.)b - b 154 
bicyclic peptide 
(UK18) 30 min (i.v.)
b 1.5 d (i.v.)b 72b 
85 
71 
atrial natriuretic 
peptide (ANP) 5 min (i.v.)
c Fc conjugation 2.8-5.5 hrs (i.v.)c 34-66c 155 
GLP-1 
(GLP-1-Tf) 
n.a. 
transferrin 
2 d (i.v., s.c.)d - d 156 
n.a. 27 hrs (i.v.)e - e 157 
 
Half-life and factor of improvement were measured for human (a), mouse (b), rat (c), monkey (d) and rabbit 
(e) species. n.a. = not available. 
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1.2.4 Non-covalent binding to serum proteins 
The half-life of peptides can also be prolonged by binding non-covalently to long-
lived serum proteins. Peptides are directly conjugated to high affinity binding moieties, 
such as small molecules or peptides, that tether them to serum proteins after injection, 
thus impairing their renal filtration. The affinity of the reversible ligands determines the 
percentage of free and bound bioactive peptides, balancing the fraction available at the 
target site, non influential if the target is in the plasma, with the fraction saved from clear-
ance.160 This half-life extension platform offers the following advantages over the other 
strategies: 
i) an easier and less expensive chemical synthesis of peptide conjugates 
compared to the time- and cost-consuming production, purification and 
modification of large polymers or proteins; 
ii) a conserved small molecular weight (< 5-10 kDa) which preserves the tis-
sue penetration profile of the free fraction of peptide;  
iii) a site-specific coupling of the ligands with a reduced impact on the activity 
of the bioactive peptides; 
iv) a higher stability in the formulation (storage and handling); 
v) more options as application routes (e.g. oral or nasal administration). 
Numerous types of albumin-binding moieties have been characterized and used 
as ligands, and they will be later described in a dedicated section. In the following para-
graphs I presented several non-covalent binding moieties which bind in the blood other 
plasma proteins than albumin (Tab. 5).  
Peptide binders of IgGs were developed by phage display or mRNA display with 
on average weak affinities, and they were mainly used for purification purposes.161–163 
Delano et al. could isolate a 13-mer cyclic peptide which bound to IgG1 with a Kd of 25 
nM, and partially overlapped with the IgG binding site for the FcRn receptor.161 Since no 
evidence of its use for half-life extension was reported in literature, Sockolosky et al. 
recently tested its genetic fusion to a protein. The resulting IgG-binding peptide conju-
gate could bind only to human antibodies with high affinity, and this required the pre- or 
co-administration of hIgGs in mice for the in vivo experiments. Compared to the protein 
alone, the conjugate showed a 70-fold improved half-life.164  
Different bacterial IgG-binding domains (IgBDs) were recently exploited by Konter-
mann and co-workers as half-life extension strategy. They demonstrated that the binding 
domain with the highest affinity for IgG (SpGC3, 56 amino acid, 6151 Da) could efficiently 
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prolong the half-life of a scDb fusion protein around 18-fold in mice.165 This specific IgBD 
was later modified in order to modulate its binding towards the Fab fragment, avoiding 
any interaction with the Fc region responsible for the FcRn-mediated recycling. Site-di-
rected mutagenesis and phage display resulted in a new variant (SpGC3FabRR, 56 amino 
acid, 6062 Da) with the desired selective binding and further improved half-life in mice.166 
New ligands were developed for a non-covalent binding of the neonatal Fc receptor 
involved in prolonging the half-life of albumin and IgGs. A new class of affinity protein 
based on staphylococcal protein A, called affibody167, was recently screened against hu-
man FcRn by performing phage display at acidic pH.168 Characterization of the isolated 
affibodies demonstrated a nanomolar affinity at pH 6, while a much weaker binding was 
measured at pH 7.4, as desired. Preparation of a fusion protein composed of an affibody 
linked to an albumin-binding construct showed a half-life in mice two to three-fold longer 
than the construct alone. Most likely the half-life of the albumin-binding construct was 
limited by the intrinsic half-life of mouse albumin, while the affibody conjugate overcame 
this bottleneck due to the presence of the double binding partners, confirming the crucial 
role of the FcRn as well.168 In addition to affibodies, phage selected peptides have been 
developed against this specific receptor. A cyclic peptide could efficiently block the inter-
action between FcRn and IgG, bind to the receptor at an acidic pH, and allow the recy-
cling of a fused protein. However, no half-life related applications were reported.169,170 
A few other human serum proteins were or could be exploited for non-covalent 
binding half-life extension. Transthyretin, with a half-life in humans of two days, was used 
for tethering peptides through a reversible small molecule binder (Kd AG10 = 4.8 nM). 
Conjugation of AG10 to a native and proteolytic stable gonadotropin-releasing hormone 
showed a 13- and three-fold longer half-life, respectively, upon i.v. dosing in rats. The 
greater impact on the native form strongly highlights the positive effect of non-covalent 
binding in both peptide half-life and stability.171 
A glycosaminoglycan anticoagulant derivative, which binds the plasma protein an-
tithrombin III with high affinity (Kd idraparinux = 1 nM), was chemically conjugated to 
insulin. Preclinical studies in rats showed a strong improvement in the circulating half-life 
of insulin and no side effects on the coagulation system.172 This insulin conjugate recently 
entered into a phase 1 trial, showing a half-life of three to five hours.173 Since the clinical 
trials of the original binding moiety idraparinux were discontinued due to some long-term 
side effects, potential risks related to this new strategy must be monitored carefully over 
the time.93 Finally, transferrin and its receptor were also targeted by in vitro selections 
resulting in peptides and affibodies with nanomolar affinities. However, none of them has 
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yet been used for potential half-life extension, but only for cell internalization and cancer 
targeting.174–176 
Table 5. Conjugation to plasma protein-binding molecules. 
Cargo Serum protein-
binding mole-
cule (target) 
Conjugate 
Factor Ref. 
Type ?1/2 Affinity ?1/2 
mKate 
(protein) 
5-10 min (i.v.)b 
peptide 
(IgG) 
20-40 nMa 8 hrs (i.v.)b ????a 164 
scDb 
(protein) 
1.3 hrs (i.v.)b 
SpGC3 
(IgG) 
5-6 nMa 
46-67 nMb 
23.3  (i.v.)b 18c 165 
1.3 hrs (i.v.)b 
SpGC3FabRR 
(IgG) 
29-167 nMa 
19-55 nMb 
47.8  (i.v.)b 37c 166 
albumin 
binding 
construct 
(protein) 
33 hrs (i.v.)b 
affibody 
(FcRn)  
12-50 nMa 
90-350 nMb 
61-91  (i.v.)b 2-3c 168 
mKate 
(protein) n.a. 
peptide 
(FcRn) 
1-5 ?M n.a. - 169 170 
GnRH 
(peptide) 3.5 min (i.v.)
c 
AG10 
(transthyretin) 
200-400 nMa 
46 min (i.v.)c 13c 
171 
GnRH-A 
(peptide) 58 min (i.v.)
c 180 min (i.v.)c 3c 
insulin 
(peptide) 
10 min (i.v.)c 
2.3 hrs (s.c.)a 
idraparinux 
(antithrombin III) 
6-96 nMa 
11 hrs (i.v.)c 
3-5 hrs (s.c.)a 
66c 
1.5-2.5a 
111 
172 
173 
- - 
peptide (trans-
ferrin receptor) 
15 nMa - - 174 
- - 
affibody 
(transferrin) 
400 nMa - - 175 
- - 
peptide 
(transferrin) 
70-120 nMa - - 176 
Half-life, affinity and factor of improvement were measured for human (a), mouse (b), and rat (c) species. 
n.a. = not available. 
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1.3 - Albumin as platform for half-life exten-
sion 
Peptides have tipically short plasma half-life and several extension technologies 
have been developed so far to solve this limitation, as previously illustrated in the second 
section. Among them, there has been a lot of interest lately in exploiting serum albumin 
to modulate the pharmacokinetic properties of a variety of peptides and small mole-
cules.177 Albumin is an interesting protein candidate since it possesses intrinsic biochem-
ical and biophysical properties that make it perfectly suitable for new clinical and phar-
maceutical applications.178 This third section will highlight the main features of albumin, 
including its exquisite drug carrier properties for the half-life extension of peptides, which 
is the main goal of the research project presented in this thesis. 
1.3.1 Structural properties 
Albumin is the most abundant protein in plasma (40 g??-1, 600 ?M) with a molecular 
weight of 66.5 kDa. It is a non-glycosylated single polypeptide chain comprising 585 
amino acids in the mature form. It contains 17 disulfide bridges that contribute to its sta-
bility and a single odd Cys residue in position 34, which alone makes up 80% of the free 
thiols in plasma. Its amino acid composition is characterized by a high percentage of 
ionic amino acids, with 83 and 98 positively and negatively charged residues, respec-
tively (UniProtKB - P02768). The resulting negative net charge highly increases its solu-
bility in aqueous solution.178  
The secondary structure of albumin is composed of 67% ?-helix without any ?-
sheet element. The tertiary structure is organized as a monomer with a globular heart-
shape and dimensions of 80 x 80 x 30 Å. Albumin is ordered in three homologous do-
mains, named I (1-195), II (196-383) and III (384-585), with similar amino acid sequences 
and structures.179 Despite these similarities, each domain has peculiar interactions with 
the others and the relative orientations create an asymmetric module that allocates sev-
eral ligand binding sites (Fig. 22).  
Each domain contains two subdomains, denominated A and B, with four and six ?-
helices, respectively. The overall structure is extremely stable over a wide range of pH 
from 4.0 to 9.0,179 though its fold and shape are pH dependent.180 In the pH range 4.3-
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8.0 albumin conserves its neutral (N) heart-shaped form. Below pH 4.3, albumin under-
goes a transition to a fast-migrating (F) form that has a lower helical content and de-
creased solubility. Further reducing the pH to values lower than 2.7 causes a transition 
to the extended (E) form, which seems to resemble a molten globule state. Above pH 
8.0, a transition to the basic (B) form displays, again, a lower helical content but, in con-
trast, higher binding affinity for some molecules. A full denaturation of albumin can occur 
only through the application of very harsh conditions related to dramatic changes in pH 
and temperature, or through prolonged incubation with chaotropic agents.180 
 
Figure 22. Crystal structure of human albumin. The illustration shows the tertiary structure of human albumin 
in complex with stearic acid (PDB: 1e7e). The three domains of albumin are shown in purple (IA), red (IB), 
green (IIA), orange (IIB), blue (IIIA), and violet (IIIB). Yellow sticks depicture disulfide bridges, and yellow 
spheres highlight the available Cys 34 in domain IA. Reprinted (open access) from 181, this article is available 
under the terms of CC-BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
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1.3.2 Metabolism and receptors 
The plasma concentration of albumin is the result of a sophisticated equilibrium 
among different synthesis, degradation and distribution mechanisms in the body. Albu-
min is produced in the liver in an amount of around 10-15 grams per day. A healthy 
person of 70 kilograms has approximately 360 grams of albumin, one third of which is 
located in the blood and the remaining is in the extravascular compartment. 80% of this 
second protein pool is distributed between muscles and skin. Several tissues daily catab-
olize an amount of albumin that is comparable to the produced one, and this leaves a 
maximum circulatory half-life of 19 days.177,178,182 
The long half-life of albumin is mainly related to its structural properties and the 
ability to binding the neonatal Fc receptor. Molecular weight and net negative charge are 
the key properties that limit albumin renal elimination, while the pH-dependent recycling 
process mediated by the receptor avoids intracellular lysosomal degradation.132 Muta-
genesis and co-crystallization studies revealed that the binding site for FcRn is localized 
on domain III, and it does not overlap with the IgG binding site on the receptor. The 
residues important for the interaction with FcRn are four His, one in the FcRn (H166) and 
three on albumin (H464, H510 and H535), and four Trp in the FcRn (W51, W53, W59 
and W61), revealing that the binding is both pH and hydrophobically driven.183,184  
Interestingly, the FcRn receptor is also involved in the rescue of albumin from the 
glomerular filtration.132,177 Every day, several kilograms of albumin passes through the 
kidney, but only three to six grams are filtered out in the glomerulus, with less than 1% 
that actually enters into the urine. Nearly all of this filtered fraction is recovered by the 
FcRn, which acts in the kidneys by a transcytosis process that transports albumin 
through the cytoplasm of the cells and releases it back into the blood.132,177 In addition to 
FcRn, the megalin/cubilin complex is also involved in albumin reabsorption from renal 
excretion. Cubilin is a glycoprotein anchored to the membrane that lacks its own intra-
cellular domains for endocytosis, which are added through an interaction with megalin. 
The resulting complex has high affinity for albumin and it is capable of performing the 
desired transcytosis process.177,181 
In addition to these receptors, albumin can bind to three glycoprotein receptors 
(gp18, gp30 and gp60) also responsible for its recycling, degradation and intracellular 
transport.177,181 Gp18 and gp30 are two receptors that display high affinity for the non-
native or modified albumin, which is in this way internalized and degraded in the lyso-
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somes. This suggests a specific role of these receptors as scavengers for old, de-
naturated and non-functional albumin and other proteins.177,181 In contrast, gp60/albondin 
is a receptor that binds only the native albumin. It is mainly present in the vascular en-
dothelium and takes part in the transcytosis process of albumin. Upon binding, the albu-
min-gp60 complex interacts with caveolin-1 and together they form vesicles assigned for 
the transport of albumin to the other side of the endothelial cells.177,181  
All of these receptors contribute to albumin homeostasis and long half-life in hu-
mans, allowing it to take part in numerous physiological activities. The multitasking prop-
erties of albumin, in this way, are directly contrasted with other plasma proteins, which 
tend to exert a single specific function.179  
1.3.3 Physiological functions  
The main physiological role of albumin in the blood is to preserve the colloid os-
motic pressure (COP). Molecular weight, high concentration and overall negative charge 
are critical for conserving and attracting water into the bloodstream, maintaining blood 
volume and pressure.179,182 The presence of almost 200 charged residues in its se-
quence also determines its role as a pH plasma buffer, while the sulfhydryl group of 
Cys34 acts as antioxidant scavenger for several radicals. Other effects on the vascular 
structure and dilatation as well as on blood coagulation are documented.179,182 
Another important function of albumin is its capacity of binding, and transporting, a 
broad range of endogenous and exogenous compounds in a covalent and non-covalent 
manner.179 These compounds include therapeutic drugs, fatty acids, bilirubin, hemin, 
hormones, peptides, protein domains, metal ions, divalent cations, nitric oxide and many 
others.178,179 Their ability to bind to albumin is often univocal and characterized by high 
affinity and binding site selectivity at low concentrations. Nevertheless, secondary un-
specific binding sites are also present. All together, they modulate the solubility, metab-
olism and distribution of these ligands, affecting their pharmacokinetic profiles.177,179 
Both covalent and non-covalent binding to albumin are nowadays widely exploited 
and they make it a suitable carrier for several different therapeutics. In particular, the 
capacity of albumin to extravasate from the bloodstream, reaching the lymphatic system 
and accumulating in cancerous or inflamed areas, arose a strong clinical interest for ex-
tending the half-life of peptides and oncology drugs using albumin as platform.185 
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1.3.4 Fusion or conjugation to albumin 
Compared to PEGylation and Fc conjugation extension strategies, fusion to albu-
min (Fig. 23) gained a certain interest only in the 1990s, and so far a single drug based 
on this format reached the market.117 Albiglutide (formely Albugon, Tanzeum (US) or 
Eperzam (EU), GSK) is composed of two copies of a DPP-4-resistant GLP-1 analogue 
genetically fused to human albumin, and is used to treat type 2 diabetes. The dimer was 
introduced to reduce the negative impact of the fusion on peptide’s potency, and this 
dimeric format displayed the same effects as the native peptide in animal models. The 
conjugate has a half-life of five to seven days in human, which doubles that of the GLP-
1 peptibody dulaglutide, allowing for once a week s.c. injection.186 
 
Figure 23. Genetic fusion to albumin. Schematic structure of a representative albumin fusion protein Al-
buferon. Adapted with permission from 187, reprinting license nr. 4047510754542, copyright © 2016 Royal 
Society of Chemistry. 
There are currently several examples of peptides fused to the N- and C- termini of 
albumin (Tab. 6). However, the majority of fused products are still proteins, such as cy-
tokines, coagulation factors and antibody fragments.117 Among peptides, one interesting 
example consists on the genetic fusion to albumin of the B-type natriuretic peptide (BNP). 
The peptide was fused as a single copy at the N-terminus of human albumin, showing a 
strong loss in potency. Therefore, it was prepared as dimer to compensate the reduced 
activity. The final BNP construct showed a retained activity and an increased half-life in 
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mice, and improvements up to 200 to 400-fold were seen, depending on the route of 
administration.188 
Insulin was also genetically fused to albumin. The two A and B chains of insulin, 
linked naturally by two disulfide bonds, were instead connected by a short linker and 
fused to the N-terminus of albumin as single-chain analogue. The resulting conjugate 
retained insulin activity and had an increased half-life of up to seven hours in mice.189 
Recently, a tandem copy of exendin-4 fused to albumin displayed a 90-fold longer half-
life in monkeys compared to its native counterpart.190 
When recombinant fusion is not possible, peptides can be covalently attached to 
albumin through chemical conjugation (Fig. 24). This technique mainly exploits either the 
free thiol group of Cys34 through maleimide coupling or non-specific modifications of the 
Lys residues present on the surface of albumin. Kratz and co-workers developed a new 
strategy for albumin conjugation either directly in vivo, called the Drug Affinity Complex 
(DAC™), or just before injection, known as Preformed Conjugate-Drug Affinity Complex 
(PC-DAC™). The rational behind this strategy was the linkage of drugs with reactive 
moieties that can covalently bind albumin in a site-specific manner.185 This technique 
was successfully applied to numerous peptides. The most advanced drug is an exendin-
4 maleimide derivative that was conjugated to albumin (CJC-1134-PC), and showed an 
increased half-life to approximately eight days in human upon s.c. administration.191 An-
other group conjugated an analogue of enfuvirtide, a 36 amino acids linear peptide in-
hibitor of HIV-1 fusion, to albumin, exploiting maleimide as thiol reactive group. The final 
albumin conjugate had a half-life between nine to 15-fold longer in monkeys and rats, 
respectively.192 
 
Figure 24. Chemical conjugation to albumin. Schematic description of in vivo thiol–maleimide conjugation. 
Adapted with permission from 187, reprinting license nr. 4047510754542, copyright © 2016 Royal Society of 
Chemistry. 
Different criteria are used to determine the most suitable strategy to apply for 
peptides between fusion and conjugation to albumin, such as applicability to drug pipe-
line, site of modification, expression system and other manufacturing considerations. 
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However, both options are more versatile than Fc fusion proteins and solve some of their 
previously discussed limitations (sub-section 1.2.3). The monomeric structure of albumin 
and the absence of glycosylation sites facilitate the recombinant production in non-mam-
malian cells, provide an easier purification, and ensure the homogeneity of the prod-
ucts.93 More accessible modification sites, usually far from each other in the sequence, 
allow for an easier creation of bispecific conjugates with reduced risks of cross-reactiv-
ity.193–195 The absence of effector functions reduces unwanted activation of the immune 
system, while the smaller size allows for a higher tissue penetration.185 Nevertheless, 
these covalent strategies with both IgGs and albumin still share some critical prob-
lems117,133 that include:  
i) limited parenteral routes of administration, mainly i.v. and s.c.; 
ii) loss of activity of fusion partners due to steric hindrance, not always res-
cued using different linker length, flexibility/rigidity, and positioning;  
iii) preparation of new therapeutic entities and drug formulations that could in-
troduce immune responses against the native protein; 
iv) candidates with low solubility and stability, and a high risk of aggregations, 
which are all potentially concomitant causes of immunogenicity, 
v) lack of novelty and relatively difficult to covering with a patent. 
The main disadvantages here underlined can be solved with smaller half-life ex-
tension platforms, as described in sub-sections 1.2.4 and 1.3.5. 
Table 6. Peptide fusion or conjugation to albumin. 
Cargo Albumin 
Factor Ref. 
Type ?1/2 Type ?1/2 
GLP-1 analogue 
(albiglutide) 1-1.5 hrs (s.c.)
a 
albumin 
fusion 
5-7 d (s.c.)a 80-120a 123 186 
B-type natriuretic 
peptide (BNP) 3 min (n.a.)
b 
11 hrs (i.v.)b 
19 hrs (i.v.)b 
220-380b 188 
insulin 
(albulin) n.a. 
7 hrs (i.v., s.c.)b - b 189 
exendin-4 
(E2HSA) 0.6 hrs (s.c.)
c 53.4 (s.c.)c 89c 190 
exendin-4 
(CJC-1134-PC) 2.5 hrs (s.c.)
a 
albumin 
conjugation 
8 d (s.c.)a 77a 125 191 
enfuvirtide ana-
logue (C34) 
1.7 hrs (i.v.)d 
??????????????c 
25.8 hrs (i.v.)d 
102.4 hrs (i.v.)c 
15d 
9c 
192 
Half-life and factor of improvement were measured for human (a), mouse (b), monkey (c) and rat (d) species. 
n.a. = not available. 
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1.3.5 Non-covalent binding to albumin  
As discussed in sub-section 1.2.4, the half-life of peptides in blood can also be 
prolonged by tethering them non-covalently to long-lived serum proteins, such as albu-
min. From a therapeutic point of view, the capacity of albumin to act as a non-covalent 
“taxi” for a huge plethora of exogenous and endogenous molecules can be exploited for 
prolonging the half-life of peptides.93,160 The choice of a reversible binding strategy 
should allow an easy and efficient control of the fraction of active drug that still conserves 
a reasonable clearance time.160 Characterization of the binding pockets of these mole-
cules distributed in the three domains of albumin provides a solid base for the develop-
ment of newly designed albumin-binding ligands to use as extension tags (Tab. 7).177  
1.3.5.1 Albumin binding sites  
In the 1970s, Sudlow and co-workers characterized the two most significant bind-
ing sites of albumin that are available for the interaction with a high number of com-
pounds.98,196 The Sudlow’s site I, named warfarin-azapropazone binding site, is a pocket 
composed of the six helices of subdomain IIA. This binding site generally accomodates 
dicarboxilic acids and/or bulky heterocyclics carrying a central negative charge. It con-
tains the only Trp residue of albumin (W214) and it is characterized by two clusters of 
polar residues, located at the bottom (Y150, H242 and R257) and at the entrance (K195, 
K199, R218 and R222) of the pocket. All ligands of the site I interact with the hydroxyl 
group of Y150, and they can potentially make two other hydrogen bonds with H242 and 
either K199 or R222 (Fig. 25a).98,196 
The Sudlow’s site II, also known as the benzodiazepine binding site, is similar to 
site I and it is composed of six helices of subdomain IIIA. It is smaller and less flexible 
than site I, and can discriminate ligands based on their size and stereoselectivity. Site II 
generally accommodates aromatic carboxylic acids with a peripheric negative charge 
that is located distantly from the hydrophobic center of the molecule. The pocket is again 
apolar with a single polar cluster located near the entrance (Y411, R410, K414 and 
S489). Ibuprofen and diazepam, the two main ligands of site II, recognize the hydroxyl 
group of Y411 while the other residues contribute to the formation of salt-bridges and 
hydrogen-bond interactions (Figure 25b).98,196 
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Figure 25. Schematic representation of (a) warfarin bound to Sudlow's site I, and (b) ibuprofen bound to-
Sudlow's site II. Drug carbon atoms are colored in green and backbone atoms of the residues building up 
the sites are colored in yellow. Adapted with permission from 196, reprinting license nr. 4047530294372, 
copyright © 2010 Elsevier B.V. All rights reserved. 
The two Sudlow’s sites partially overlap with the binding pockets of the best known 
albumin ligand, namely fatty acids.197 Fatty acids act in numerous metabolic processes, 
such as in the synthesis of cellular membranes, they function as hormones and second-
ary messengers, and they serve as a reservoir of energy. Fatty acids are composed of 
a medium-long carbon chain with a negatively charged carboxylic head at one end.198 
Flexible and straight fatty acids lacking carbon-carbon double bonds are defined as sat-
urated. In contrast, the presence of one or multiple double bonds makes unsaturated 
fatty acids, which are further divided into cis or trans configurations. The double bond 
positions are indicated as ? (from methyl end) or ? (from carboxylic end). Saturated 
myristic, palmitic and stearic acids with 14, 16 and 18 carbons, respectively, are the most 
common fatty acids found in animals and they are daily introduced with the diet.198   
One mole of albumin usually transports up to two moles of fatty acids, shielding 
their hydrophobic character and strongly increasing their sub-micromolar solubility in 
plasma.197 The fatty acid-binding properties of albumin were analyzed in the mid-1970s 
by Spector. With relatively limited information, he could review the presence of five bind-
ing sites for saturated and unsaturated fatty acids containing 6 to 18 carbons.199 Each 
fatty acid binds the five sites with a different association constant (Ka), and a clear cor-
relation between the length of the side chain and the affinity was reported. Short-medium 
fatty acids (6 to 12 carbons) bound albumin with Kd values between 60 and 0.5 ?M, while 
the longest ones (14 to 18 carbons) had ten-fold higher affinities for albumin (Kd values 
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below 50 nM).199 The high binding affinity of the myristic acid (C14) for human albumin 
was recently confirmed by Kragh-Hansen et al..200
The position of these binding sites was revealed by Curry and co-workers who 
crystalized albumin in complex with five saturated fatty acids containing 10 to 18 carbons. 
They showed that fatty acids can bind up to seven different binding sites on albumin, and 
the shortest one with 10 carbons had two additional binding pockets (Fig. 26).197 The 
common binding sites are distributed in the three domains as follows: site 1 in subdomain 
IB, site 2 at the interface between subdomains IA and IIA, site 3 and 4 in subdomain IIIA 
(Sudlow's drug-binding site II), site 5 in subdomain IIIB, site 6 at the interface between 
subdomains IIA and IIB, and site 7 in subdomain IIA (Sudlow's drug-binding site I). Equal 
mechanisms of binding were observed for the first five sites, with the carboxylic acid 
interacting with basic and polar residues independently from the length of the chain and 
the size of the hydrophobic cavities. In contrast, the acid moiety does not play a role in 
the binding sites 6 and 7, which then consist solely of a hydrophobic binding pocket.197  
 
Figure 26. Structures of albumin complexed with five different fatty acids. The protein secondary structure 
is shown schematically and the domains are color-coded as follows: I, red; II, green, III, blue. The A and B 
sub-domains are depicted in dark and light shades, respectively. Bound fatty acids are shown in a space-
filling representation and colored by atom type (carbon, grey; oxygen, red). Reprinted with permission from 
197, reprinting license nr. 4047530712891, copyright © 2000 Academic Press. All rights reserved. 
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1.3.5.2 Albumin-binding ligands 
Fatty acids are the most exploited endogenous ligand of albumin used for half-life 
extension. So far, the lipidation of peptides was the only non-covalent strategy that has 
led to the development of three approved drugs. These peptide drugs are insulin and 
GLP-1 derivatives currently on the market for the treatment of type 1 or 2 diabetes and 
obesity: insulin detemir (Levemir, Novo Nordisk), liraglutide (Victoza, Novo Nordisk) and 
insulin deglutec (Tresiba, Novo Nordisk).99 Lipidated peptides approved or under inves-
tigation and relative limitations will be described in the sub-sections 1.3.6 and 1.3.8.  
Other endogenous molecules used as albumin binders are bile acids. When con-
jugated to insulin, they showed a certain degree of affinity for albumin and formed s.c. 
deposits that were gradually released in the blood, displaying a glucose-control activity 
longer than 24 hours in pigs.201 However, both fatty acids and bile acids show relative 
weak affinities for albumin and low solubilities that severely limited their application to 
several peptide drugs.99,202 
Organic binding moieties structurally similar to exogenous drugs (e.g. warfarin, ib-
ruprofen and diazepam) have been also generated for non-covalent interactions with 
albumin. Genentech coupled several organic compounds, based on sulfonamide or 
phosphate ester moieties, to a peptide inhibitor of the coagulation factor VIIa.202,203 The 
best conjugate could tightly bind albumin and improved the in vivo half-life up to 46-fold 
in rabbits.203 
Other albumin ligands resembling the structures of fatty acids or small molecules 
have been identified by Neri and co-workers from the screening of DNA encoded chem-
ical libraries.204,205 Even though sub-nanomolar albumin binders have been recently iso-
lated from these libraries, only a few 4-(p-iodophenyl) butyric acid derivatives were so 
far characterized in vivo.204 The best molecule had a high nanomolar affinity for human 
albumin, and could efficiently prolong the half-life of small molecules or recombinant pro-
teins.204,206,207 The attachment of this molecule to two contrast agents increased their 
half-life of approximately 50 to 100-fold in mice.204 This compound was also conjugated 
to a tumor-targeting ligand, composed of folic acid and DOTA chelator, and to an engi-
neered scFv antibody fragment, translating into longer half-lives and higher tumor uptake 
in mice models.206,207 
Alternatively to small molecules, an increasing number of peptides and protein do-
mains have been used as albumin-binding molecules. A few peptides were isolated from 
phage selection against albumin, but only one of them exhibited a binding affinity suitable 
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for in vivo experiments.208,209 Dennis et al. developed a cyclic peptide, named SA21, 
which was fused to a Fab fragment and prolonged its half-life more than 25 times in 
rabbits and mice.208 The peptide was later applied to other small proteins and it showed 
promising preclinical results.210,211 The development of SA21, its conjugation to a bicyclic 
peptide and the related issues experienced in our laboratory will be further discussed in 
the sub-sections 1.3.7 and 1.3.8.  
Several albumin-binding domains (ABDs) were discovered in bacterial proteins. So 
far, the best characterized ABD derives from the streptococcal G protein G148-GA3, 
which is actually composed of three IgG and three albumin binding domains.212 The af-
finity for albumin of one of the three ABDs was strongly improved by phage display and 
rational design, reaching Kd values in the femtomolar range for human albumin.213 De-
spite a relatively small size (46 amino acid, 5110 Da), this high-affinity ABD variant 
(ABD035) positively impacted on the pharmacokinetics of various proteins at which it 
was recombinantly fused.214–217 In contrast with the results obtained using fatty acids or 
albumin-binding peptides218,219, the capacity of ABD of prolonging the half-life of conju-
gates does not correlate with increased binding affinities for albumin, suggesting an in-
trinsic limit connected to either the FcRn-mediated recycling or albumin half-life.220 
In a recent study, Levy et al. compared two exendin-4 conjugates obtained by ap-
pending to its C-terminus either the optimized ABD035 (46 residues) or a shorter version 
of the peptide SA21 (11 residues).221 Exendin-4 modified with SA21 had a ten-fold higher 
potency than the ABD variant, probably related to a different steric hindrance that played 
a bigger role in the ABD conjugate with the highest affinity for albumin. In contrast, a 
much weaker binding affinity of SA21 for albumin strongly impacted on conjugates’ phar-
macokinetics in monkeys, and gave half-lives of two and 14 days for SA21 and ABD 
variants, respectively, counterbalancing the reduction in activity.221  
A more recent trend is the development of albumin-binding antibodies. Phage dis-
play selections against albumin led to the isolation of fully human domain antibodies 
(AlbudAbs) with a high binding affinity for albumin and half-lives similar to that of albumin 
itself (?1/2 = 24 vs. 35 hrs of mouse albumin; ?1/2 = 43-53 vs. 53 hrs of rat albumin).222 This 
platform was already applied to exendin-4, creating a molecule (GSK2374697) that had 
a half-life from six to ten days in a phase 1 trial in human.223 Similarly, scFvs and nano-
bodies (fragments based on the variable domains of camelid heavy chain antibodies) 
were also developed as albumin binders with promising results.224–226 
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Table 7. Conjugation to albumin-binding molecules. 
Cargo Albumin-binding 
molecule 
Conjugate 
Factor Ref. 
Type ?1/2 Affinity  ?1/2 
insulin 
(peptide) 
2.3 hrs (s.c.)a 
myristic acid 4.2 ?Ma 5-7 hrs (s.c.)a 2-3a 99 
111 
227 
228 
? glu-hexadecenoic 
diacid 
1.8 ?Ma 25 hrs (s.c.)a 11a 
GLP-1 
(peptide) 
1-1.5 hrs 
(s.c.)a ? glu-palmitic acid n.a. 
11-15 hrs 
(s.c.)a 
7-15a 99 123 
insulin 
(peptide) 
n.a. 
cholic acid 
derivatives? 13 ?Ma n.a. - 201 
fVIIa 
inhibitor 
(peptide) 
7.6 min (i.v.)b 
naphthalene acyl-
sulfonamide 
n.a. 30 min (i.v.)b 4b 202 
4.8 min (i.v.)b 
diphenylcyclo-hexa-
nol phosphate ester 
n.a. 222 min (i.v.)b 46b 203 
fluorescein 
(chemical) 4.6 min (i.v.)
c 
6-(4-(p-iodophenyl) 
butanamido) 
hexanoate 
108-330 
nMa 495 min (i.v.)
c 108c 
204 
Gd-DTPA 
(chemical) 8.6 min (i.v.)
c 3.3 ?Ma 408 min (i.v.)c 47c 
scFv 
(protein) 
20-30 min 
(i.v.)c 
3.2, 3.6 
?Ma,c 16.6 hrs (i.v.)
c 33-50c 206 
Fab 
(protein) 
53 min (i.v.)b 
SA21 
467, 320, 7,  
266 nMa,b,c,d 
Similar to 
SA21b 
32.4 hrs (i.v.)b 37b 
208 
24 min (i.v.)c 10.4 hrs (i.v.)c 26c 
UK18 
(peptide) 30 min (i.v.)
c 
321-354 
nMa 
14-24 nMc 
24-27 hrs 
(i.v.)c 
48-54c 71 
exendin-4 
(peptide) 
30 min (i.v.)d 
1560, 210, 
610 nMa,d,e 
11 hrs (i.v.)d 
2 d (i.v.)e 
22d 
- e 
221   
ABD035 
16, 18, 123 pMa,d,e 
 
5, 8, 40 
pMa,d,e 
16 hrs (i.v.)d 
14 d (i.v.)e 
32d 
- e 
2.5 hrs (s.c.)a AlbudAbs 
34-600 
nMa,c,d 
6-10 d (s.c.)a 58-96a 222 223 
anti-IL-6R 
(nanobody) 4.3 hrs (i.v.)
e nanobody 22 nMa 5-6.6 d (i.v.)e 28-37e 224 
Fab 
(protein) 0.5 hrs (i.v.)
c scFv 
5, 162, 7, 
3, 54 
nMa,b,c,d,e 
84.2 hrs (i.v.)c 168c 225 
Fab 
(protein) 
1.8-4 hrs (i.v.)c 
n.a. 
scFv 
3, 4, 3 
nMa,c,e 
62 hrs (i.v.)c 
8 d (i.v.)e 
16-34c 
- e 
226 
Half-life, affinity and factor of improvement were measured for human (a), rabbit (b), mouse (c), rat (d) and 
monkey (e) species. n.a. = not available. 
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1.3.6 Lipidation of peptides 
The physiological metabolism of fatty acids as well as their ability to bind albumin 
with a high affinity inspired the use of post-translational acylation as a safe and natural 
platform for prolonging the half-life and the mode of action of peptides and small proteins. 
So far, this strategy was successfully exploited by the Danish pharma company Novo 
Nordisk that launched three acylated peptide drugs on the market for the treatment of 
diabetes and obesity.99 
Kurtzhals et al. pioneered the development of the first clinically available acylated 
insulin analogue in 1995.227 Lys29 in the B chain of insulin was conjugated to different 
saturated fatty acids (10-16 carbons), and Thr30 was removed. The insulin analogue 
carrying the C14 myristic acid [LysB29-tetradecanoyl des(B30) insulin] bound albumin with 
Kd values of 4.2 and 10 ?M at 25°C and 37°C, respectively, which was two to three orders 
of magnitude lower than free fatty acids (Fig. 27a). Subcutaneous injection of this C14 
conjugate in rabbits resulted in a prolonged effect on blood-glucose levels.227 Similar 
results were confirmed in pig experiments and showed an important correlation between 
binding affinity for albumin and in vivo half-life.218 In addition, its binding affinity was un-
affected by the co-presence of potential competitors, such as free fatty acids and several 
well-known albumin-binding drugs.229 This myristoylated insulin analogue was approved 
in 2004 as insulin detemir (Levemir) for the treatment of type 1 diabetes. The drug has a 
half-life of five to seven hours upon s.c. injection in human, which is 50 to 100-fold longer 
than insulin alone in blood (four to six minutes, i.v.; 2.3 hours, s.c.)110,111, allowing either 
once or twice-daily dosing.230 The half-life prolongation is not exclusively related to its 
ability to bind albumin in blood circulation, but is also associated with the route of admin-
istration and the formulation. In presence of phenol and Zn2+, insulin detemir self-assem-
bles into hexameric–dihexameric units, protracting its blood absorption from the subcu-
taneous deposit site.231 
Ten years later, Jonassen et al. developed a longer-acting acylated insulin for 
once-daily injection.228 The new insulin analogue, approved as insulin degludec 
(Tresiba), conjugated a longer 16 carbons dicarboxylic fatty acid to the LysB29 through 
a ?-Glu linker, thus introducing two net negative charges (Fig. 27c) that led to improved 
affinity and solubility. Insulin deglutec has a 2.4-fold stronger affinity for albumin than 
insulin detemir at 25°C, and a much larger oligomerization upon s.c. injection thanks to 
the terminal carboxylic acid.228 These changes resulted in a half-life of 25 hours in hu-
mans and a glucose-lowering effect that persisted for more than 42 hours, giving one the 
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best pharmacokinetic and pharmacodynamic profiles among the currently approved in-
sulin formulations.232  
As broadly reported in the previous section, the improvement of the GLP-1 half-life 
is of great interest and several extension platforms have been successfully applied. Ac-
ylation also led to the approval of liraglutide (Victoza) in 2009, a once-daily GLP-1 ana-
logue used in the treatment of type 2 diabetes and later obesity.123 Knudsen et al. per-
formed a structure-activity relationship (SAR) study of 36 acylated analogues of GLP-1, 
varying i) peptide sequence, ii) site of modification, iii) fatty acid, and iv) linker. Several 
derivatives were equipotent or better than GLP-1, and showed a more than ten-fold pro-
longed half-life in pigs upon s.c. injection.123 Among them, the future liraglutide retained 
the potency of GLP-1 and resulted in promising pre-clinical studies in animals. The final 
structure is composed of GLP-1 conjugated to Lys26 with a 16-carbon palmitic acid via 
a ?-Glu linker, and with the Lys34 replaced by Arg (Fig. 27b).233 A direct measurement 
of its affinity has not been performed, but dialysis studies confirmed a strong albumin 
binding.234 The half-life in human has been calculated as eight hours and 11-15 hours 
upon i.v. and s.c. injection, respectively, a remarkable improvement compared to the 
native GLP-1 (1.5 minutes, i.v.; 1-1.5 hours, s.c.).123,235 As with insulin analogues, the 
long half-life of liraglutide is also related to self-association with a slow release from the 
site of injection. In addition to this, a reduced susceptibility to enzyme degradation was 
noted, probably due to an albumin protective effect upon binding.235 
These positive results stimulated research into new variants of insulin and GLP-1, 
and expanded the acylation strategy towards other peptides. Recently, Novo Nordisk 
developed a new analogue of GLP-1, semaglutide, and the documents for its approval 
have been recently submitted to the FDA.236 Starting from the sequence of liraglutide 
and applying the same criteria of optimization, Lau et al. synthesized 45 new variants. 
They tested i) longer fatty acids or diacids, as done with insulin deglutec, ii) different 
linkers between Lys26 and fatty acids, and iii) new amino acid substitutions for increasing 
the enzymatic stability against DDP-4.237 The selected candidate semaglutide was mod-
ified at Lys26 with a octadecanoic diacid (18 carbons and two carboxylic acids) through 
a long linker composed of two 8-amino-3,6-dioxaoctanoic acid (O2Oc) units and a ?-Glu 
(Fig. 27d). It also has Ala8 substituted by the unnatural amino acid 2-aminoisobutyric 
acid. By applying only these few modifications, semaglutide displayed much better prop-
erties than liraglutide, similarly to what has been already observed with insulin detemir 
and insulin deglutec. Despite a lower binding for the receptor, the potency of semaglutide 
was still equivalent to GLP-1 and liraglutide. Its binding affinity for albumin was six-fold 
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stronger than liraglutide providing semaglutide with a four-fold longer half-life in pigs 
upon i.v. injection, and a 48 hour lowering-effect on blood glucose in mice after s.c ad-
ministration.237 In humans semaglutide showed a half-life of 155-185 hours, ten and 100-
fold longer than liraglutide and GLP-1, respectively, allowing once weekly s.c. dosing.238 
 
Figure 27. Examples of lipid moieties used for half-life extension of biopharmaceuticals. (a) Myristic acid 
(insulin detemir). (b) Palmitic acid linked to a ?-Glu linker (liraglutide). (c) Hexadecanoic diacid with a ?-Glu 
linker (insulin degludec). (d) Octadecanoic diacid coupled to a linker consisting of ?-Glu and two 8-amino-
3,6-dioxaoctanoic acid units (semaglutide). Reprinted with permission from 99, reprinting license nr. 
4047140757234, copyright © 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. 
Several other peptides were modified with acylated moieties and showed promis-
ing pre-clinical results. A pancreatic polypeptide was modified with the ?-glu-C16 fatty 
acid moiety used in liraglutide. It exhibited retained in vitro stability and affinity for the 
receptor, and a seven-fold longer half-life in rats upon i.v. injection.239 Insulin end exen-
din-4 were modified with a 16-carbon hexadecanoic acid terminating in a sulfonate anion. 
The derivatives had better affinity for albumin and much higher solubility than insulin 
detemir. This translated into five to ten-fold prolonged glucose-lowering effects in mice 
after both i.v. and s.c. administration.240 The same acylated motif used for semaglutide 
was also applied to insulin on Lys22, increasing the number of fatty acid carbons to 22. 
The resulting conjugate, called insulin-327, showed interesting liver-specific effects in 
dogs and a prolonged half-life.241 Several other lipidated peptides and small proteins 
were differently acylated, such as neuromedin U, a GLP-1/GIP co-agonist, calcitonin, 
oxyntomodulin, human growth hormone and others, providing derivatives with enhanced 
pharmacokinetic profiles.99 
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Finally, an innovative combination of fatty acids and glyco moieties was recently 
proposed by Jensen and co-workers for extending the half-life of GLP-1.242 The improved 
backbone of liraglutide was conserved and Lys26 was modified with one or two units of 
mucic acid, a galactose derivative, linked to three different fatty acids via a ?-Glu linker. 
All of the new conjugates had activity and solubility in the same range of GLP-1 and 
liraglutide, and could form oligomers as well. The apparent binding affinities for albumin 
were approximately 1-2.5 ?M for all of the glycolipidated peptides, equivalent to what 
they measured for liraglutide, and this translated into comparable in vivo pharmacologi-
cal effects after s.c. dosing in mice.242  
1.3.7 Albumin-binding peptides 
Albumin is known to bind not only low molecular weight molecules but also pep-
tides and proteins, such as insulin, bradykinin and interferons, and several hundreds of 
other binders were identified or predicted.243,244 This observation suggested the applica-
tion of in vitro techniques for the screening of peptides that can bind albumin with a high 
affinity and can be used as carriers for half-life extension.208,209 Differently from chemical 
small moieties, albumin-binding peptides can be easily fused to any protein or peptide, 
either recombinantly or chemically during solid-phase synthesis.160  
Towards this goal, in 2002 Dennis et al. used phage display to isolate peptides, 
with two fixed Cys residues and varying loop sizes, that bind albumin with high affinity.208 
They selected several disulfide cyclized binders for rabbit, rat and human albumin, and 
a clone sharing a high binding for all of the three species was further subjected to affinity 
maturation. The best albumin binder was an 18 amino acid peptide called SA21 (Ac-
RLIEDICLPRWGCLWEDD-NH2). The selected peptide bound albumin from different 
species with affinities of 7 ± 2 nM (mouse), 266 ± 8 nM (rat), 320 ± 22 nM (rabbit), and 
467 ± 47 nM (human). The pharmacokinetics of SA21 alone was tested in rabbits upon 
i.v. injection, and showed an 18-fold prolonged half-life compared to an unrelated control 
peptide. The fusion of SA21 to the C-terminus of a Fab antibody fragment efficiently 
prolonged the half-life of the protein up to 37-fold in rabbits and 26-fold in mice after i.v. 
administration.208 The importance of developing high-affinity peptide binders was con-
firmed in a following study where SA21 variants with weaker binding for albumin were 
prepared and fused to a Fab fragment.219 The different conjugates showed a five to ten-
fold reduced binding affinity for albumin and this correlated with two to three times shorter 
half-lives, confirming the results obtained in previous studies with different fatty acid-
modified insulin analogues.218,219 
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The capacity of SA21 to improve the half-life of bicyclic peptides was recently in-
vestigated in our laboratory. Through the chemical conjugation of SA21 to UK18, Heinis 
and co-workers proved that a non-covalent binding to albumin could improve both phar-
macokinetic and metabolic characteristics of peptide conjugates without affecting their 
activity (Fig. 28).71 They demonstrated that the chemical conjugation did not interfere 
with the binding towards the corresponding protein targets, retained for both SA21 and 
UK18. Experiments in mice showed a prolonged circulation time of the bicyclic peptide 
from 30 minutes to 24 hours after i.v. dosing, and the conjugate remained fully intact and 
functional for more than 48 hours.71 In a second study, they showed that the same con-
jugate distributed into tumor tissues in high concentrations, not limited by the high affinity 
of SA21 for the endogenous murine albumin.245  
 
Figure 28. Schematic drawing of (a) UK18 and (b) UK18-SA21. Key chemical structures such as the mesit-
ylene molecule TBMB in the bicyclic peptide, the disulfide bridge in the albumin binding peptide, the triazole 
linker, and the fluorescein (highlighted in green) are shown. (c) Concentration of UK18 and UK18-SA21 in 
murine blood upon i.v. injection. Compounds were applied intravenously, blood samples were taken at the 
indicated time points, and the concentration of conjugate was measured by UFLC and/or ELISA. Adapted 
with permission from 71, copyright © 2012 American Chemical Society. 
1.3.8 Limitations of albumin-binding ligands 
The use of non-covalent albumin-binding ligands based on fatty acids or peptides 
is a great technique for extending the half-life of peptides.93,99,160 However, previously 
reported examples reveal some serious limitations, concerning their binding properties, 
solubility, and ease of synthesis, that must be taken into consideration for future appli-
cations. In order to give these techniques mainstream relevance, insights into the devel-
opment of newly improved albumin-binding ligands should be envisioned to maximize 
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their biochemical properties and minimize the production steps. All of the current inves-
tigations into this area indicate that researchers are aware of this, and strong improve-
ments are needed for competing with high affinity protein-based albumin binders.213,222   
First, both albumin-binding ligands based on fatty acids or peptides have a rela-
tively low affinity for human albumin that does not allow a full exploitation of these tech-
niques. Fatty acids, upon coupling to peptides, bind to albumin with an approximately 
100- to 1000-fold weaker affinity compared to their free forms.200,227 There is also a prob-
lem that can occur with testing albumin binders in species other than humans, such as 
for the cyclic peptide SA21. This compound has a lower affinity for human albumin com-
pared to other species, which will result in a shorter half-life of the conjugates in human 
plasma compared to the measured values in rat and mouse.208,221 A few minor modifica-
tions to either fatty acids or peptides could have a strong positive impact on their binding 
affinity and, thus, pharmacokinetics profiles. For example, these effects could be 
achieved for i) fatty acids, by introducing negative moieties close to the hydrophobic 
chain to replace the carboxylic acid lost in the coupling,99,228,237,242 and for ii) peptides, by 
applying in vitro evolution screenings with either innovative combinatorial libraries or mol-
ecule formats based on known albumin ligands.54,58,60 
Second, these conjugates often show a low solubility that limits the final concen-
tration that can be applied in patients. The high lipophilicity of fatty acids is known to 
negatively affect the solubility of acylated derivatives.202 The cyclic peptide SA21 also 
has a poor solubility in physiological buffers caused by the presence of many hydropho-
bic amino acids.208 Its conjugation to several bicyclic peptides resulted in final products 
with strongly impaired solubility (unpublished data). However, recent successful exam-
ples reported in literature of acylated peptides variants with one or more negative 
charges as enhancers (e.g. diacids or hydrophilic linkers) display an improved aqueous 
solubility.99 A higher peptide solubility can also be achieved by shortening the sequence 
and replacing hydrophobic residues not involved in the binding. 
Third, the preparation of these conjugates often involves difficult synthetic pro-
cesses. The syntheses of either very long conjugates (> 30-40 coupling reactions)221 or 
separated bioactive components71,245, which often require orthogonal protecting groups, 
need sequential steps of purification and coupling, therefore making this conjugation time 
consuming and very expensive. For example, the acylation of peptides is typically per-
formed by fatty acid modification of the N?-amine of Lys side chains or the N-terminus, 
and this modification can take place either in solution or on resin.99 When done on resin, 
acylation is quite straightforward and the fatty acid can be coupled selectively during 
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SPPS. Usually, a single step of purification is enough to get the desired product. In con-
trast, acylation in solution is more demanding. It often results in heterogenous mixtures 
and requires multiple purification steps which affect the overall yield.99 Similarly to this 
second aspect, modification of peptides with complex albumin-binding molecules, such 
as SA21, introduces some synthetic issues. For example, SA21 has a long sequence 
with a disulfide bridge that complicates the direct conjugation to peptides on resin and 
greatly reduces the yield due to the multiple steps of purification needed (Fig. 29).208 
Easier synthesis of the conjugates can be achieved by shortening the peptide for simpler 
attachment during SPPS, removing unwanted disulfide bridges, and/or using specific 
residues carrying orthogonal protecting groups when modifications on resin are required. 
 
Figure 29. Synthesis of UK18-SA21. UK18 was synthesized with a C-terminal alkyne group (propargylgly-
cine linked to UK18). SA21 was synthesized with an N-terminal azide group (5-azido-pentanoic acid linked 
via a Gly linker to SA21). The UK18 derivative was cyclized by reaction with TBMB and the SA21 derivative 
was cyclized by oxidation. The two fragments were linked together by Huisgen cycloaddition. Reprinted with 
permission from 245, reprinting license nr. 4052131274235, copyright © 2015 American Association for Can-
cer Research. 
As a solution to these problems of currently existing albumin binding ligands, the 
research project presented in this thesis combines the excellent albumin binding proper-
ties of fatty acids and our expertise in the rational evolution of peptide affinities. The goal 
is to solve the problems discussed for both acylation and peptide-based extension strat-
egies through a fusion of the two techniques. 
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Peptides applied intravenously suffer from a rapid clearance from the blood circu-
lation by renal filtration. Their exceptionally short half-life prevents the application to dis-
eases that require prolonged drug exposure.93 Several strategies have been applied to 
extend the in vivo half-life of peptides, including fusion to long-lived serum proteins, 
PEGylation and conjugation to albumin-binding molecules.93,99,117 The latest strategy is 
particularly attractive as it does not significantly increase the size of peptides. However, 
existing molecules or peptides binding to albumin present relatively weak affinities, low 
solubility in physiological buffers, and difficult synthesis of the conjugates.202,204,208,227 
The first goal of this research project was the development of an albumin-binding 
tag more in line with our needs, taking into consideration the previously mentioned limi-
tations. Specifically, I aimed to engineering a ligand that presents:  
i) high affinity for human albumin in the low-medium nanomolar range (< 50 nM); 
ii) small format for an easy and economic synthesis of therapeutic conjugates; 
iii) high solubility of resulting conjugates ?????????????????????????????? ?? ?-1).  
 
Figure 30. Schematic representation of a bioactive peptide (in blue) modified with a peptide-fatty acid chi-
mera. Interactions involved in the binding from both fatty acid and peptide are shown as red dots. 
Towards this end, I conceived the ligand design shown in Figure 30 in which a fatty 
acid is conjugated to a short peptide, both parts interacting with human albumin. While 
fatty acids are reported to bind albumin with a certain affinity (Kd values between 2 to 5 
?M upon conjugation to peptides)227,228, a random peptide does not. Therefore, a suitable 
amino acid sequence needs to be evolved in order to form additional contacts and thus 
increase the binding affinity of the chimera for albumin. 
Since a high affinity was expected to translate into a prolonged half-life 218,219, as 
secondary goal I conjugated the developed albumin-binding tag to three bioactive bicy-
clic peptides and checked their pharmacokinetic profiles in different animal models.  

 71 
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3.1 - Development of a high affinity albumin-
binding tag 
Towards the development of a high affinity peptide-fatty acid tag, in a first step I 
established an efficient synthetic strategy for the preparation of this molecule format by 
automated solid-phase peptide synthesis (SPPS). An optimized procedure was required 
for the straightforward and economic synthesis of several peptide-fatty acid variants that 
were later screened for albumin binding. Another aim of this step was the identification 
of a fatty acid that could efficiently bind albumin in the context of the new format. In a 
second step, I tested the solubility in aqueous solution of the peptide-fatty acid tag cou-
pled to two different bicyclic peptides. In a third step, I evolved the sequence of the pep-
tide through iterative rounds of synthesis and affinity testing by applying as screening 
methodology a fluorescence polarization assay against human albumin. Fourth, I char-
acterized the binding of the optimized tag for rat albumin and in human serum. Finally, I 
confirmed its binding affinity for albumin by isothermal titration calorimetry. 
3.1.1 Synthesis and albumin binding of a peptide modified 
with different fatty acids 
A strategy was developed for the automated synthesis of linear peptides carrying 
a fatty acid modification at an amino acid side chain. The selected peptide format had a 
7-mer sequence H-XXXKXXX-NH2, with the amine side chain of Lys (K) orthogonally 
protected with a Dde (1-(4,4-dimethyl-2,6-dioxycyclohex-1-ylidene)ethyl) group, and X 
was any possible amino acid. A short PEG2 linker was added at the N-terminus and 
coupled with fluorescein (F) to enable the measurement of the binding affinity for albumin 
by fluorescence polarization. The central Lys(Dde) residue was selectively deprotected 
with 2% hydrazine, and the free amine was reacted with the carboxylic head of a fatty 
acid to form an amide bond (Fig. 31). The described procedure was fully automated for 
the synthesis of peptide-fatty acid variants on a standard peptide synthesizer. 
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Figure 31. General scheme for the synthesis of a peptide-fatty acid tag. X represents any amino acid; (F) is 
fluorescein, ? (dash) between (F) and N-terminus is PEG2. 
Peptide cleavage from the resin and side chain deprotection were carried out in 
standard acidic conditions, and the crude products purified by HPLC. The short length of 
the linear peptides allowed for syntheses with minimal side products and efficient purifi-
cations, as confirmed by mass spectrometry and analytical HPLC (Fig. 32). A typical 
yield for a small-scale synthesis (0.03 mmol) was approximately 60-70% of the expected 
amount that was calculated considering a maximal efficiency for each coupling step, flu-
orescein and fatty acids included. 
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Once established the synthesis, the binding affinity of the peptide-fatty acid tag for 
human albumin was tested using the sequence (F)-PEG2-SSSKSSS-NH2 (Fig. 32a) 
modified at the Lys side chain with either one of the three most abundant fatty acids 
present in human blood (myristic, palmitic or stearic; Fig. 32b-d, respectively).198 The 
initial sequence was based on six hydrophilic Ser residues mainly for solubility purposes. 
 
Figure 32. Characterization of three different peptide-fatty acid tags. (a) Structure of the peptides. RP-HPLC 
chromatograms (left panel) and deconvoluted mass spectra (right panel) of (b) myristoylated, (c) pal-
mitoylated, and (d) stearoylated peptides. Amino acids shown as single letter code; fluorescein, PEG2 and 
fatty acid tail shown as structural formula. 
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Peptides carrying myristic, palmitic or stearic acid bound human albumin with Kd 
values of 1900 ± 200, 1080 ± 120 and 1480 ± 150 nM (Fig. 33a), respectively, with affin-
ities comparable to the approved acylated insulins.227,228 The results showed that an af-
finity maturation of the Ser-based sequence was required to approach the desired low-
medium nanomolar binding affinity for albumin. The affinity for albumin was also deter-
mined in human serum in the presence of all of the other blood components, which can 
either nonspecifically bind the peptide-fatty acid tag or compete for the same albumin 
binding sites (e.g. free fatty acids). Dilutions of serum were performed considering the 
average concentration of albumin in the blood (600 ?M).178 The peptide modified with the 
palmitic acid showed a binding affinity for albumin in human serum of approximately a 
factor two better respect to the two other peptide-fatty acid tags (Fig. 33b). Therefore, 
palmitic acid was chosen as albumin ligand for peptide maturation, and named Kpalm 
when conjugated to Lys in the peptide sequence.  
 
Figure 33. Binding of the three peptide-fatty acid tags. Fluorescence polarization isotherms with (a) human 
albumin and (b) human serum. (c) Structure of the peptides and dissociation constants. Amino acids shown 
as single letter code; (F) is fluorescein; myr is myristic acid, palm is palmitic acid; ste is stearic acid; ???????? 
between (F) and Ser-based tag is PEG2. 
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3.1.2 Solubility of bicyclic peptides conjugated to different al-
bumin-binding tags 
The strategy described above was applied for the synthesis of four tagged bicyclic 
peptides in order to determine the impact of the peptide-fatty acid tag on the conjugates’ 
solubility in physiological buffer (Fig. 34). The peptide-fatty acid tag was appended to the 
peptides’ C-termini during SPPS, spaced by a short PEG2 linker. The N-terminus of bi-
cyclic peptides was kept inaccessible to fatty acid modification using a Boc-protected 
amino acid. Lys(Dde) residue was deprotected and the free amine was conjugated with 
palmitic acid. After cleveage from the resin, the cyclization of the bicyclic peptides with 
the thiol-reactive molecule TBMB was carried out in a mixture of MeCN and aqueous 
buffer, pH 8.0, 30°C for 1h, and then the reaction mixture was purified.  
 
Figure 34. Synthesis of a bicyclic peptide conjugated to a peptide-fatty acid tag. X represents either Ser or 
Gly residues.  
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A single step of purification gave on average 30% yield of tagged bicyclic peptides 
with 90% purity (Fig. 35). The four conjugates were prepared using as model two well-
characterized phage display selected bicyclic peptides, UK1870 and PK1568, that were 
conjugated with two peptide-fatty acid tags, GGGKpalmGGG (Fig. 35a, UK18-GKG; 35b, 
PK15-GKG) or SSSKpalmSSS (Fig. 35c, UK18-SKS; 35d, PK15-SKS).  
 
Figure 35. Characterization of the four conjugates used in solubility assay. Structure (left panel), RP-HPLC 
chromatograms (central panel) and deconvoluted mass spectra (right panel) of (a) UK18-GKG, (b) PK15-
GKG, (c) UK18-SKS, and (d) PK15-SKS. Amino acids shown as single letter code; TBMB, PEG2 and palmitic 
acid shown as structural formula. 
The idea was to determine the maximum solubility of the conjugates by measuring 
the absorbance of saturated solutions in PBS. However, one of the chosen bicyclic pep-
tides did not contain aromatic residues, not allowing direct measurements of absorbance 
at 280 nm. Therefore, the molar extinction coefficients at wavelengths where peptide 
bond usually absorbs light, which is in the UV range 190-230 nm246, were calculated for 
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all constructs. Even if proteins and peptides show a ?max at around 190 nm, the absorb-
ance at 205 nm is usually preferred to avoid instrument-related technical limitations, and 
problems with intensities that are too high to be accurately measured.246 To maximize 
the reproducibility of the assay and reduce the risk of external influences, measurements 
at 210 and 220 nm were performed as well. The choice of the solvent was also crucial 
since several physiological buffers exert a certain degree of absorbance.247 Both milliQ 
water and PBS were tested and did not give absorbance in the selected range. 
The molar extinction coefficients (?nm) in milliQ water were calculated by preparing 
serial dilutions of conjugates, initially fully dissolved at a concentration of one mg?ml-1. 
Absorbances were registered and plotted against peptide concentrations, allowing the 
creation of “wavelength-specific calibration curves”, in which the slope of the linear re-
gression indicates the molar extinction coefficient (Fig. 36). 
 
Figure 36. Calibration curves of the four conjugates. Conjugates UK18-GKG (first line), PK15-GKG (second 
line), UK18-SKS (third line) and PK15-SKS (fourth line).  
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In literature, extinction coefficients at 205 nm can be estimated by multiplying the 
molecular weight of a protein by a fixed absorptivity equal to 31 ml?mg-1?cm-1.248 A more 
precise equation, called Scopes method, considers the absorbance of the aromatic side 
chains introducing a value related to an Abs280/Abs205 ratio.247 However, both equations 
did not consider the individual participation of the other amino acid side chains. A new 
method which overcomes this limitation was recently proposed, and a related website is 
available for calculating the molar extinction coefficients (http://spin.niddk.nih.gov/clore) 
starting from peptide sequences.248  
Since the four conjugates analyzed contained two extra amide bonds from the 
PEG2 linker and the coupled palmitic acid, I included them in the calculation as two Gly 
residues. In this model, Gly and Ser contribute equally, thus the different peptide-fatty 
acid tags were non-influential, and the two resulting ?205 coefficients were:  
- 81700 M-1 cm-1 for tagged UK18; 
- 83270 M-1 cm-1 for tagged PK15. 
These calculated ?205 coefficients were compared to the experimental ones (Fig. 
37), showing a difference lower than 10% for both derivatives with the Ser-based tag, 
while the discrepancy was much higher with the Gly-based one (20-30%). These results 
gave already a first indication about the peptide solubility, since a better approximation 
was obtained with the Ser-based tag. It is possible that the Gly derivatives were not fully 
dissolved, thus lowering the effective measured concentration. In addition, the extinction 
coefficients measured at 210 and 220 nm were lower, as expected.246 
 
 
Figure 37. Molar extinction coefficients of the four conjugates. Amino acids shown as single letter code; 
palm is palmitic acid; ? ??????????????? ????????between Gly- or Ser-based tags is PEG2.
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The solubility in PBS was determined by preparing saturated solutions of conju-
gates at a theoretical concentration of ten mg?ml-1, let them equilibrate at room temper-
ature and centrifuged twice, before performing several serial dilutions and recording ab-
sorbances at the three different wavelengths (Fig. 38a). Conjugates’ concentrations were 
calculated by applying the Lambert-Beer equation counting the experimental ?nm coeffi-
cients, dilution factors and molecular weights. 
 
 
Figure 38. Solubility of the four conjugates. (a) Spectra of absorbance of the four different conjugates. (b) 
Solubility of the four different conjugates at three different wavelengths and their average. Amino acids 
shown as single letter code; palm is palmitic acid; ? is wavelengths?? ??????? between Gly and Ser is PEG2. 
The maximal solubility was reduced from more than ten mg?ml-1 (UK18 and PK15, 
data not shown) to approximately 0.2-0.7 mg?ml-1 if the tag was GGGKpalmGGG, and to 
1.8-3.0 mg?ml-1 if the tag was SSSKpalmSSS (Fig. 38b). Tagged PK15 derivatives were 
two times more soluble than the corresponding UK18 ones, indicating different intrinsic 
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solubility of the bicyclic peptides. Comparison between the different tagged formats 
showed that the Ser-based tag was four to eight times more soluble than the Gly-based 
one, demonstrating that the solubility can be modulated by the amino acid sequence of 
the peptide and possibly be further enhanced with suitable substitutions. Since the de-
sired solubility higher than one mg?ml-1 was reached for the palmitoylated Ser-based tag, 
I thus continued the development of the high affinity albumin-binding tag with this se-
quence as starting point.  
3.1.3 Affinity maturation of the albumin-binding tag  
The peptide-fatty acid (F)-PEG2-SSSKpalmSSS-NH2 tag, with a Kd value of 1080 ± 
120 nM, was subjected to iterative cycles of synthesis and affinity testing in order to 
improve the binding affinity for albumin. Towards this goal, variants of the peptide-fatty 
acid tag were synthesized substituting one of the six Ser residues at a time to either Trp 
(W), Tyr (Y), Leu (L), Asp (D), Glu (E) or Gly (G) (Fig. 39). Amino acids presenting hy-
drophobic and negatively charged side chains were preferably screened since it is well 
known how these moieties are the structural requirements for the binding to human al-
bumin.178 Aromatic residues Trp and Tyr were chosen as capable of establishing hydro-
phobic interactions and hydrogen bonds, and together with Asp and Glu were considered 
the most promising residues for the affinity maturation. Leu was selected among all of 
the hydrophobic amino acids due to its longer branched side chain. Due to the presence 
of Ser in the starting sequence, no other polar residues were screened. Gly was included 
to check if a higher degree of flexibility would favor certain binding conformations.  
The synthetic strategy shown in sub-section 3.1.1 (Fig. 31) was applied for the 
automated synthesis of all of the peptide variants carrying the palmitic acid. The binding 
affinity for human albumin was measured by fluorescence polarization. The standard 
deviations were lower than the 15% of the Kd values and facilitated the detection of rel-
atively small affinity differences among variants. In each maturation cycle, the peptide-
fatty acid variant with the best affinity was selected for the next step, the amino acid 
substitution fixed and the process repeated. If different amino acid substitutions were 
showing similar improvements: i) the negatively charged residues Asp and Glu were se-
lected as they normally enhance the solubility, with Glu preferred for stability reason due 
to the propensity of Asp to isomerize into iso-Asp, racemize into D-Asp or hydrolyze 249; 
ii) the hydroxylic Tyr was preferred over Trp. If different amino acid positions inside the 
sequence led to similar affinities, the substitution closest to the central palmitoylation was 
fixed to firstly evolve the peptide from this anchor towards the two peptide ends.  
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Figure 39. Schematic representation of the strategy applied for the evolution of the peptide moiety. Libraries 
of peptide-fatty acid variants were synthesized by individually replacing each variable position with six spe-
cific amino acids. These variants were then screened against human albumin. The substitution showing the 
best improvement was fixed and a new round of selection started, replacing the remaining variable positions.  
In the first cycle (Fig. 40), 36 variants were synthesized and all the peptides modi-
fied with Asp and Glu showed strong improvements, independently from the position. Six 
of them showed around two-fold increase in binding affinity. This might be related to the 
restoring of the negative charge of the fatty acid, which was lost due to the coupling with 
Lys. Hydrophobic residues were not well tolerated, except for the second position. Trp 
reduced the affinity of the starting peptide more than a factor three. Gly acted as neutral 
residue without affecting the affinity. Following the criteria previously defined, the first 
selected variant had a Glu fixed in position five (Kd = 520 ± 50 nM).  
In the second cycle (Fig. 41), 30 variants of (F)-PEG2-SSSKpalmESS-NH2 were syn-
thetized and again Asp or Glu peptides showed an improvement in binding affinity. Six 
of them had a two-fold better Kd value. The substitutions placed after the fixed Glu had 
a slightly lower impact, suggesting a potential incompatibility. Observations made in the 
first cycle about hydrophobic residues and Gly were confirmed. A negative charged core 
around the palmitoylation was created fixing a Glu in position three (Kd = 250 ± 30 nM). 
In the third cycle (Fig. 42), substituents of the remaining four Ser positions deter-
mined the synthesis of 24 variants of (F)-PEG2-SSEKpalmESS-NH2. A two-fold improved 
binding affinity was found among peptides substituted in position two for both hydropho-
bic and negatively charged residues. The result was not unexpected due to a better tol-
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erability previously observed for the aromatic residues in that specific position. The mat-
uration continued via two different paths, both with a fixed residue in position two, which 
was either Glu (Kd = 140 ± 15 nM, cycle 4a; Fig. 43) or Tyr (Kd = 123 ± 9 nM, cycle 4b; 
Fig. 44).  
 
Figure 40. Binding affinity of the 1st cycle tag variants. (a) Sequences and dissociation constants, and (b) 
binding signature plot. Peptide marked with asterisk was fixed for the next round; dotted line indicates the 
binding affinity of the starting peptide; amino acids shown as single letter code; (F) is fluorescein; palm is 
palmitic acid; ? (dash) between (F) and N-terminus is PEG2. 
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Figure 41. Binding affinity of the 2nd cycle tag variants. (a) Sequences and dissociation constants, and (b) 
binding signature plot. Peptide marked with asterisk was fixed for the next round; dotted line indicates the 
binding affinity of the starting peptide; amino acids shown as single letter code; (F) is fluorescein; palm is 
palmitic acid; ? (dash) between (F) and N-terminus is PEG2. 
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Figure 42. Binding affinity of the 3rd cycle tag variants. (a) Sequences and dissociation constants, and (b) 
binding signature plot. Peptides marked with asterisk were fixed for the next round; dotted line indicates the 
binding affinity of the starting peptide; amino acids shown as single letter code; (F) is fluorescein; palm is 
palmitic acid; ? (dash) between (F) and N-terminus is PEG2. 
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Starting from the fourth cycle, variants with Asp and Gly were not synthetized any-
more. Asp substitutions did not give any advantage over Glu, while binding affinities of 
Gly peptides were always neutral compared to the Ser counterparts. In the 4a path aris-
ing from (F)-PEG2-SEEKpalmESS-NH2 (Fig. 43), no significant improvements were meas-
ured among the 12 variants analyzed. Only a couple of them showed a small increase 
in the binding affinity, suggesting that the fixed Glu in position two forced the peptide in 
a conformation which did not allow other stronger interactions.  
 
Figure 43. Binding affinity of the 4ath cycle tag variants. (a) Sequences and dissociation constants, and (b) 
binding signature plot. Dotted line indicates the binding affinity of the starting peptide; amino acids shown as 
single letter code; (F) is fluorescein; palm is palmitic acid; ? (dash) between (F) and N-terminus is PEG2.. 
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In contrast, the second path 4b gave much better results. Three variants out of 
the 12 based on (F)-PEG2-SYEKpalmESS-NH2 (Fig. 44) exhibited nearly a factor two im-
provement in the binding affinity when Ser were replaced with Glu, independently from 
the position. Trp dramatically reduced the affinity, while Tyr and Leu had basically a neu-
tral behavior.  
 
Figure 44. Binding affinity of the 4bth cycle tag variants. (a) Sequences and dissociation constants, and (b) 
binding signature plot. Peptides marked with asterisk were fixed for the next round; dotted line indicates the 
binding affinity of the starting peptide; amino acids shown as single letter code; (F) is fluorescein; palm is 
palmitic acid; ? (dash) between (F) and N-terminus is PEG2. 
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Since the Kd values of the three best variants were identical (Kd Glu-1 = 79 ± 10 
nM; Kd Glu-6 = 79 ± 8 nM; Kd Glu-7 = 76 ± 7 nM), I decided to keep the three sequences 
as templates and change the two remaining positions with either Tyr or Glu, since these 
amino acids resulted to be the most promising for further binding affinity improvements. 
This strategy led to the synthesis of nine variants (Fig. 45) with three Glu peptides in 
common among the different paths. Two of them converged to the same best peptide-
fatty acid tag, that was (F)-PEG2-EYEKpalmESE-NH2 (Kd = 46 ± 4 nM).  
 
Figure 45. Binding affinity of the 5th cycle tag variants. (a) Sequences and dissociation constants, and (b) 
binding signature plot. Peptide marked with asterisk was fixed for the next round; dotted line indicates the 
binding affinity of the starting peptide; amino acids shown as single letter code; (F) is fluorescein; palm is 
palmitic acid, ? (dash) between (F) and N-terminus is PEG2. 
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Finally, in order to complete the selection and replace all of the different Ser resi-
dues, two last variants were prepared (Fig. 46a). Tyr substitution gave a slightly better 
affinity (39 ± 3 nM), leading to the final sequence of the evolved peptide-fatty acid tag 
(F)-PEG2-EYEKpalmEYE-NH2, later abbreviated as (F)-tag (Fig. 46b). Its affinity was 27-
fold improved respect to the starting point and satisfied the need of generating a high-
affinity albumin-binding tag with a Kd value in the low-medium nanomolar range. 
 
Figure 46. Binding affinity of the 6th cycle tag variants and characterization of the evolved tag. (a) Sequences 
and dissociation constants. (b) Structure (upper panel), RP-HPLC chromatogram (lower panel, left) and 
deconvoluted mass spectrum (lower panel, right) of the (F)-tag. Amino acids shown as single letter code; 
(F) is fluorescein, palm is palmitic acid; ? (dash) between (F) and N-terminus is PEG2; fluorescein, PEG2 
and palmitic acid shown as structural formula. 
The binding affinity of the (F)-tag was compared to those ones reported for the 
albumin-binding peptide SA21 and the approved acylated insulins (Fig. 47).71,208,227,228 
The evolved tag showed an affinity for human albumin ten- and more than 50-fold higher, 
and this should translate into a much more prolonged half-life extension in human.  
 
Figure 47. Binding affinity of evolved tag, SA21 and acylated insulins. Amino acids shown as single letter 
code; (F) is fluorescein; palm is palmitic acid; Cys residues involved in the disulfide bridge are underlined. 
In the table: Kds measured by a) fluorescence polarization, b) surface plasmon resonance, and c) albumin 
immobilized on agarose.  
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The best tag variants selected in each cycle were compared in the same plate and 
the resulting binding curves are shown in Figure 48. The graphic clearly shows that the 
binding was improved by a factor two in the first four rounds of evolution, and finally the 
affinity slowly reached the targeted range in the last cycles.  
 
Figure 48. Binding isotherms of the evolved tag and precursors with human albumin. Amino acids shown 
?????????????????????????????????????????????? ??????? ??????????? ????????between (F) and tag variants is PEG2. 
3.1.4 Binding to rat albumin and human albumin in serum 
The binding affinity of the best tag variants was also determined in human serum 
and for rat albumin (Fig. 49). Rat albumin was tested to understand if rats were suitable 
as animal model for in vivo pharmacokinetic studies. Fluorescence polarization with hu-
man serum showed affinities comparable to that determined with pure human albumin, 
confirming a specific binding of the tag variants to the protein even in presence of fatty 
acids and other blood components (Fig. 49b). Experiments with rat albumin showed that 
the final (F)-tag binds the orthologous protein with a Kd value of 220 ± 30 nM, six-fold 
weaker than that for human albumin, but still in a range of affinity suitable for the desired 
in vivo experiments in rats (Fig. 49a).  
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Figure 49. Binding of the evolved tag and precursors with different albumins. Fluorescence polarization 
isotherms with (a) rat albumin and (b) human serum. (c) Dissociation constants. Amino acids shown as 
single letter code; (F) is fluorescein; palm is palmitic acid?? ????????between (F) and tag variants is PEG2. 
In addition to the best tag variants, all the peptides from the last three cycles were 
tested with human serum and rat albumin (Fig. 50). The results with human serum con-
firmed the binding trend about high affinity and specifity for human albumin. In contrast, 
affinities for rat albumin showed that the selected tag variants were not always corre-
sponding to the best binders, except for the evolved (F)-tag, suggesting a different pat-
tern of interactions in the binding site.  
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Figure 50. Binding of the evolved tag and last variants with different albumins. Dissociation constants. Amino 
?????????????????????????????????????????????????????????? ??????? ??????????????????? between (F) and tag 
variants is PEG2. 
3.1.5 Isothermal titration calorimetry  
The binding affinity of the evolved (F)-tag (Fig. 46) was further studied by isother-
mal titration calorimetry (ITC) in order to validate the results obtained in the fluorescence 
polarization screening. ITC was also used to investigate the number of binding sites on 
albumin and the enthalpic and entropic thermodynamic parameters. 
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ITC experiments were carried out in duplicate using a concentration of (F)-tag in 
the syringe (40 ?L at 500 ?M) ten-fold higher than the concentration of albumin in the cell 
(300 ?L at 50 ?M). Number and volume of injections were varied to get a sufficient re-
lease of heat for peak integration as well as a clear picture of the binding events (Fig. 
51a, 51d). Peptide titrated into buffer showed a certain degree of heat release related to 
either nonspecific interactions or buffer mismatch. However, heat changes were always 
lower than the experimental ones and thus subtractable from these data (Fig. 51b, 51e).  
 
Figure 51. ITC profile of (F)-tag binding to human albumin. Raw data and binding isotherms obtained by 
integrating the titration of peptide into protein with (a) 19 (2 ?L each) or (d) 38 (1 ?L each) injections. Binding 
isotherms obtained by integrating the titrations of peptide into protein (black), peptide into buffer (green) and 
buffer into protein (blue) with (b) 19 or (e) 38 injections (same experimental conditions). Two-sites binding 
model fitting of titration of peptide into protein with (c) 19 or (f) 38 injections after blanking them. 
The isotherms (Fig. 51c, 51f) were fitted with a two-sites binding model. They 
showed the same curve shape reported for one of the three theoretical ITC isotherms 
observed for a ligand that binds to two independent binding sites on a protein (Fig. 52).250 
If the ligand binds with similar affinity and enthalpy change on both binding sites, the two 
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events are close enough to be thermodynamically indistinguishable and a single curve 
is obtained (Fig. 52a). If the ligand binds with different affinities, the shape of the curve 
is strickly related to enthalpy changes. Figure 52b shows a situation in which the binding 
site with the highest affinity has the strongest enthalpy change. In contrast, in Figure 52c 
the same high-affinity binding site demonstrates the weakest enthalpy change. 
 
Figure 52. Possible experimental isotherms in a two-sites binding model. (a) A system where affinity and 
enthalpy are indistinguishable. Systems where higher affinity correlates with either a (b) stronger or a (c) 
weaker exothermic enthalpy change. Adapted with permission from 250, reprinting license nr. 
4047541382989, copyright © 2007 Elsevier Inc. All rights reserved.  
In both experiments (Fig. 51c, 51f) the curves were similar to the isotherm shown 
in Figure 52c and differences in binding affinities and enthalpy changes were measured. 
Applying this model, the binding site with the highest affinity had the weakest enthalpy 
change (K2: Kd = 53 ± 29 nM, ?H ? -0.5 kcal?mol-1), while the binding site with reduced 
affinity showed a stronger enthalpy change (K1: Kd = 2.3 ± 1.0 μM, ?H ? -8.5 kcal?mol-1) 
(Fig. 53a). This Kd value for the K2 binding site confirmed the nanomolar affinity of the 
(F)-tag measured by fluorescence polarization, thus recommending the use of this tech-
nique for a faster and easier calculation of the binding strength of acylated peptides. In 
addition, the presence of more than one binding sites on albumin was consistent with 
data reported in literature for fatty acids.197  
Thermodynamic parameters were further analyzed and gave some insights into 
the potential binding mechanism of the (F)-tag (Fig. 53b). Both binding events were ther-
modynamically favorable since the values of Gibbs free energy (?G) were negative. 
However, the binding was guided in a different manner. As expected in this model, the 
binding site with the highest affinity (K2) correlated with a weaker enthalpy change. As 
consequence, this first event was mainly entropy-driven (-T?S ? -9.5 kcal?mol-1?K-1), with 
hydrophobic interactions as well as conformational changes playing a crucial role in the 
overall affinity. On the other hand, the second event took place in a binding site where 
the (F)-tag had a 40-fold weaker affinity (K1) and it was strongly enthalpy-driven (?H ? -
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8.5 kcal?mol-1), suggesting a major involvement of hydrogen and van der Waals bonds, 
with in contrast unfavorable conformational changes, as confirmed by the loss of entropy.  
 
Figure 53. Thermodynamic parameters calculated using a two-sites binding model. (a) Table with corre-
sponding values, and (b) signature plot of average values. In the table: a) Kd calculated as reciprocal of the 
Ka, b) ?G = ?H - T?S, and c) Temperature at 25°C = 298.15 K. 
According to these data, I could hypothesize that all of the moieties on the (F)-tag 
were important for binding to K2 site on albumin with high affinity, in particular the hydro-
phobic parts (?S). After the saturation of this site, (F)-tag also took part in a second 
binding event on site K1, where hydrogen bonds (?H) prevailed on the hydrophobic in-
teractions. Therefore, I might speculate that the hydrophobic parts did not fit properly in 
the second site, and in consequence they were not able to find a “partner ligand” on 
albumin, thus not contributing actively to the binding. 
3.1.6 Role of fluorescein in albumin binding  
I finally tested if the hydrophobic N-terminal fluorescein contributed to the albumin 
binding of the tag since it has already been reported that it has a certain affinity for this 
serum protein (Kd ? 70 ?M).204 A second tag format was synthetized by coupling the 
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fluorescein to the C-terminus through a click chemistry reaction (Fig. 54a). An alkyne 
residue was placed at the C-terminal end, separated from the sequence by a short PEG2 
linker. The N-terminus was acetylated with acetic anhydride, the Lys(Dde) selectively 
deprotected and the free amino group modified with palmitic acid. The purified peptide 
was finally subjected to a click chemistry reaction71 and re-purified, resulting in a 95% 
pure fluorescein labeled tag-(F) (Fig. 54b).  
 
Figure 54. Synthesis and characterization of the tag fluorescein labeled at the C-terminus. (a) Synthesis, 
(b) structure (upper panel), RP-HPLC chromatogram (middle panel) and deconvoluted mass spectrum 
(lower panel) of the tag-(F). Ac is acetyl group; (F) is fluorescein. Amino acids shown as single letter code; 
fluorescein, triazole ring, PEG2 and palmitic acid shown as structural formula. 
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Fluorescence polarization assays were performed with human albumin, human se-
rum, and rat albumin. The C-terminal labeled tag-(F) bound human albumin with Kd val-
ues of 1-1.5 ?M, which were 30 to 40-fold weaker than the affinity measured for the N-
terminal labeled (F)-tag. This result pointed out that fluorescein labeling had an impact 
on the binding of the tag for human albumin. Most probably this moiety acted as an eighth 
amino acid and, in combination with the palmitic acid, placed the peptide in a precise 
pocket on albumin surface, inducing a site-specific evolution. Thus, the tag format de-
signed without the N-terminal fluorescein lost these crucial interactions and its binding 
affinity dropped to 1??M. In contrast, only a factor two decrease in affinity was observed 
for tag-(F) with rat albumin, confirming a different binding specificity of the tag between 
the two species (Fig. 55). 
 
Figure 55. Binding of the N- and C-fluorescein labeled tag with different albumins. (a) Fluorescence polari-
zation isotherms with human albumin (left panel), rat albumin (middle panel) and human serum (right panel). 
(b) Dissociation constants. Amino acids shown as single letter code; (F) is fluorescein; palm is palmitic acid, 
? (dash) between tag and (F) at both peptide ends is PEG2. 
To confirm this observation, a competitive assay was performed using the non-
labeled tag as competitor (Fig. 56a). Fixed concentrations of (F)-tag and albumin were 
incubated with an increasing amount of competitor, and the displacement quantified by 
fluorescence polarization. IC50 values were graphically determined (Fig. 56b) and ana-
lyzed by applying the equation developed by Rossi and Taylor.251 The calculated Kd value 
of 720 ± 100 nM was 20-fold weaker than the affinity measured for the N-terminal labeled 
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(F)-tag. The affinity of the non-labeled tag was consistent with the value found for tag-
(F) (Fig. 55), and confirmed the role of fluorescein in the binding. 
 
Figure 56. Characterization and competitive assay of the non-labeled tag. (a) Structure (left panel), RP-
HPLC chromatogram (upper right panel) and deconvoluted mass spectrum (lower right panel) of the tag. (b) 
Fluorescence polarization isotherm with (F)-tag, human albumin and increasing concentration of tag. Amino 
acids shown as single letter code; palmitic acid shown as structural formula. 
These data were compared to ITC experiments and implemented the analysis. The 
low affinity of (F)-tag in the K1 binding site correlated with the value obtained for the non-
labeled tag in fluorescence polarization. The K1 binding event showed a weak entropic 
contribution, suggesting that the hydrophobic structures were not efficiently involved in 
the binding, even if they were physically present. Most likely, the binding mechanism of 
the tag lacking the N-terminal fluorescein was also enthalpy-driven, independently from 
the site of interaction, due to the absence of this hydrophobic moiety. These results re-
ciprocally confirmed that fluorescein conjugation had a positive impact on the binding 
affinity, but only when it is placed in a precise position in the sequence. 
ITC experiments with non-labeled tag and co-crystallization of (F)-tag with albumin 
would have given a stronger support to this hypothesis. A colleague tried to crystalize 
(F)-tag with albumin by applying conditions established in literature.197 Small crystals of 
either albumin with only fatty acids, used as stabilizing agents, or with fatty acids and 
(F)-tag were obtained. The yellow color observed in the crystal confirmed the presence 
of (F)-tag (data not shown). However, it was not possible to determine the electron den-
sity of the tag itself, probably due to the negative influence of multiple low affinity binding 
sites and/or the flexibility of the tag. Crystallization trials were not further investigated. 
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3.2 - Application of the albumin-binding tag 
to two bioactive peptides 
Having generated a high affinity peptide-fatty acid tag, I applied it to two bicyclic 
peptides that were previously developed in our laboratory. In a first step, I synthesized 
four conjugates connecting the two bicyclic peptides to the tag at either one of the two 
ends. In a second step, I tested the effect of bicyclic peptides on the tag affinity for albu-
min and, at the same time, the impact of the tag on bicyclic peptides’ inhibitory activity 
against the relative targets. In a third step, I assessed the plasma stability of the conju-
gates in human plasma. Finally, I performed pharmacokinetic studies in rats of the N-
terminal tagged bicyclic peptides, the tag itself and one of the bicyclic peptide alone. 
3.2.1 Synthesis of tagged bicyclic peptides  
The two bioactive bicyclic peptides used as models were PK128 and UK18 (sub-
section 1.1.6).69,70  UK18 was previously tested in vivo and it suffered from a fast renal 
clearance, with a half-life of  30 minutes upon i.v. injection in mice.71 The conjugates 
were synthesized by appending the tag to both N- and C-peptides’ termini, spaced by a 
short PEG2 linker, directly during SPPS.  The synthetic strategies that were applied are 
described in sections 3.1, and they are here schematically represented (Fig. 57). 
Lys(Dde) residue was deprotected on resin and the free amine acylated with palmitic 
acid. After cleveage, both peptides were cyclized with TBMB in a mixture of MeCN and 
aqueous buffer, and then the reaction mixture was purified. 
The tagged bicyclic peptides were differently modified according to the experi-
ments that had to be carried out. The formats to be tested in fluorescence polarization 
assays were labeled with fluorescein, either directly at the N-terminus (Fig. 57a), which 
was also the format selected for pharmacokinetic studies, or by click chemistry at a C-
terminal alkyne residue (Fig. 57b). The formats destined for inhibition assays were not 
labeled, due to the potential interference that fluorescein might have with the fluorogenic 
substrate used in these tests. In this case, the N-terminal format was acetylated with 
fluorescein replaced by an acetyl group (caption of Fig. 57 for details), while the C-ter-
minal one was kept unmodified at the alkyne residue. 
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Figure 57. Synthesis of bicyclic peptides conjugated to the evolved peptide-fatty acid tag. Synthesis of (a) 
N-terminal and (b) C-terminal formats. (F) is fluorescein. Acetylation of the N-terminal tagged format was 
carried out using 6 equiv. of Ac2O and 6 equiv. of DIPEA in DCM, 1 hr at room temperature under shaking.   
3.2.2 Albumin binding and solubility 
After a single step of cyclization and HPLC purification, all the fluorescein labeled 
peptides had purity greater than 95% and around 40% yield (Fig. 58b-e). As control, the 
bicyclic peptide UK18 alone was synthesized and labeled at the N-terminus with fluores-
cein (Fig. 58a).  
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Figure 58. Characterization of UK18 and the four fluorescein labeled conjugates. Structure of the peptides 
(left panel), RP-HPLC chromatograms (central panel) and deconvoluted mass spectra (right panel) of (a) 
(F)-UK18, (b) (F)-tag-UK18, (c) (F)-tag-PK128, (d) UK18-tag-(F), and (e) PK128-tag-(F). Amino acids shown 
as single letter code; fluorescein, TBMB, PEG2 ??????? ?????????????????????????????? ????????????????? 
between (F), tag and bicyclic peptide is PEG2. 
The binding affinity of the fluorescein labeled conjugates was measured for human 
albumin, human serum, and rat albumin (Fig. 59). Compared to the (F)-tag alone, the N-
tagged bicyclic peptides (Fig. 58b-c) bound human albumin with Kd values in the high 
nanomolar range (Kd of (F)-tag = 39 nM vs. Kds of conjugates ? 150-200 nM), with a 
three to five-fold weaker binding affinity. The same extent of reduction was found for rat 
albumin (Kd of (F)-tag = 220 nM vs. Kd of conjugates ? 700-800 nM). The fluorescein 
labeled bicyclic peptide (F)-UK18 did not bind to albumin at all, and the same result can 
be expected for peptide (F)-PK128.  
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Figure 59. Binding of (F)-tag, bicyclic peptides and N-tagged bicyclic peptides with different albumins. Flu-
orescence polarization isotherms with human albumin (left panel), rat albumin (middle panel) and human 
serum (right panel) of (a) UK18  and (c) PK128  conjugates. (b and d) Dissociation constants. Amino acids 
???????????????????????????????????????????????????????????????????????????? ??????? ??????????? ????????between 
(F), tag and bicyclic peptide is PEG2. 
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The solubility of the N-tagged bicyclic peptides chosen for pharmacokinetic studies 
was investigated in the physiological buffer PBS as described in sub-section 3.1.2. The 
presence of fluorescein allowed to determine peptide’s concentration by measuring the 
absorbance at 495 nm, using a molar extinction coefficient equal to 68,000 M-1?cm-1 
(Thermo Scientific). The two conjugates (F)-tag-UK18 and (F)-tag-PK128 showed a 
good solubility of 1.23 ± 0.35 mg?ml-1 and 1.18 ± 0.18 mg?ml-1, respectively, which satis-
fied our needs, being higher than one mg?ml-1 (Fig. 60). Compared to the previous results 
(solubility of 1.8-3.0 mg?ml-1, sub-section 3.1.2), the slightly lower solubility can be ex-
plained with the introduction of fluorescein, which at the same time removed the N-ter-
minal positive charge and introduced a hydrophobic moiety.  
 
Figure 60. Solubility calculation of the N-tagged bicyclic peptides. Spectra of absorbance of (a) (F)-tag-
UK18 and (b) (F)-tag-PK128. Average values of four measurements are indicated. 
Fluorescence polarization assays of the C-tagged bicyclic peptides (Fig. 58d-e) 
showed a three to five-fold reduction of the binding affinities, similar to what previously 
measured for the N-tagged ones (Fig. 61). Thus, considering the higher Kd value of the 
tag-(F) peptide alone, the C-tagged bicyclic peptides bound albumin in the low micromo-
lar range (Kd of tag-(F) = 1060 nM vs. Kd of conjugates ? 3-5 ?M). As previously observed, 
this second format had a lower impact on the decrease of binding affinity for rat albumin. 
These results underlined that the bicyclic peptides influenced the binding affinity of 
the tag for albumin to the same extent, independently from the site of conjugation. The 
best tag format labeled with fluorescein at the N-terminus, namely (F)-tag, did not show 
a dramatic loss in binding efficacy for albumin, giving an affinity still three and more than 
ten-fold better than albumin-binding peptide SA21 and acylated insulin analogues, re-
spectively (sub-section 3.1.3). The main difference in affinity between the N- and C-
tagged formats arose only from the position of fluorescein in the peptide sequence. 
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Figure 61. Binding of tag-(F), bicyclic peptides and C-tagged bicyclic peptides to different albumins. Fluo-
rescence polarization isotherms with human albumin (left panel), rat albumin (middle panel) and human 
serum (right panel) of (a) UK18 and (c) PK128 conjugates. (b and d) Dissociation constants. Amino acids 
shown as single letter co??????????????????????????????????????????????????? ??????? ??????????? ??????? between 
(F), tag and bicyclic peptide is PEG2. 
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3.2.3 Inhibition of proteases  
Acetylated tagged bicyclic peptides modified and purified once by HPLC gave con-
jugates with purity greater than 95% and again around 40% yield (Fig. 62c-f). The bicyclic 
peptides UK18 and PK128 were still available in the laboratory and used as references, 
after checking their purity and stability (Fig. 62a-b).  
 
Figure 62. Characterization of UK18, PK128 and the four non-labeled conjugates. Structure of the peptides 
(left panel), RP-HPLC chromatograms (central panel) and deconvoluted mass spectra (right panel) of (a) 
UK18, (b) PK128, (c) tag-UK18, (d) tag-PK128, (e) UK18-tag and (f) PK128-tag. Amino acids shown as 
single letter code; propargylglycine, TBMB, PEG2 and palmitic acid shown as structural formula. 
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The capacity of these four conjugates to inhibit their protease targets was as-
sessed in inhibition assays. These assays were carried out by incubating the target pro-
teases with different concentration of conjugates, and adding a fluorogenic substrate that 
is cleaved and emits accordingly to the percentage of enzyme not inhibited. IC50 values 
were graphically determined and, applying the Chang-Prusoff equation, the inhibition 
constants were calculated. In order to simulate the physiological situation in the plasma, 
where the tagged bicyclic peptides are supposed to inhibit their targets in presence of 
high concentrations of albumin, the assay was also performed in a buffer containing 
highly pure human albumin.71  
 
Figure 63. Inhibition of UK18 and conjugates against uPA. (a) Graphs of enzymatic activity tested without 
albumin (left panel) or in presence of two different concentrations (2.5 ?M, middle panel, and 25 ?M, right 
panel). (b) Inhibition constants????????????????????????????????????????? ??????? ??????????? ????????between 
tag and bicyclic peptide is PEG2. 
UK18 alone exhibited a Ki of 55 ± 9 nM against its target uPA (urokinase-type 
plasminogen activator), confirming the values already published (Fig. 63).70 The N-
tagged UK18 inhibited uPA with unchanged potency independently from the concentra-
tion of albumin. On the other hand, the C-tagged UK18 showed a five to ten-fold worse 
Ki values compared to the peptide alone (Fig. 63). Most likely, the presence of the tag 
reduced the accessibility of the second ring of the bicyclic peptide to the catalytic site, 
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and the effect was even amplified by albumin binding hindrance. These results confirmed 
the previous structural X-ray analysis that evidenced the involvement of the residues 
around the second ring, mainly Glu-8, Arg-10 and Arg-12, in making interactions with the 
target.70  
 
Figure 64. Inhibition of PK128 and conjugates against PK. (a) Graphs of enzymatic activity tested without 
albumin (left panel) or in presence of two different concentrations (2.5 ?M, middle panel, and 25 ?M, right 
panel). (b) Inhibition constants????????????????????????????????????????? ??????? ??????????? ????????between 
tag and bicyclic peptide is PEG2.  
PK128 alone had the same Ki of 350 ± 40 pM reported in literature for its target PK 
(plasma kallikrein) (Fig. 64).69 In contrast with UK18 conjugates, the N-tagged PK128 
inhibited PK with a Ki value 30-fold weaker than the peptide alone, while the C-tagged 
PK128 had Ki value almost unchanged, suggesting that the N-terminal region of the bi-
cyclic peptide is involved in the interactions with the binding pocket of the target. These 
results were not unexpected, since PK128 belongs to a consensus which was mainly 
conserved in the first peptide loop.69 Both PK128 conjugates showed an increase in the 
Ki values when tested in presence of albumin (2.5 or 25 ?M). With the highest albumin 
concentration used, the reduction in the activity was around 200-fold for the N-tagged 
bicyclic peptide, and 80-fold for the C-tagged one (Fig. 64). These results confirmed that 
the introduction of the tag at the N-terminus sterically hindered the inhibition of plasma 
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kallikrein more than in the C-terminal format, and this effect was further enhanced when 
the tag was bound to albumin.  
In conclusion, the tag differently influenced peptide activity according to the posi-
tion in which it was appended. Only for UK18, the N-terminal tagged format presented 
unchanged potency in all of the experimental conditions tested. This specific case was 
quite promising since that conjugate had also the best albumin binding format with the 
N-terminus labeled with fluorescein. In contrast, PK128 showed a more significant de-
crease in its activity in the same N-terminal format, underlying how the effects of the tag 
positioning are peptide-dependent and cannot be easily predicted. 
3.2.4 Inhibition of the intrinsic coagulation pathway 
The potency of PK128 and its conjugates was further assessed by measuring their 
capacity to prolong the activated partial thromboplastin time (aPTT), which is the time 
required for plasma to coagulate upon external activation of the intrinsic coagulation 
pathway.80 Plasma kallikrein plays an important role in this pathway, and its blocking 
might be used as enhancer in the treatment of thrombosis and related diseases.82 The 
aPTT of the tagged bicyclic peptides was determined ex vivo by incubating different con-
centrations of conjugates in plasma and triggering the coagulation with CaCl2 (Fig. 65).  
 
Figure 65. Coagulation parameter aPTT for PK128 and conjugates in human plasma. Peptide’s activity was 
measured upon incubation at 37°C with human plasma and pathromtin; coagulation was triggered by CaCl2. 
The bicyclic peptide alone prolonged the aPTT in a concentration dependent man-
ner, and the concentration needed to get a doubling of the coagulation time (EC2x) was 
equal to 5 ?M. In contrast, the two conjugates did not strongly prolong the coagulation 
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time and the estimated EC2x was much higher than 20 ?M. The reduced effect on the 
coagulation pathway correlated with the lower inhibitory activity measured for both con-
jugates in presence of albumin. Because of these negative results, aPTT tests were not 
performed with rat plasma, which I initially wanted to use as animal model in a PK-related 
inflammatory study of carrageenan-induced paw edema.252 PK128 conjugates were 
kept, together with the UK18 ones, as models for pharmacokinetic studies in rats.  
3.2.5 Plasma stability of tagged bicyclic peptides 
The stability of the tagged bicyclic peptides UK18 and PK128 in blood plasma was 
assessed with an assay previously developed in our laboratory, in which peptides are 
firstly incubated in plasma, and then their residual activity is quantified by inhibition as-
says.91 The test has the aim to reveal the fraction of peptide and/or its metabolic deriva-
tives that are still functional and could efficiently inhibit the target, independently from the 
proteolytic events that might have already occurred (e.g. removal of terminal amino acids 
or ring opening). Tagged bicyclic peptides were incubated for two days in human plasma 
at 37°C and samples were collected at eight different time points. Before analyzing the 
samples, plasma was diluted in assay buffer and heat-inactivated to avoid nonspecific 
cleavage activity of other blood proteases on the fluorogenic substrate. The inhibition 
constant measured for the first time point was considered as reference for the maximum 
percentage of residual activity, and all of the other values were calculated accordingly.  
The unmodified bicyclic peptides showed strong differences in their stability. Half 
of the bicyclic peptide UK18 was still active after one day (t1/2 = 34.9 ± 9.8 hrs) (Fig. 66a), 
while PK128 was completely inactivated in few hours (t1/2 = 1.8 ± 0.3 hrs) (Fig. 66b). The 
relatively good plasma stability of UK18 confirmed previous observations according to 
which the fraction of intact peptide after 24 hours was still a 40% of the starting amount.71 
In contrast, all of the tagged bicyclic peptides were fully functional and resistant to pro-
teases for more than two days. The improvement in terms of stability was more pro-
nounced for PK128 (> 25-fold), and the strong protective effect on its degradative pattern 
was most likely associated to the binding to albumin, as already well documented for the 
GLP-1 analogue Liraglutide.253   
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Figure 66. Stability of bicyclic peptides and conjugates in human plasma. The percentage of peptide still 
active at the different time points determined as ratio with the initial inhibition constant 
(Ki(t=5min)/Ki(t=Xmin)*100) for (a) UK18 and conjugates and (b) PK128 and conjugates. 
3.2.6 Pharmacokinetics in rats 
Pharmacokinetic experiments were carried out in rats to test the elimination half-
life of the two N-terminal tagged bicyclic peptides PK128 and UK18, tag and UK18 alone. 
The in vivo studies (injection and blood collection) were performed by the American com-
pany Washington Biotechnology, Inc. (Baltimore, MD, USA). Peptides had purity higher 
than 95% and they were prepared as 10 mM stocks in DMSO. Intravenous administra-
tions (200 ?l) were performed after dilution of the peptide stocks in PBS, pH 7.4, 0.01% 
SDS to a final concentration of 130 ?M. The relative doses were 0.5 mg?kg-1 for tagged 
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bicyclic peptides, 0.3 mg?kg-1 for UK18 and 0.25 mg?kg-1 for tag. Three rats for each 
peptide were used, blood samples collected at eight different time points, processed to 
plasma and sent to us for further analyses. 
3.2.6.1 Detection and quantification of peptides in plasma 
Peptide quantification in plasma samples was performed using a HPLC system 
coupled to a fluorescence detector, after applying an optimized protein precipitation pro-
tocol. These experiments required the setting of the proper excitation wavelength for 
fluorescein, which was different in the acidic condition used in HPLC, and the investiga-
tion of the detection limit of the instrument. 
Fluorescein has four different ionic forms according to the pH of the solution in 
which it is dissolved, and each of them presents a pH-dependent spectrum of absorption. 
At physiological pH, the main form is the di-anionic fluorescein, with quantum yield of 
0.93 and the strongest maximum absorbance at 490 nm. Solvents used in HPLC are 
commonly prepared at acidic pH adding trifluoroacetic acid. At this pH, fluorescein is 
either in its neutral or cationic format, with lower quantum yield (0.31 and 0.17, respec-
tively) and maximum absorbance at around 440 nm.254 In contrast, fluorescein emission 
spectra are pH-independent with a maximum between 520-530 nm, and only the signal 
intensity varies as function of the excitation wavelength used.255 These results were ex-
perimentally confirmed by measuring absorption and emission spectra of fluorescein in 
different conditions (Fig. 67).  
 
Figure 67. Absorption and HPLC detection limits of fluorescein. (a) Absorbance of a fixed concentration of 
fluorescein prepared in three solvents with different pH. (b) Chromatograms of different concentrations of 
fluorescein run RP-HPLC buffer (water + 0.01% TFA) with excitation at 445 nm and emission at 535 nm.  
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At pH 7.4 fluorescein confirmed its maximum absorbance at 490 nm. In contrast, 
this parameter was lower and shifted to 440-450 nm when fluorescein was diluted in 
HPLC solvent (pH 2.0) or milliQ water (pH 5.0). At nearly 460 nm fluorescein presented 
its characteristic isosbestic point, with an equal absorption for all of the pH values (Fig. 
67a).255 The maximum emission was in the expected range at around 535 nm for all the 
conditions tested (data not shown). The sensitivity in HPLC was checked running a flu-
orescein dilution series up to 1 nM and setting the detector at 445 and 535 nm as exci-
tation and emission wavelengths, respectively. In this condition, a clear area under the 
curve (AUC) was visible also for the lowest concentration used, indicating a detection 
limit sufficient for evaluating concentrations in the single digit nanomolar range (Fig. 67b). 
All the following HPLC experiments were run by applying this optimized setting.  
 
Figure 68. Calibration curves for pharmacokinetic studies. Linear regression calculation of the four peptides 
(a) (F)-tag-UK18 (a), (b) (F)-tag-PK128, (c) (F)-tag and (d) (F)-UK18.  
A new protocol of protein precipitation was developed for detecting fluorescein la-
beled peptides in plasma. Plasma proteins had to be first denatured using the chaotropic 
agent guanidinium hydrochloride, able to disrupt the structure of proteins and to enhance 
consequently the release of the tag bound to albumin. Proteins were then precipitated 
with cold ethanol and removed by centrifugation. The supernatant containing the peptide 
was dried under vacuum and then dissolved for HPLC analysis. Before the precipitation 
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step, a fixed concentration of fluorescein as internal standard had been added in each 
sample in order to adjust later the AUCs of the peptides. Quantification of the peptides 
after each precipitation protocol showed an average recovery higher than 90% compared 
to the same peptide concentrations freshly prepared in buffer. Following this procedure, 
calibration curves were prepared using serial dilutions of each fluorescein labeled pep-
tides in rat plasma and later used for peptide quantification (Fig. 68). 
3.2.6.2 Plasma half-life in rats 
The zoomed chromatograms of the four peptide formats tested in each rat are here 
reported (Fig. 69 and 70), while whole HPLC runs are shown in the supporting infor-
mation (Fig. S1-S4). The conjugate (F)-tag-UK18 showed a single peak in all the sam-
ples, and it was visible in plasma for more than 24 hours (Fig. 69a). The absence of 
degradation products proved the protective effect of the conjugation. In contrast, the con-
jugate (F)-tag-PK128 had a faster clearance from the blood, with the last detectable peak 
at eight hours (Fig. 69b). Starting from the one hour time point, a small peak eluting 
before the intact peptide was observed, probably due to a proteolytic event. However, 
the fraction was not taken into account for peptide quantification due to its negligible size.  
 
Figure 69. RP-HPLC chromatograms of N-tagged bicyclic peptides. Chromatograms of plasma samples for 
(a) (F)-tag-UK18 and (b) (F)-tag-PK128. An extra peak observed for (F)-tag-UK18 in the central panel was 
coming from plasma and suggested an incomplete protein precipitation step. 
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The (F)-tag alone was clearly present in rat plasma up to 48 hours and, despite its 
linear format, it was fully intact thanks to the high affinity for albumin that hindered it from 
proteases (Fig. 70a). In addition, the branched fatty acid in the middle of the sequence 
probably offered an extra protection, as already observed for peptides synthesized in 
dendrimeric formats.256 In contrast, the bicyclic peptide (F)-UK18 was fully cleared from 
the blood circulation in less than one hour, and 80% was partially degraded within four 
minutes (Fig. 70b). However, the residual inhibitory activity of UK18 in plasma had a 
much longer duration (?1/2 = 34.9 ± 9.8 hrs) than its clearance time in vivo. Therefore, the 
whole peak was used for the quantification, considering the peptide, even if partially de-
graded, still functional. 
 
Figure 70. RP-HPLC chromatograms of tag and bicyclic peptide UK18. Chromatograms of plasma samples 
for (a) (F)-tag (a) and (b) (F)-UK18.  
The metabolic stability of the bicyclic peptide UK18 was further investigated ex vivo 
in rat plasma to understand its pattern of degradation. The peptide was incubated at 
37°C for 72 hours, the plasma proteins were precipitated and the peptide analyzed by 
HPLC and LC-MS (Fig. 71a-b). Both chromatograms had the same pattern of the in vivo 
samples, with a peak eluting before the intact peptide. Mass analyses revealed that this 
first peak contained two UK18 fragments with either hydrolysis or loss of a Gly residue. 
Considering the degradation pattern already studied for UK18 when incubated in human 
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plasma71, I speculated that the second ring opened between Arg12 and Gly13 and, af-
terward, the Gly residue was cleaved (Fig. 71c).  
 
Figure 71. Plasma stability of (F)-UK18. Chromatograms of intact (black) and incubated (red) peptide in rat 
plasma analyzed by (a) RP-HPLC and (b) LC-MS chromatograms. (c) Masses detected in the indicated 
peaks and potential structures of peptide fragments corresponding to the masses. Amino acids shown as 
???????????????????????????????????????? ????????between (F) and bicyclic peptide is PEG2. 
Using the calibration curves previously prepared, the AUCs of each time point were 
converted in concentrations. Blood processing to plasma after collection halves its vol-
ume, thus if a peptide distributes only in plasma should double its concentration. The 
concentrations of the tag and the N-tagged bicyclic peptides after five minutes were al-
most the double of the theoretical values in blood upon i.v. injection, suggesting that 
these peptides stayed mainly in plasma due to their binding to albumin. In addition, this 
result showed that the recovery of the peptides from plasma in each protein precipitation 
step was quantitative. In contrast, the bicyclic peptide UK18 showed a six-fold lower 
plasma concentration, indicating a fast distribution and/or elimination. The concentra-
tions were plotted versus time and analyzed with a two-compartment model (biexponen-
tial equation: Cp ?????-??t ?????-??t). Pharmacokinetic parameters were determined as re-
ported in literature (Fig. 72), and a table with the equations used is reported in the sup-
porting information (Tab. S1). 257 
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Figure 72. Pharmacokinetic profiles in rats. (a) Plasma concentrations plotted versus time upon i.v. injec-
tions. (b) Table with the parameters calculated for each peptide; (F) is ????????????? ??????????????2. 
The two tagged bicyclic peptides and the tag alone presented similar distribution 
half-lives of around one hour, but they were cleared differently. Tagged UK18 showed 
an elimination half-life of 7.4 ± 0.2 hours, while tagged PK128 had a shorter half-life of 
2.9 ± 0.7 hours, that might be partially caused by the small proteolytic process observed 
(Fig. 69b). Instead, the tag alone had a longer elimination half-life of 12.3 ± 0.4 hours, 
which is related to its four-fold higher binding affinity for rat albumin (Kd of (F)-tag = 220 
nM vs. Kd of conjugates ? 700-800 nM). The short half-life of the bicyclic peptide UK18 
was approximately 18 ± 1 min, confirming the fast clearance previously observed in mice 
experiments.71 This value for UK18 was confirmed comparing the injected dose and the 
back extrapolated amount of peptide in plasma after i.v. injection (Cp0), which resulted to 
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be again six-fold lower. In contrast, the Cp0s of the tagged bicyclic peptides were con-
sistent with the injected doses. In conclusion, the N-terminal tag prolonged the circulation 
time and preserved the stability of UK18 of around 25-fold to over seven hours in rats. 
Scientific literature and EMA reported a plasma half-life of only three to four hours 
for liraglutide and insulin deglutec upon s.c. injection in rats.253,258,259 Therefore, consid-
ering the different route of administration used in our in vivo studies and the high protec-
tion of the conjugation, the tagged bicyclic peptides resulted more promising in the same 
animal model, and they might translate in a terminal half-life of several days in human. 
Other important parameters calculated from the biexponential equation were the 
area under the curve (AUC), the clearance (CL) and the volume of distribution (VD) (Fig. 
72b). The AUC is used to quantify the fraction of a drug that reaches and stays in the 
plasma, and thus could exert its biological effect. As expected, it correlated with the half-
lives and showed, for example, that the tagged UK18 would be 100-fold more active than 
the non-tagged bicyclic peptide in vivo. 
The CL expresses the volume of plasma which is purified from a drug in a certain 
period: higher values of CL indicates a faster removal and a shorter elimination half-life. 
The peptide with the shortest half-life, UK18, had a clearance of half-liter per hour, while 
all the other peptides were cleared only few milliliters in the same unit of time.  
Finally, the VD describes the volume in which a drug distributes in the total body. It 
is commonly related to the weight, which was on average 200 grams for the rats used in 
our experiments. Considering this aspect, the VD of the tag and the tagged bicyclic pep-
tides was approximately 15 ml, consistent with the blood volume of the rats. This defini-
tively proved that the tagged bicyclic peptides distributed mainly in the bloodstream, 
where they were fully bound to albumin. In contrast, the VD of UK18 was much higher 
due to a fast and non-specific tissue distribution. 
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3.3 – Application of the albumin-binding tag 
to a FXII inhibitor for therapeutic use 
The high affinity peptide-fatty acid tag was finally applied to a promising version of 
a highly specific inhibitor of FXIIa previously developed in our laboratory (sub-section 
1.1.6).81,90,91 The newly developed FXII inhibitor displayed an excellent inhibitory activity, 
target selectivity and plasma stability, with a Ki value of around 300-500 pM. However, 
pharmacokinetic studies in rabbits revealed that its half-life was too short to efficiently 
exert its pharmacological activity in vivo (unpublished data). Therefore, I initially synthe-
sized a few conjugates carrying the tag at the N-terminus, but I observed a strong reduc-
tion in the inhibitory activity against FXIIa in both enzymatic and coagulation assays. 
Subsequently, I tested conjugates with different combinations of linker lengths between 
the bicyclic peptide and the tag, and I changed the positioning of the tag. The aim was 
to retain FXIIa inhibitory activity and exploit the tag binding format with the highest affinity 
for albumin. Among the various combinations, the most active conjugate was i.v. injected 
in rabbits and it demonstrated that the conjugation prolonged the half-life of the inhibitor 
and allowed an efficient blocking of the intrinsic coagulation pathway.  
3.3.1 First generation: tag at the N-terminus 
The first conjugates were synthesized by appending the tag at the N-terminus of 
the bicyclic peptide FXII inhibitor and varying the length of the linker in between, which 
was composed of a single Gly or an increasing number of short PEG2 units up to five 
copies. The tag was modified at the N-terminus with either fluorescein for the binding 
assay or an acetyl group for the inhibition assay to avoid interference with the fluorogenic 
substrate. This step was followed by deprotection of Lys(Dde) and acylation of its free 
amine with palmitic acid. After cleveage from the resin, the FXII inhibitor was cyclized 
with TATA in a mixture of MeCN and aqueous buffer, and then purified by HPLC. The 
presence of the desired conjugates was confirmed by mass spectrometry and the purity 
assessed by analytical HPLC (Fig. 73 and 75).  
3.3.1.1 Albumin binding 
Fluorescein labeled conjugates (Fig. 73) were used in fluorescence polarization 
assays to measure the binding affinity for human albumin in serum and for rabbit albumin 
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(Fig. 74). Rabbits were chosen for in vivo studies due to i) an easier quantification of the 
intrinsic coagulation time, since the inhibition of FXIIa in rabbit plasma affects the aPTT 
to a larger extent compared to other animal plasma (unpublished data), and ii) the pos-
sibility to collect big volumes of plasma, being rabbit the animal model with the highest 
blood volume among all the commonly used rodents. 
 
Figure 73. Characterization of the first-generation of fluorescein labeled FXII inhibitor conjugates. Structure 
of the peptides (left panel), RP-HPLC chromatograms (central panel) and deconvoluted mass spectra (right 
panel). Amino acids shown as single letter code; F* and R* represent p-fluoro Phe and ?-homo Arg, respec-
tively; X represents unnatural amino acid newly substituted; fluorescein, TATA, PEG2 and palmitic acid 
shown as structural formula. 
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Figure 74. Binding of (F)-tag and the first-generation of fluorescein labeled FXII inhibitor conjugates with 
different albumins. Fluorescence polarization isotherms with (a) human serum and (b) rabbit albumin. (c) 
Dissociation constants. Amino acids shown as single letter code; F* and R* represent p-fluoro Phe and ?-
homo Arg, respectively; X represents unnatural amino acid newly substituted; (F) is fluorescein; palm is 
??? ??????????? ??????????????????????????????????2. 
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The first-generation of fluorescein labeled conjugates bound human albumin in se-
rum in the high nanomolar range (Kd of (F)-tag = 37 nM vs. Kd?????????????????????-220 
nM), showing a three to five-fold decrease compared to the (F)-tag alone (Fig. 74a). The 
longer the linker between the tag and the bicyclic peptide, the stronger the negative im-
pact was on albumin binding affinity of the tag. This trend was confirmed with rabbit 
albumin. The (F)-tag alone showed a Kd of 320 ± 40 nM, around nine-fold weaker than 
for human albumin. Conjugates with the shortest linkers (Gly and single PEG2) showed 
the best binding, with only a factor two decrease in affinity (Kd??????????????????500-750 
nM). As the number of PEG2 units increased, the binding affinity for rabbit albumin 
dropped to a Kd value of 1.4 ?M for the conjugate with the longest linker (Fig. 74b). How-
ever, the three to five-fold of affinity reductions were consistent with the results obtained 
in human serum.  
3.3.1.2 Inhibition of FXIIa 
The acetylated conjugates (Fig. 75) were tested for inhibitory activity against FXIIa 
both in presence and absence of human albumin (Fig. 76). While establishing the activity 
assay conditions, I found out that the fluorogenic substrate used for FXIIa was sensitive 
to traces of proteases present in the commercially available human albumin. This deter-
mined a reduction in the concentration of albumin to add in the buffer from 25 to 10 ?M, 
and an increase in the enzyme concentration in order to ensure a clear signal over the 
non-specific background. The Ki value of the bicyclic peptide FXII inhibitor measured in 
absence of albumin was used as reference for comparison with the conjugates.  
The FXII inhibitor alone showed the expected high picomolar inhibition constant (Ki 
= 0.46 ± 0.08 nM) (unpublished data). As observed for PK128 conjugates (sub-section 
3.2.3), the Ki value of the FXII inhibitor was reduced when conjugated to the tag. Inter-
estingly, the results showed that the distance between tag and FXII inhibitor played a 
crucial role, with conjugates having longer linkers that presented better Ki values. In ab-
sence of albumin, there was a 14-fold decrease in inhibitory activity for the conjugate 
with the longest linker (5xPEG2, Ki = 6.6 ± 1.8 nM) and a 32-fold for that one with the 
shortest linker (G, Ki = 14.9 ± 0.6 nM) (Fig 76a). The potency was further reduced in 
presence of albumin, and considering the same two conjugates the Ki values were 28- 
and 252-fold lower, respectively (5xPEG2, Ki = 13 ± 1 nM; G, Ki = 116 ± 16 nM) (Fig. 
76b).  
These results suggested that, first of all, the tag placed at the N-terminus partially 
hindered the capacity of the FXII inhibitor to efficiently access and inhibit the catalytic 
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site of the target with its first ring.81 This lowering effect on the inhibition constants was 
even more evident in conjugates with short linkers between the tag and the bicyclic pep-
tide, probably due to the steric hindrance of the closer albumin bound to the tag. 
 
Figure 75. Characterization of the first-generation of acetylated FXII inhibitor conjugates. Structure of the 
peptides (left panel), RP-HPLC chromatogram (central panel) and deconvoluted mass spectra (right panel). 
Amino acids shown as single letter code; F* and R* represent p-fluoro Phe and ?-homo Arg, respectively; X 
represents unnatural amino acid newly substituted; TATA, PEG2 and palmitic acid shown as structural for-
mula. 
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Figure 76. Inhibition of FXII inhibitor and the first-generation of acetylated FXII inhibitor conjugates against 
FXIIa. Graphs of enzymatic activity tested (a) without or (b) in presence of 10 ?M albumin. (a) Inhibition 
constants. Amino acids shown as single letter code; F* and R* represent p-fluoro Phe and ?-homo Arg, 
respectively; X represents unnatural amino acid newly substituted; palm is palmitic acid. 
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3.3.1.3 Inhibition of the intrinsic coagulation pathway 
The most used test to evaluate the potential therapeutic activity of FXII inhibitors 
is an ex vivo coagulation assay that measures aPTT in plasma. As illustrated in sub-
section 3.2.4, this test shows the role that a specific protein, in our case FXIIa, plays in 
the intrinsic coagulation pathway, and the efficiency of its blocking. The activity of the 
FXII inhibitor and the first-generation of acetylated conjugates was determined by meas-
uring their aPTT in both human and rabbit plasma at a fixed concentration (10 ?M) (Fig. 
77).  
 
Figure 77. Coagulation parameter aPTT for the first-generation of acetylated FXII inhibitor conjugates in 
different plasma. The activity of the conjugates was measured upon incubation at 37°C with human (a) or 
rabbit (b) plasma and pathromtin or actin, respectively; coagulation was triggered by CaCl2. 
The FXII inhibitor alone strongly prolonged the aPTT in both plasma types, and the 
much stronger effect observed with rabbit plasma (eight-fold in rabbit vs. three-fold in 
human) was related to the intrinsic sensitivity of the assay. In human plasma, all of the 
conjugates gave a weak effect with an average prolongation factor of only 1.5, and the 
conjugate carrying the longest linker (5xPEG2) was slightly better than the others. Any-
way, its relative coagulation time was half that of the unmodified bicyclic peptide. This 
same conjugate was still the best in rabbit plasma, as well, but it was almost three times 
less efficient than the FXII inhibitor. The impacts of each conjugate on the coagulation 
time nicely correlated with the linker length trend previously observed for the inhibitory 
activity. In fact, the format with the longest linker showed the best inhibitory results 
among all the tested conjugates, while also retaining a good affinity for human albumin. 
However, the negative impact of the tag on the FXII inhibitor activity was still too high. In 
order to avoid any possible intereference at the N-terminus region of the bicyclic peptide, 
a second format with the tag appended at peptide’s C-terminus was tested. 
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3.3.2 Second generation: tag at the C-terminus 
The second generation of conjugates consisted of a C-terminally branched (F)-tag 
attached to the FXII inhibitor as follows. Briefly, the bicyclic peptide was synthesized with 
an N-terminal Boc-protected amino acid and inserting a C-terminal GKG sequence, 
which presented an orthogonally protected Lys(Dde). After the selective deprotection of 
this residue, the synthesis of the tag sequence was started on the free amine side chain, 
spaced by zero to three PEG2 units. The tag was either fluorescein labeled or acetylated 
at N-terminus as described above. The Lys(Dde) of the tag was deprotected and its free 
amine modified with palmitic acid. After cleveage from the resin, the FXII inhibitor was 
cyclized with TATA in a mixture of MeCN and aqueous buffer, and then purified by HPLC. 
The desired conjugates were confirmed by mass spectrometry and the purity assessed 
by analytical HPLC (Fig. 78 and 80).  
3.3.2.1 Albumin binding 
The binding affinity of fluorescein labeled conjugates (Fig. 78) was again deter-
mined for human albumin in serum and for rabbit albumin (Fig. 79).  
 
Figure 78. Characterization of the second-generation of fluorescein labeled FXII inhibitor conjugates. Struc-
ture of the peptides (left panel), RP-HPLC chromatograms (central panel) and deconvoluted mass spectra 
(right panel). Amino acids shown as single letter code; F* and R* represent p-fluoro Phe and ?-homo Arg, 
respectively; X represents unnatural amino acid newly substituted; fluorescein, TATA, PEG2 and palmitic 
acid shown as structural formula. 
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The second-generation conjugates bound human albumin in serum in the high na-
nomolar range (Kd of (F)-tag = 37 nM vs. Kd????????????????? 140-180 nM), showing a 
three to five-fold reduction in binding affinity similar to that measured for all the other N-
terminal tagged bicyclic peptides. The previous trend correlating the linker lengths with 
the Kd of the conjugates for both human and rabbit albumin was also confirmed. The 
conjugate without the PEG2 unit showed the best affinity (138 and 510 nM for human 
and rabbit albumin, respectively), while the other formats spaced by one or three PEG2 
units exhibited a small but clear decrease in binding (Fig. 79).  
 
Figure 79. Binding of (F)-tag and the second-generation of fluorescein labeled FXII inhibitor conjugates with 
different albumins. Fluorescence polarization isotherms with (a) human serum and (b) rabbit albumin. (c) 
Dissociation constants. Amino acids shown as single letter code; F* and R* represent p-fluoro Phe and ?-
homo Arg, respectively; X represents unnatural amino acid newly substituted; (F) is fluorescein; palm is 
??? ??????????? ???????????ween (F) and tag is PEG2.  
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3.3.2.2 Inhibition of FXIIa 
In terms of inhibition, the three second-generation acetylated conjugates (Fig. 80) 
inhibited the target with on average a Ki value of 2.5 nM without albumin, and 6 nM in 
presence of albumin, five- and 14-fold weaker compared to FXII inhibitor alone, respec-
tively (Fig. 81). These conjugates all displayed a factor two improvement of Ki over the 
best first-generation conjugate (5xPEG2, Ki without albumin = 6.6 nM, Ki with albumin = 
13 nM). The homogeneity of the results obtained with the three conjugates suggested 
that a maximum improvement in the inhibitory activity was probably reached with this 
kind of format. The position of the tag seemed to play a more important role, since linker 
differences among conjugates were not longer influencing the Ki values. Even though the 
loss in inhibitory activity was still high in presence of albumin, aPTT tests were repeated 
with the hope to confirm the better results obtained with these conjugates. 
 
Figure 80. Characterization of the second-generation of acetylated FXII inhibitor conjugates. Structure of 
the peptides (left panel), RP-HPLC chromatograms (central panel) and deconvoluted mass spectra (right 
panel). Amino acids shown as single letter code; F* and R* represent p-fluoro Phe and ?-homo Arg, respec-
tively; X represents unnatural amino acid newly substituted; TATA, PEG2 and palmitic acid shown as struc-
tural formula. 
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Figure 81. Inhibition of FXII inhibitor and the second-generation of acetylated FXII inhibitor conjugates 
against FXIIa. Graphs of enzymatic activity tested (a) without or (b) in presence of 10 ?M albumin. (c) Inhi-
bition constants. Amino acids shown as single letter code; F* and R* represent p-fluoro Phe and ?-homo 
Arg, respectively; X represents unnatural amino acid newly substituted; palm is palmitic acid. 
3.3.2.3 Inhibition of the intrinsic coagulation pathway 
The aPTT of the second-generation of acetylated conjugates was assessed in both 
human and rabbit plasma at a fixed inhibitor concentration (10 ?M) (Fig. 82). Results in 
human plasma had the same weak effect previously measured for the first-generation of 
conjugates, with a prolongation of the coagulation time only equal to a factor 1.5. Actu-
ally, a longer prolongation was expected since the Kis values measured for these conju-
gates were better than those of the first-generation counterparts. Most likely, once the 
conjugates are incubated in physiological conditions (e.g. human plasma with 600 ?M 
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albumin), binding to albumin and resulting steric hindrance are the main cause of activity 
reduction, independent of a free or hindered N-terminus. It was expected that the three 
conjugates would display a similar impact on aPTT prolongation in rabbit plasma be-
cause the Ki values were identical. However, one of them, the conjugate with the longest 
PEG linker, prolonged the coagulation time two-fold better than the others, though its 
impact was still half of the desired effect shown by the FXII inhibitor alone. The evidence 
that the conjugate with the longest PEG linker showed again the best result further sup-
ported the idea about the negative impact of albumin hindrance on peptide’s activity, and 
directed the choice towards the final format to test. 
 
Figure 82. Coagulation parameter aPTT for the second-generation of acetylated FXII inhibitor conjugates in 
different plasma. The activity of the conjugates was measured upon incubation at 37°C with (a) human or 
(b) rabbit plasma and pathromtin or actin, respectively; coagulation was triggered by CaCl2. 
3.3.3 Third generation: longer N-terminal linker 
Since the distance between the albumin-binding tag and the bicyclic peptide ap-
peared to be crucial for its inhibitory activity, the linker length was increased using very 
long PEG units. In addition, considering the homogeneity of the results exhibited by the 
C-terminal tagged FXII inhibitors and the complex synthesis they required, it was decided 
to work again on the N-terminus modified conjugate. Therefore, a single third-generation 
conjugate composed of a N-tagged bicyclic peptide with three units of a PEG24 linker 
(3xPEG24) between the (F)-tag and the FXII inhibitor was produced. In this case, only the 
fluorescein labeled conjugate was synthetized, prepared and characterized as described 
above for the first-generation of conjugates (Fig. 83c). In addition, the FXII inhibitor alone 
was synthesized and labeled at the N-terminus with fluorescein and was used as control 
in binding assays (Fig. 83a). 
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Figure 83. Characterization of the fluorescein labeled FXII inhibitor and (F)-tag-3xPEG24-FXII inhibitor. (a) 
Structure of the FXII inhibitor, (b) RP-HPLC chromatogram (central panel), and deconvoluted mass spectrum 
(right panel). (c) Structure of (F)-tag-3xPEG24-FXII inhibitor, (d) RP-HPLC chromatogram, (e) m/z, and (f) 
deconvoluted high resolution mass spectra. Amino acids shown as single letter code; F* and R* represent 
p-fluoro Phe and ?-homo Arg, respectively; X represents unnatural amino acid newly substituted; fluorescein, 
TATA, PEG2 and palmitic acid shown as structural formula. 
The (F)-tag-3xPEG24-FXII inhibitor showed a Kd of 224 ± 11 nM for human albumin 
in serum and a Kd of 1600 ± 300 nM for rabbit albumin, both five-fold weaker than the 
tag alone and consistent with the previous results obtained for the other conjugates (Fig. 
84). As already observed for the N-tagged first-generation conjugates, the major length 
of the linker resulted in a slightly negative impact on the binding affinity (e.g. for rabbit 
albumin: Kd of tag = 320 nM, Kd of tag-PEG2 conjugate = 650 nM, Kd of tag-5xPEG2 
conjugate = 1400 nM). The fluorescein labeled FXII inhibitor did not bind to albumin at 
all, as expected. 
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Figure 84. Binding of (F)-tag and (F)-tag-3xPEG24-FXII inhibitor with different albumins. Fluorescence po-
larization isotherms with (a) human serum and (b) rabbit albumin. (c) Dissociation constants. Amino acids 
shown as single letter code; F* and R* represent p-fluoro Phe and ?-homo Arg, respectively; X represents 
unnatural amino acid newly substituted; (F) is fluorescein; palm is palmiti???????? ????????????????????????
tag is PEG2. 
The inhibition assay was performed using the fluorescein labeled third-generation 
conjugate, instead of the acetylated format previously used. In fact, the fluorescein moi-
ety revealed to not interfere with the assay, probably due to the low concentrations of 
inhibitor tested. The conjugate showed the same single digit nanomolar inhibitory activity 
(Ki ?????????3 nM) with and without albumin in the assay, with a potency only six-fold 
weaker than the FXII inhibitor alone (Fig. 85). Compared to the two best conjugates, in 
presence of albumin this conjugate inhibited FXIIa two to four-fold better (second-gener-
ation, Ki = 5.8 ± 1.7 nM; first-generation, Ki = 13 ± 1 nM). This promising result clearly 
confirmed the negative impact of albumin hindrance, which thus could be strongly re-
duced with an even longer linker.  
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Figure 85. Inhibition of FXII inhibitor and (F)-tag-3xPEG24-FXII inhibitor against FXIIa. Graphs of enzymatic 
activity tested (a) without or (b) in presence of 10 ?M albumin. (c) Inhibition constants. Amino acids shown 
as single letter code; F* and R* represent p-fluoro Phe and ?-homo Arg, respectively; X represents unnatural 
amino acid newly substituted; palm is palmitic acid. 
Finally, the aPTT of the (F)-tag-3xPEG24-FXII inhibitor was assessed at three dif-
ferent concentrations (10, 5 and 2 ?M). The same concentrations were tested for the two 
most promising conjugates from the first- and second-generation (Fig. 86). The FXII in-
hibitor confirmed the excellent results obtained previously. At all of the concentrations 
tested, the bicyclic peptide alone prolonged the aPTT more than a factor two and eight 
for human and rabbit plasma, respectively (unpublished data). The third-generation con-
jugate did not give any improvements compared to the previous two formats when incu-
bated with human plasma, still not showing more than a factor 1.5 in the prologation of 
the coagulation time. In contrast, it did, however, showed a prolongation time equal to 
the unmodified FXII inhibitor when tested in rabbit plasma at the highest concentration. 
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Figure 86. Coagulation parameter aPTT for FXII inhibitor and the best FXII inhibitor conjugates in different 
plasma. The activity of the conjugates was measured upon incubation at 37°C with (a) human or (b) rabbit 
plasma and pathromtin or actin, respectively; coagulation was triggered by CaCl2.  
At the lower concentration of 5 ?M, (F)-tag-3xPEG24-FXII inhibitor was still able to 
prolong the coagulation time by more than six-fold, and its EC5x and EC2x (the concen-
trations needed to get five- and two-fold longer coagulation times) were calculated to be 
around 4 and 2 ?M in rabbit plasma, respectively. On the other hand, it was only possible 
to estimate an EC2x of around 4 ?M for the other conjugates (Fig. 87). By further analyzing 
the EC2x and the less used EC11.5x of the three conjugates and FXII inhibitor alone in 
both human and rabbit plasma, I noticed that on average the three conjugates had a 30 
to 50-fold weaker activity. Since the EC2x of the FXII inhibitor in human plasma is at 
around 1 ?M, the same relative aPTT value with the three conjugates could be obtained 
only using concentrations higher than 30 ?M.  
Despite an unsatisfactory prolongation of the coagulation in human plasma, the 
result obtained in rabbit plasma with the (F)-tag-3xPEG24-FXII inhibitor was extremely 
promising for the in vivo animal experiments that we had planned. According to the aPTT, 
concentrations up to 2 ?M of the (F)-tag-3xPEG24-FXII inhibitor can be detected and 
should allow a quantification of its in vivo activity over a prolonged period of time, as-
suming that the tag increases the half-life as it was previously observed in rats.  
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Figure 87. Coagulation parameters aPTT (extrapolated EC values) for FXII inhibitor and the best FXII inhib-
itor conjugates in plasma.  
Finally, the specificity of the (F)-tag-3xPEG24-FXII inhibitor towards its target was 
assessed against a panel of six structurally related or functionally important proteases 
(Fig. 88). Five proteases out of six were inhibited less than 30% at the highest inhibitor 
concentration tested (10 ?M). Only trypsin, which is a protease not present in the blood, 
was inhibited more than 50% with a Ki = 6 ± 1.8 ?M, 2,000-fold higher than the Ki for the 
specific target. The conjugate was almost three times less active than the FXII inhibitor 
alone over trypsin (unpublished data), showing also a reduction in its activity against 
unwanted targets. 
 
Figure 88. Specificity of the (F)-tag-3xPEG24-FXII inhibitor. Residual activities of FXIIa and a range of serine 
proteases measured at different concentrations of conjugate, using different fluorogenic substrates. 
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3.3.4 Pharmacokinetics and in vivo activity in rabbits 
Pharmacokinetic experiments were carried out in rabbits for the third-generation 
conjugate (F)-tag-3xPEG24-FXII inhibitor (Fig. 83c). The in vivo studies (injection and 
blood collection) were outsourced to the American company Washington Biotechnology, 
Inc. (Baltimore, MD, USA). Because pharmacokinetic studies of the FXII inhibitor were 
already performed in rabbits by the colleagues who developed it (unpublished data), a 
well-defined amount of peptide was prepared in order to get a similar concentration in 
the animals upon i.v. injection. Some issues were experienced during the synthesis of 
the conjugate, performed with new batches of Fmoc-PEG24-OH amino acid that were 
less pure and stable than the first batch. The presence of side products required multiple 
steps of purification, and a subsequent loss in yield. Initially, the purity was only assessed 
via LC-MS in order to discriminate between the desired conjugate and the impurities. 
The overall purity of the final compound as assessed in analytical HPLC was only around 
75-80%, with small peaks detected after the final compound (Fig. 89a). These peaks 
could be later characterized and showed the same mass of the desired product, sug-
gesting that a full cyclization of the bicyclic peptide probably did not occur as desired. 
There is no mass change upon cyclization with TATA, and thus the mass remains equal 
and could not be distinguished in LC-MS, which does not run as long of a gradient as 
the HPLC. Nevertheless, before sending the peptide for pharmacokinetic studies, pep-
tide’s activity and binding affinity for albumin were tested by aPTT and fluorescence po-
larization, respectively. Since all the samples gave the expected results (Fig. 89b-c), the 
conjugate was considered suitable for the aim of the in vivo study.  
The final amount of peptide produced was around 42 mg, which was divided 
equally into three samples, each of them dissolved in 3.5 ml of PBS, pH 7.4, 0.01% SDS. 
Rabbits were i.v. injected with 3 ml of a 570 ?M (F)-tag-3xPEG24-FXII inhibitor (5 mg?kg-
1 in PBS, pH 7.4, 0.01% SDS) solution, resulting in a final blood concentration of approx-
imately 14 ?M. Blood samples were collected at ten different time points and immediately 
processed to plasma using tubes treated with Na citrate to avoid the coagulation cas-
cade, since the main goal of the test was to see a prolonged in vivo effect of the conjugate 
on the intrinsic coagulation pathway.  
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Figure 89. Quality control of the up-scaled produced (F)-tag-3xPEG24-FXII inhibitor stock solutions for in 
vivo experiments. (a) RP-HPLC chromatogram, (b) fluorescence polarization isotherms and (c) coagulation 
parameter aPTT of the three batches sent for pharmacokinetic studies. The color code used for aPTT col-
umns and binding isotherms in the fluorescence polarization graph are the same. 
3.3.4.1 Plasma half-life in rabbits 
Applying the same protocol of protein precipitation previously described in sub-
section 3.2.6, plasma samples and calibration curves were prepared and run in HPLC 
with a fluorescence detector in order to detect the conjugate. For both samples and cal-
ibrations, only the AUCs of the main peak were integrated and used for peptide quantifi-
cation in plasma. Again, a fixed concentration of internal standard was added in each 
sample as a control to adjust the AUCs of the peptides. The zoomed chromatograms of 
the peptide tested in three different rabbits are here reported (Fig. 90) while full runs are 
shown in the supporting info (Fig. S5). 
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Figure 90. RP-HPLC chromatograms of the (F)-tag-3xPEG24-FXII inhibitor. Chromatograms of rabbit plasma 
samples collected at different time points. 
The (F)-tag-3xPEG24-FXII inhibitor showed the same peak pattern previously ob-
served in the HPLC. Their ratio and decrease over the time were similar to each other, 
confirming their behavior as fractions of the correct tagged bicyclic peptide. A completely 
new small peak appeared after one hour (retention time = 12 min, Fig. S5) and might be 
a degradation product of the not fully modified peptides. However, the low concentration 
did not allow its collection and characterization. The main peak of the conjugate was still 
detectable in plasma after 24 hours and only its AUCs were taken into account for pep-
tide quantification in plasma (Fig 91a). The initial concentration in plasma was calculated 
considering the relative purity of the sample (75%) and it was doubled to account for the 
observation that the peptide tagged to albumin will be located mainly in plasma (sub-
section 3.2.6). After five minutes, the concentration was exactly in the expected range 
(19 ?M), confirming that tagged bicyclic peptides remain in plasma. The concentrations 
were plotted versus time, analyzed with a two-compartment model (biexponential equa-
tion: Cp ?????-??? ?????-???) and pharmacokinetic parameters determined (Fig. 91d).257  
The (F)-tag-3xPEG24-FXII inhibitor had a half-life in the same range as the previ-
ously tested tagged bicyclic peptides in rats. The distribution half-life was around one 
hour, and the elimination half-life was 5.2 ± 0.4 hours. Compared to the half-life of the 
FXII inhibitor alone in rabbits (13 ± 2 min), previously determined by LC-MS detection 
(unpublished data), the tag prolonged its elimination time by around 24-fold in rabbits. 
The short half-life of the bicyclic peptide was consistent with the fast clearance measured 
for UK18 in rats (Fig. 72, sub-section 3.2.6).  
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Figure 91. Pharmacokinetic profiles in rabbits of the (F)-tag-3xPEG24-FXII inhibitor and FXII inhibitor. (a) 
Plasma concentrations plotted versus time upon i.v. injections in the three rabbits determined for the conju-
gate by RP-HPLC (black line) and LC-MS (green line) and for FXII inhibitor (red line). Linear regression 
calculation of the conjugate quantified by (b) RP-HPLC and (c) LC-MS.  (d) Pharmacokinetic parameters. 
???????????????????? ??????????????????????????????????2 
The other pharmacokinetic parameters AUC, CL and VD were calculated and gave 
the expected values (Fig. 91d). AUCs correlated with the half-lives and showed that the 
conjugate would be 200-fold more active than its non-tagged format in vivo. Similarly, 
the clearance of the FXII inhibitor was one liter per hour, while the tagged bicyclic peptide 
was cleared 100-fold more slowly. Finally, the volume of distribution, calculated consid-
ering for rabbits a weight of around 2-2.5 kilograms, gave a value for the (F)-tag-
Chapter 3 – Results and discussion 
140 
3xPEG24-FXII inhibitor consistent with its distribution mainly in the bloodstream (approx-
imately 120 ml), while the VD of the bicyclic peptide alone was much higher due to a rapid 
non-specific tissue distribution.  
Since the half-life of the FXII inhibitor alone was previously determined by LC-MS, 
one of the plasma series was analyzed using this detection strategy for direct compari-
son. The optimized protocol of plasma protein precipitation was applied for the prepara-
tion of calibration curves and peptide quantification by LC-MS, integrating only the AUC 
of the peak with the correct mass (Fig. 91a and 91c). A fixed concentration of the albu-
min-binding peptide SA21 was added as an internal standard. Even though the experi-
ment was performed once, the resulting pharmacokinetic parameters were in the same 
range previously calculated, and confirmed the quality and reliability of the measure-
ments performed with the fluorescence detector (Fig. 91d).  
3.3.4.2 Prolonged inhibition of the intrinsic coagulation pathway  
Thanks to the prolonged circulation time of the (F)-tag-3xPEG24-FXII inhibitor in 
rabbits, its ability to block the intrinsic coagulation pathway could be tested from in vivo 
samples. The different plasma samples were analyzed by aPTT, adding actin and CaCl2 
as previously described. A pre-dosing sample, collected from each rabbit just before in-
jecting the conjugate, was used as blank. The conjugate solutions in PBS were first 
checked by aPTT to test the stability and activity of the stocks sent for the pharmacoki-
netics (Fig. 92). Once their quality was verified, they were used as a control at a fixed 
concentration in parallel with each aPTT experiment performed using plasma samples. 
 
Figure 92. Coagulation parameter aPTT for the (F)-tag-3xPEG24-FXII inhibitor stock solutions returned after 
pharmacokinetic studies. The activity of the conjugate was measured upon incubation at 37°C with rabbit 
plasma and actin, respectively; coagulation was triggered by CaCl2. 
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The results from in vivo samples showed that the prolonged half-life of the (F)-tag-
3xPEG24-FXII inhibitor allowed an efficient blockage of the intrinsic coagulation for more 
than eight hours, the last time point at which a clear EC2x was still detectable, when this 
pathway was externally triggered (Fig. 93). I observed that, even if the conjugate con-
centrations measured by HPLC were similar among the three rabbits, samples from rab-
bit 2 showed a longer coagulation time in the first time points. In addition, the relative 
prolongation times were slightly lower than expected, even considering the three-fold 
dilution required to perform the assay. Taken together, these observations indicated an 
in vivo variability that is difficult to predict. However, the results clearly showed that, in 
case of thrombotic events in blood, the conjugate would be able to efficiently prevent the 
activation of the cascade for a prolonged period of time. Given the seven-fold higher 
affinity of the (F)-tag-3xPEG24-FXII inhibitor to human albumin and known allometric scal-
ing effects among different species, the weaker impact of the conjugate on aPTT meas-
ured in human plasma will be probably compensated by a much longer in vivo half-life in 
humans. Therefore, an expected half-life of more than one day should offer, at the ap-
propriate peptide’s plasma concentrations, a solid protection over the time that strongly 
reduces the risk of thrombosis triggered by pathological or external factors. 
 
Figure 93. Coagulation parameter aPTT for the (F)-tag-3xPEG24-FXII inhibitor in rabbits. The activity of the 
conjugate on plasma samples collected at different time points was measured upon incubation at 37°C with 
actin, respectively; coagulation was triggered by CaCl2. 
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Lipidation is an established strategy for extending the circulation time of peptides 
as showcased by the approved drugs insulin detemir, insulin degludec and liraglutide. In 
these peptide drugs, fatty acids such as myristic or palmitic acid are appended to an 
amino acid within the peptide sequence of the drug itself. Peptides bind via the fatty acid 
to serum albumin, thus delaying their blood clearance.123,227,228 It is expected that the 
half-life of these or other peptides can be further prolonged by embedding the fatty acid 
into a portable peptide sequence that enhances the binding to albumin. In fact, studies 
on acylated insulin analogues and albumin-binding peptides demonstrated that stronger 
affinities for albumin correlated with prolonged half-lives.218,219 
Herein, I conceived a chimeric tag based on a fatty acid coupled to a Lys residue 
within a short peptide sequence that can be appended directly to bioactive peptides dur-
ing their synthesis. I optimized the strategy to create this kind of conjugates on resin by 
automated SPPS, and succeeded in obtaining the desired products with high yield and 
purity by a single step of purification in a straightforward and economic manner. The 
solubility of these conjugates in aqueous solution correlated with the polarity of the acyl-
ated peptide sequence, showing that amino acid variations can strongly improve this 
important parameter. Initial albumin binding assays by fluorescence polarization identi-
fied a peptide sequence of seven residues modified with a palmitic acid as the best pep-
tide-fatty acid format. 
The affinity of this tag was improved by evolving the peptide sequence through six 
iterative rounds of amino acid substitution and binding assays for more than 150 variants. 
In addition to the palmitic acid, negatively charged or hydrophobic amino acids, flanking 
the central acylated Lys, were essential for increasing the affinity, resulting in a specific 
sequence of four Glu and two Tyr residues. The evolved tag exhibited a Kd of 39 nM for 
human albumin, improving the binding of the initial format by 27-fold. In addition, this tag 
was ten to more than 50-fold better than all the peptide- or fatty acid-based albumin 
binders developed so far.71,208,227,228 The fluorescein moiety, initially added to the N-ter-
minus of the tag to perform fluorescence polarization assays, revealed to be actually 
essential for the binding affinity. Another technique named isothermal titration calorime-
try confirmed the result obtained by fluorescence polarization. In addition, the tag was 
able to bind rat and rabbit albumin with Kd values of 220 and 320 nM, respectively. This 
result proved that rats and rabbits could be valid animal models for in vivo pharmacoki-
netic studies of peptides conjugated to our albumin-binding tag.  
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The following step was the application of the evolved tag to two bioactive bicyclic 
peptides, UK18 and PK128, previously developed in our laboratory.69,70 The tag was ap-
pended at either one of the two ends and the biochemical properties of the conjugates 
were characterized. The tag, when coupled to the N-terminus of the bicyclic peptides, 
kept the desired nanomolar affinity for human albumin. In contrast, tag conjugation had 
a different positioning- and peptide-dependent impact on the activity of the bicyclic pep-
tides. For example, the N-terminal tagged UK18 retained its inhibitory activity, while the 
same conjugate format affected the potency of PK128. In addition, tag conjugation im-
proved the proteolytic stability of bicyclic peptides, since they were intact and still func-
tional upon prolonged incubation in plasma, in contrast to the non-tagged counterparts. 
Finally, the presence of four negatively charged amino acids in the tag sequence deter-
??????????????????????????????????????????????? ?? ?-1, despite the long hydrophobic tail 
of palmitic acid. Pharmacokinetic studies in rats of the UK18 conjugate revealed that the 
tag could prolong the circulation time of the bicyclic peptide 25-fold upon i.v. injection. 
This conjugate had a half-life of over seven hours, longer than the approved drugs lirag-
lutide and insulin deglutec in rats.253,258,259 In this sense, it might be conceivable to re-
place the albumin binding moieties used in those drugs with the tag here described. 
All of these observations offered a valuable starting point for the half-life extension 
of the most advanced bicyclic peptide developed in our laboratory so far, a highly specific 
antagonist of the activated coagulation factor XII.81,90,91 The testing of different synthetic 
structures of conjugates led to an optimized format that conserved both inhibitory activity 
against FXIIa and high affinity for albumin. In vivo experiments showed a 24-fold pro-
longed half-life in rabbits upon i.v. injection that translated into an efficient blockage of 
the intrinsic coagulation pathway for up to eight hours.  
In conclusion, I developed a chimeric tag that combines the excellent albumin bind-
ing properties of fatty acids and the effective rational evolution of peptide affinity. This 
tag binds human albumin with low-medium nanomolar Kd, while it shows approximately 
six to nine-fold weaker affinity for rat and rabbit albumin. Tag conjugation to three bioac-
tive peptides improves their pharmacokinetic profiles in these animal models. Consider-
ing the different affinity for human albumin as well as the allometric scaling, it is likely 
that peptide drugs modified with this tag can achieve half-lives of more than one day in 
humans. If such conjugates are administrated as a depot, an even longer exposure may 
be reached.  
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Thus, I hope that the tag presented in this work will be of interest for a large re-
search and business audience in academic and industry labs because it is easily appli-
cable to virtually any peptide moiety, including small proteins. This technology could be 
also useful for pharmaceutical industry, since with this tag it should be possible to expand 
the application range of peptide therapeutics from the current mostly short-lived agents 
that act mainly as receptor agonists to long-acting peptide drugs that can also address 
targets that require actions over extended time periods, such as the inhibition of enzymes 
or receptors. 
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Material 
Abbreviation or 
product code Name Supplier 
- Fmoc and boc-protected amino acids 
GL Biochem 
(Shanghai, China) 
- Fmoc-rink amide AM resin 
- N-Fmoc-propargylglycine 
HBTU O-benzotriazole-?????????-tetramethyl-uronium-hex-afluoro-phosphate 
HOBt 1-hydroxybenzotriazole 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate 
DCC N,N-dicyclohexylcarbodiimide 
Sigma-Aldrich 
(Steinheim, Germany) 
5(6)-FAM 5(6)-carboxyfluorescein 
TBMB 1,3,5-tris(bromomethyl)benzene 
TATA 1,3,5-triacryloyl-1,3,5-triazinane 
TFA trifluoroacetic acid reagent plus 99% 
NaASC Sodium ascorbate 
TBTA tris((1-benzyl-1H-1,2,3-triazol-4-yl)methyl) amine 
CuSO4 Copper(II) sulfate 
- Phenol 
- Ethanol 
HCOOH Formic acid 
DMSO Dimethylsulfoxide 
DCM Dichlorometane 
A1653 - A4327 Human albumin 
A6272 Rat albumin 
A0639 Rabbit albumin 
H4522 Human serum 
C7078 Casein from bovine milk 
PEG24 Fmoc-NH-[PEG]24-CH2CH2COOH 
PurePEG 
(San Diego, CA, USA) 
PEG2 Fmoc-NH-[PEG]2-CH2COOH 
Iris Biotech GmbH 
(Marktredwitz, Germany) Lys(Dde) N-alpha-(1-(4, 4-dimethyl-2,6-dioxocyclohex-1-yli-dene)ethyl)-N-epsilon-(9-Fmoc)-L-lysine 
NH2-NH2 Hydrazine hydrate (hydrazine 64%) 
Acros Organics 
(Geel, Belgium) 
- Diethyl ether 
- Piperidine 
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Myr (C14) Myristic acid 
TCI 
(Zwijndrecht, Belgium) 
Palm (C16) Palmitic acid 
Ste (C18) Stearic acid 
??????? Guanidinium hydrochloride 
EDT 1,2-ethanedithiol 
NH4HCO3 Ammonium bicarbonate 
Applichem 
(Darmstadt, Germany) 
Na2HPO4 Disodium phosphate 
KH2PO4 Potassium dihydrogen phosphate 
Tween-20 Polysorbate 20 
SDS Sodium dodecyl sulfate 
Tris Tris(hydroxymethyl)aminomethane 
DIPEA N,N-diisopropylethylamine 
Roth 
(Karlsruhe, Germany) 
DMF Dimethylformamide 
NaCl Sodium chloride 
KCl Potassium chloride 
MgCl2 Magnesium chloride 
CaCl2 Calcium chloride 
MeCN Acetonitrile Fisher Scientific 
(Loughborogh, UK) TFA Trifluoroacetic HPLC grade 
- Thioanisole 
Alfa Aesar 
(Karlsruhe, Germany) 
- Acetic anhydride (Ac2O) 
Merck 
(Honenbrunn, Germany) 
5(6)-FAM azide 5(6)-carboxyfluorescein azide 
Tenova Pharmaceuticals 
(San Diego, CA, USA) 
- 
Fluorogenic substrates: 
Z-Gly-Gly-Arg-AMC, Z-Phe-Arg-AMC, 
Boc-Gln-Gly-Arg-AMC, H-D-Val-Leu-Lys-AMC 
Bachem 
(Bubendorf, Switzerland) 
- Enzymes: PK, FXIIa, FXIa, trypsin, thrombin, plasmin Molecular Innovations 
Innovative Research 
(Novi, MI, USA) - Human, rat and rabbit plasma 
Pathromtin* SL Silicon dioxide particles, plant phospholipids in HEPES buffer system 
Siemens 
(Erlangen, Germany) Dade/Actin 
Cephalin, extract from dehydrated rabbit brain contai-
ning 0.1 mM ellagic acid 
CaCl2 solution Calcium chloride solution 
All reagents were used as received without further purification. 
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Peptide synthesis 
???????????????????????????????????????????????????????????????????????????????
sizer (AAPPTec) by standard Fmoc solid-phase chemistry on Rink Amide resin (0.26 
mmol/g resin, 0.03 mmol scale), using DMF (99.5% pure) as a solvent. The coupling was 
carried out twice for each natural amino acid (4 equiv.) using HBTU (4 equiv.), HOBt (4 
equiv.) and DIPEA (6 equiv.). The coupling of unnatural amino acids (2 equiv.) was per-
formed once using HATU (2 equiv.) and DIPEA (4 equiv.). Fmoc groups were removed 
using a 20% v/v solution of piperidine in DMF. Washing steps were performed with DMF.  
Fluorescein and acetyl modifications at the N-terminus 
Peptides were modified with 5(6)-FAM (2 equiv.), DCC (2 equiv.) and HOBt (4 equiv.) in 
3 ml DMF and shaken for 1 hr at 400 rpm for N-terminal fluorescein labeling. Peptides 
were modified with Ac2O (6 equiv.) and DIPEA (6 equiv.) in 3 ml DCM and shaken for 1 
hr at 400 rpm for N-terminal acetylation. 
Peptide acylation with fatty acids 
Lys(Dde) was selectively deprotected by incubating the resin 3 times with 2% hydrazine 
hydrate in DMF for 3 min at 400 rpm, which also cleaved the Fmoc groups. The N-termi-
nus was protected by Boc in unlabeled peptides not modified with fluorescein or acetyl. 
Peptides were acylated at the Lys side chain by the addition of free fatty acid (2 equiv.), 
DCC (2 equiv.) and HOBt (4 equiv.) in 3 ml DMF and shaken for 2 hrs at 400 rpm.  
Peptide cleavage and deprotection 
Final peptides were deprotected and cleaved from the resin under reducing conditions 
(90% TFA, 2.5% H2O, 2.5% thioanisole, 2.5% phenol, 2.5% EDT) for 4 hrs with shaking 
at room temperature. The resin was removed by vacuum filtration, and the peptides were 
precipitated with cold diethyl ether (50 ml) and incubation for 30 min at -20°C, and pel-
leted by centrifugation. The precipitated peptides were washed twice with cold diethyl 
ether (30 and 20 ml, respectively). Peptides were either lyophilized or directly purified. 
Chemical cyclization 
Crude peptide (9 ml, 1.2 mM) was dissolved in 40% v/v MeCN and 60% v/v aqueous 
reaction buffer (60 mM NH4HCO3, pH 8.0) and cyclization linker TBMB or TATA was 
added (1 ml, 15 mM in MeCN). The final reagent and solvent concentrations in the reac-
tion mixture were 1 mM peptide, 1.5 mM cyclization linker, 50% v/v aqueous reaction 
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buffer, and 50% v/v MeCN. The reaction mixture was incubated at 30°C in a water bath 
for 1 hr and then lyophilized.  
Fluorescein modification at the C-terminus 
Peptides were modified on a propargylglycine residue by click chemistry for C-terminal 
fluorescein labeling. Alkylated peptide (10mM), 5(6)-FAM azide (12 mM) and TBTA (20 
mM) in DMSO were mixed with a catalytic mixture composed by CuSO4 (20 mM) and 
NaASC (100 mM) in H2O, and the volume adjusted with DMSO. The final reagent and 
solvent concentrations in the reaction mixture were 1 mM peptide, 1.2 mM 5(6)-FAM 
azide, 2 mM TBTA, 2 mM CuSO4, 10 mM NaASC, 30% v/v H2O and 70% v/v DMSO. 
The reaction proceeded at room temperature overnight.  
Peptide purification 
Short peptides acylated with fatty acid were purified by semi-preparative reversed-phase 
HPLC (PrepLC 4000-Waters system, Vydac C18 TP1022, 250 × 22 mm, 10 ?m) using a 
???????????????? ?? ??-1 and a linear gradient of 50-90% v/v solvent B in 15 min. Cyclized 
peptides acylated with fatty acid were purified by semi-preparative reversed-phase 
HPLC (PrepLC 4000-Waters system, Vydac C18 TP1022, 250 × 22 mm, 10 ?m) using a 
???????????????? ?????-1 and a linear gradient of 30-80% v/v solvent B in 30 min. Peptides 
modified by click chemistry were purified by semipreparative reversed-phase HPLC 
(PrepLC 4000-Waters system, XBridge BEH300 Prep C18 column, 9.4 mm × 250 mm, 
10 ???? ?????????????????????????????? ?? ??-1 and a linear gradient of 30-80% v/v solvent 
B in 30 min. Fractions containing the desired peptide were lyophilized.  
Solvents: A, 99.9% v/v H2O and 0.1% v/v TFA; B, 99.9% v/v MeCN and 0.1% v/v TFA. 
HPLC and mass spectrometric analysis 
The mass of purified peptides was determined by electrospray ionization mass spec-
trometry (ESI-MS) in positive ion mode on a single quadrupole liquid chromatograph 
mass spectrometer (LCMS-2020, Shimadzu). The purity was assessed by RP-HPLC 
(Agilent 1260 HPLC system) using a C18 column (Agilent ZORBAX 300SB-C18, 4.6 mm 
× 250 mm, 5 ?m). Peptides used in the solubility assay were run with a flow rate of 1 
??????-1 in a linear gradient 0-50% v/v solvent B over 15 min, while all the other peptides 
were run with a linear gradient of 0-100% v/v solvent B over 15 min (A: 94.9% v/v H2O, 
5% v/v MeCN and 0.1% v/v TFA; B: 94.9% v/v MeCN, 5% v/v H2O and 0.1% v/v TFA). 
 
Chapter 5 – Material and methods 
155 
Fluorescence polarization albumin binding assay 
Human albumin (A1653), rat albumin (A6272), rabbit albumin (A0639), and human se-
rum (H4522) were serially diluted (2-fold) in phosphate buffer saline (PBS; 10 mM 
Na2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl,), pH 7.4, 0.01% v/v Tween-20. 
The highest concentrations were 28 ?M for human albumin, 26 ?M for rat albumin, 29 
?M for rabbit albumin and 25 ?M for human albumin from serum (assuming a concentra-
tion of albumin equal to 600 ?M in serum). 45 ?l of the dilutions were added to 15 ?l of 
fluorescent peptide (100 nM) in black 96-well half area microtiter plates. The concentra-
tions of albumin in the assay plate were ranging from 21 ?M (human albumin), 19.5 ?M 
(rat albumin), 21.75 ?M (rabbit albumin) and 18.75 ?M (human albumin in serum) to 
around 40 nM. The final concentration of fluorescent peptide was 25 nM in all wells. 
Fluorescence anisotropy was measured with an Infinite M200Pro plate reader (Tecan) 
using an excitation filter at 485 nm and an emission filter at 535 nm. Dissociation constant 
of fluorescent peptide (Kd) was determined by nonlinear regression analysis of anisot-
ropy versus the total concentration of proteins [P]T using the following equation71 : 
 
A is the experimental fluorescence anisotropy. Af and Ab are the fluorescence anisotropy 
for free and the fully bound fluorescent peptide, respectively. [L]T and [P]T represent total 
fluorescent peptide and albumin concentration, respectively. Values were calculated with 
Prism 5 (GraphPad software). 
Isothermal titration calorimetry 
Fluorescent tag (500 ?M) and human albumin (50 ?M, A1653) were prepared in PBS, 
pH 7.4, 0.01% v/v Tween-20. Titrations of fluorescein tag in the syringe (40 ?l) into hu-
man albumin in the cell (300 ?l) were carried at 25°C out with a MicroCal™ iTC200 (Mi-
croCal/GE Healthcare). 20 or 40 injections of a 2 or 1 ?l volume, respectively, were per-
formed, lasting 2 sec and spaced 180 sec. The value associated with the first peak was 
excluded. The background heat of injection, determined by injecting both fluorescent tag 
into buffer and buffer into human albumin, was measured and subtracted from the heat 
of binding. Data were analyzed using Origin for ITC software, and fitted with a two-sites 
binding model. The Gibbs free energy change was calculated using equations ?G = 
R??????Kd) = ?H-??????????????????????????-1?mol-1 and T = 298.15 K. 
? = ?? + (?? ? ??) ?  ?
?([?]? +?? + [?]?)? ?([?]? +?? + [?]?)? ? ?[?]? ? [?]??
?[?]?
? 
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Competitive fluorescence polarization albumin binding assay 
Human albumin and fluorescent tag were diluted to 300 nM and 75 nM, respectively, in 
PBS, pH 7.4, 0.01% v/v Tween-20. Acetylated tag was serially diluted (2-fold) in PBS, 
pH 7.4, 0.01% v/v Tween-20 starting from a concentration of 450 ?M. 20 ?l of each dilu-
tion was added into black 96-well half area microtiter plates. The concentrations in the 
assay plate were 100 nM for human albumin and 25 nM for fluorescent tag in all wells, 
and ranging from 150 ?M to 44 nM for acetylated tag. Fluorescence anisotropy was 
measured with an Infinite M200Pro plate reader (Tecan) using an excitation filter at 485 
nm and an emission filter at 535 nm after 15 min incubation. IC50 value was calculated 
with GraphPad Prism5 software using the log(inhibitor) vs. response variable slope 
model. Dissociation constant of acetylated tag (KdC) was determined applying the follow-
ing equation251: 
 
where: 
 
and 
 
IC50 represents concentration of unlabeled tag needed to displace 50% of fluorescent 
???????????????????????50 represents multiplied value of fluorescent tag and albumin con-
centration at IC50. A50 is the experimental fluorescence anisotropy at IC50. Af and Ab are 
the fluorescence anisotropy for free and the fully bound fluorescent tag, respectively. Kd 
is the dissociation constant for the binding equilibrium of fluorescent tag. [L]T and [P]T 
represent total fluorescent tag and albumin concentration, respectively.  
Solubility assay 
The molar extinction coefficients of unlabeled UK18 and PK15 conjugates were deter-
mined at 205, 210 and 220 nm by measuring the absorption on a GeneQuant 1300 UV-
Vis spectrophotometer (GE Healthcare) of serial dilutions in water starting from an initial 
concentration of one ??? ?-1. The solubility was measured by dissolving peptides in PBS, 
pH 7.4 at a theoretical concentration of ten ??? ?-1. A maximal amount of peptide was 
??? =
(? ? ?)?? ? ??? ? ??
([?]? ? [?]?) + (? ? ?)?? ? ([?]? ? [?]? + (? ? ?)?? ? ??)
 
??? = ???? ?
[?]?
?  
(? ? ?)?? = [?]? ?
??? ? ??
?? ? ??
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dissolved by inverting the tube at room temperature for 45 min. Non-dissolved peptide 
was removed by centrifugation for 30 min at 13,000 g and transfer of the supernatant to 
a new tube. This process was repeated once. The solubility of unlabeled UK18 and PK15 
conjugates was determined by measuring the absorption at 205, 210 and 220 nm with a 
Cary 50 UV-Vis spectrophotometer (Varian) upon serial dilutions in PBS. The solubility 
of fluorescent UK18 and PK128 conjugates was determined by measuring the absorption 
at 495 nm and using a molar extinction coefficient of 68,000 M-1cm-1 with a NanoDrop 
8000 UV-Vis spectrophotometer (Thermo Scientific) upon serial dilutions in PBS. 
Protease inhibition assays 
Ki values of UK18 and acetylated/unlabeled conjugates were determined by measuring 
residual activity of recombinant human urokinase70 (1.5 nM) in the presence of different 
dilutions of inhibitor (2-fold dilutions, ranging from 1 ?M to 0.97 nM final concentration) 
using the fluorogenic substrate Z-Gly-Gly-Arg-AMC (50 ?M final concentration). Ki values 
of PK128 and acetylated/unlabeled conjugates were determined by measuring residual 
activity of human plasma kallikrein (0.25 nM) in presence of different dilutions of inhibitor 
(2-fold dilutions, ranging from 250 nM to 0.24 nM final concentration) using the fluoro-
genic substrate Z-Phe-Arg-AMC (50 ?M final concentration). The enzymatic assays were 
performed at 25°C in a volume of 150 ?l of assay buffer (10 mM Tris-Cl, pH 7.4, 150 mM 
NaCl, 10 mM MgCl2, 1 mM CaCl2, 0.01% v/v Tween-20, 0.1% (w/v) casein (bovine milk; 
C7078)) containing 5% v/v DMSO. Activity in presence of human albumin (99% pure, 
fatty acid free; A4327) was measured at an albumin concentration of 25 ?M. 
Ki values of FXII inhibitor, acetylated tagged FXII inhibitors and fluorescent tag-3xPEG24-
FXII inhibitor were determined by measuring residual activity of human FXIIa (0.4 nM) in 
the presence of different dilutions of inhibitor (2-fold dilutions, ranging from 31.25 nM to 
0.31 nM final concentration) using the fluorogenic substrate Boc-Gln-Gly-Arg-AMC (50 
?M final concentration). The enzymatic assay was performed at 25°C in a volume of 150 
?l of assay buffer containing 1% v/v DMSO. Activity in presence of human albumin (99% 
pure, fatty acid free; A4327) was measured at an albumin concentration of 10 ?M. In-
creased concentrations of acetylated tagged FXII inhibitors (2-fold dilutions, ranging from 
1 ?M to 0.97 nM final concentration; except for FXII inhibitor and (F)-tag-3xPEG24-FXII 
inhibitor, with final concentrations kept unchanged) and of FXIIa (3 nM) were used as 
fluorogenic substrate hydrolysis by albumin preparations interfered with the assay.  
Fluorescence intensity was measured for 30 min or 1 hr using an Infinite M200Pro plate 
reader (Tecan; AMC-substrates: excitation at 368 nm, emission at 467 nm) with a read 
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every minute. Sigmoidal curves were fitted to the data using the following log(inhibitor) 
vs. response variable slope model equation: 
 
wherein x is the peptide concentration, y is the residual percentage of protease activity, 
p is the Hill slope. IC50 values were derived from the fitted curve Prism 5 (GraphPad 
software). The Ki values were calculated based on the IC50 values applying the Cheng-
Prusoff equation: Ki = IC50/(1+(S/Km) wherein IC50 is the functional strength of the inhibi-
tor, S is the total substrate concentration and Km is the Michaelis-Menten constant for 
substrate hydrolysis catalyzed by the enzyme. The following Km values were used for the 
calculation: 112 ?M for urokinase / Z-Gly-Gly-Arg-AMC 70, 165 ?M for plasma kallikrein / 
Z-Phe-Arg-AMC 69, 256 ?M for FXIIa / Boc-Gln-Gly-Arg-AMC 90. 
The specificity of fluorescent tag-3xPEG24-FXII inhibitor (2-fold dilutions, ranging from 10 
?M to 9.7 nM final concentration) was assessed by measuring the inhibition of the fol-
lowing human serine proteases: urokinase 1.5 nM, factor XIa 0.25 nM, plasma kallikrein 
0.25 nM, thrombin 1 nM, plasmin 2.5 nM, trypsin 0.1 nM. The following fluorogenic sub-
strates were used at 50 ?M final concentration: Z-Phe-Arg-AMC for plasma kallikrein, 
Boc-Phe-Ser-Arg-AMC for factor XIa, Z-Gly-Gly-Arg-AMC for urokinase, thrombin and 
trypsin, and H-D-Val-Leu-Lys-AMC for plasmin.  
Plasma stability assay 
20 ?M of UK18, PK128, and relative acetylated conjugates was incubated in human 
plasma at 37°C in a water bath. Probes were taken at different time points (5 min, 0.5, 
1, 2, 4, 8, 24 and 48 hrs), diluted to 3 ?M (urokinase inhibitors) or 0.75 ?M (plasma 
kallikrein inhibitors) with assay buffer, heat inactivated by incubation at 65°C for 20 min, 
centrifuged at 16,000 g for 5 min and the supernatant transferred to a new tube. The 
inhibitory activity of each sample was assessed by preparing a series of 2-fold dilutions 
and measuring residual protease activity for urokinase and plasma kallikrein as de-
scribed above. Residual inhibition in % was calculated using the equation 
IC50,0h/IC50,xh*100 wherein IC50,0h is the functional strength of the inhibitor at time point 0 
and IC50,xh the functional strength of inhibitor after one of the different plasma incubation 
periods mentioned above. The resulting percentages of inhibition were plotted in Prism 
5 software (GraphPad software) versus time and analyzed using a one-phase decay 
model. 
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Pharmacokinetic study in rats 
??????? ??????? ??????????? ????????????? ???????? ????-1 fluorescent UK18 and PK128 
???????????????? ????-1 ?????????????????????????? ????-1 fluorescent tag, in 200 ?l PBS, 
pH 7.4, 0.01% SDS (130 ?M) via the tail vein (3 animals per group). Blood samples (100 
?l) were collected at different time points via the orbital sinus into tubes containing EDTA, 
??????????????????????????????????????????????????????????????????????????????????????
Peptide injection and blood sample collection was performed by Washington Biotech Inc. 
following ethical standards for animal studies of the Office for Laboratory Animal Welfare 
(OLAW), a division of the U.S. Public Health Service as administered by the National 
Institutes for Health. Samples were analyzed by RP-HPLC (Agilent 1260 HPLC system) 
equipped with a fluorescence detector (Shimadzu RF-10AXL detector, excitation at 445 
nm, emission at 535 nm) using a C18 column (Agilent ZORBAX 300SB-C18, 4.6 mm x 
250 mm, 5 ?m) and a linear gradient ???????????????????????????????? ??????????????????
of 1 ml min-1 (solvent A: 94.9% v/v H2O, 5% v/v MeCN and 0.1% v/v TFA; solvent B: 
94.9% v/v MeCN, 5% v/v H2O and 0.1% v/v TFA). Plasma samples were processed 
before RP-HPLC analysis as follows. 2 ?M fluorescein was added as standard to 5 ?l 
plasma sample. 5 ?l of 7 M guanidinium hydrochloride solution, pH 2.0 (adjusted with 
HCl) was added, mixed and incubated for 10 min at room temperature to denature pro-
teins. 200 ?l of cold ethanol was added and incubated on ice for 1 hr to precipitate pro-
teins. Samples were centrifuged at 9,000 g for 15 min at 4°C and the supernatant dried 
by centrifugal evaporation under vacuum. Dried samples were dissolved by stepwise 
addition of 10 ?l DMSO and 90 ?l solvent A (99.9% v/v H2O, 0.1% v/v TFA). 95 ?l were 
analyzed by RP-HPLC. Peptides were quantified by integrating the area under the peaks, 
and normalization was based on the standard and comparison to standard curves. 
Standard curves were obtained by analyzing known peptide quantities that were dis-
solved in plasma and processed as well as analyzed using the same procedure. Phar-
macokinetic parameters were calculated using a two-compartment model.257 Time 
points: 5 min, 0.5, 1, 2, 4, 8, 24 and 48 hrs for fluorescent tag, fluorescent UK18 and 
PK128 conjugates; 4, 8, 15 min, 0.5, 1, 2, 4 and 8 hrs for fluorescent UK18. 
Coagulation assays 
aPTT (activated Partial Thromboplastin Time) was measured on a STart4 coagulation 
analyzer (Diagnostica Stago). PK128, FXII inhibitor and relative acetylated or fluorescent 
conjugates were mixed with human and rabbit plasma at known concentrations. 100 ?l 
of human plasma was incubated at 37°C with 100 ?l of Pathromtin* SL for 2 min. 100 ?l 
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of rabbit plasma with was incubated at 37°C with 100 ?l of Dade/Actin for 3 min. Coagu-
lation was triggered by addition of 100 ?l of CaCl2 solution (25 mM). The time to coagu-
lation was assessed by monitoring the movement of a steel ball in the plasma. 
Pharmacokinetic study in rabbits 
??????????????????? ?????????????????????????????????????????-1 FXII inhibitor in 1 ml 
??????????????? ???????? ????-1 fluorescent tag-3xPEG24-FXII inhibitor in 3 ml PBS, pH 
7.4, 0.01% SDS (570 ?M) via the ear vein (3 animals per group). Blood samples (1.8 ml) 
were collected at different time points via the auricular artery of the opposite ear into 
tubes containing Na citrate, processed to plasma by centrifugation at 360 g for 15 min at 
??????????????????????????????????????????????????????????????????????????????????????
by Washington Biotech Inc. following ethical standards for animal studies of the Office 
for Laboratory Animal Welfare (OLAW), a division of the U.S. Public Health Service as 
administered by the National Institutes for Health. Plasma samples were treated as the 
rat plasma samples described above. Samples from rabbits treated with fluorescent tag-
3xPEG24-FXII were analyzed by RP-HPLC using fluorescence detection and quantified 
as in the rat experiment described above. Samples from rabbits treated with FXII inhibitor 
were analyzed on a single quadrupole liquid chromatography mass spectrometer 
(LC/MS-2020, Shimadzu), using a C18 column (Phenomenex Kinetex® 2.6 μm C18 100 
????????????????????????????????????????????????????????????????????????????????????
flow ?????????? ?? ??-1 (solvent A: 94.95% v/v H2O, 5% v/v MeCN and 0.05% v/v HCOOH; 
solvent B: 94.95% v/v MeCN, 5% v/v H2O and 0.05% v/v HCOOH) and ESI detection in 
positive mode. FXII inhibitor analyzed by LC-MS was quantified based on the absolute 
intensities of the detected mass peaks (M3+ and M4+) and adjusted according to the in-
tensity of the mass peaks of the internal standard (fixed concentration of a peptide se-
quence similar to FXII inhibitor). Peptide concentrations in the plasma samples were 
calculated according to linear external standard curves obtained from dilution series of 
the peptide prepared in rabbit plasma. Pharmacokinetic parameters were calculated us-
ing a two-compartment model.257 Time points: 5 min, 0.5, 1, 2, 4, 8, 24 and 48 hrs for 
fluorescent tag-3xPEG24-FXII inhibitor; 2, 5, 10, 20 and 40 for FXII inhibitor. aPTT of 
plasma samples collected from rabbits treated with fluorescent tag-3xPEG24-FXII conju-
gate were determined as described above. Pre-dose samples were used as blank. 
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Figure S1. Pharmacokinetic study of fluorescein labeled tag-UK18 in rats. Fluorescent peptide species in 
blood samples taken from three rats at the indicated time points were analyzed by RP-HPLC and fluores-
cence detection. The blood samples were spiked with a fluorescent standard. 
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Figure S2. Pharmacokinetic study of fluorescein labeled tag-PK128 in rats. Fluorescent peptide species in 
blood samples taken from three rats at the indicated time points were analyzed by RP-HPLC and fluores-
cence detection. The blood samples were spiked with a fluorescent standard. 
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Figure S3. Pharmacokinetic study of fluorescein labeled tag in rats. Fluorescent peptide species in blood 
samples taken from three rats at the indicated time points were analyzed by RP-HPLC and fluorescence 
detection. The blood samples were spiked with a fluorescent standard. 
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Figure S4. Pharmacokinetic study of fluorescein labeled bicyclic peptide UK18 in rats. Fluorescent peptide 
species in blood samples taken from three rats at the indicated time points were analyzed by RP-HPLC and 
fluorescence detection. The blood samples were spiked with a fluorescent standard. 
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Figure S5. Pharmacokinetic study of fluorescein labeled tag-3xPEG24-FXII inhibitor in rabbits. Fluorescent 
peptide species in blood samples taken from three rats at the indicated time points were analyzed by RP-
HPLC and fluorescence detection. The blood samples were spiked with a fluorescent standard. 
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Table S1. Pharmacokinetic parameters. 
Values ?????????????????????????????????????????????????-??t ?????-??t plotted as plasma concentration (y-
axis, log scale) vs. time (x-axys). 
Name Description Symbol  Unit Equation 
dose amount of drug administered X0 ?????-1 known parameter 
plasma 
concentration 
initial concentration after i.v. 
injection at time zero Cp(0) 
?????-1 
A + B 
coefficients of 
biexponential 
equation 
distribution phase A 
y-intercept of the deter-
mined distribution line Cp 
- Cp’ 
elimination phase B  
y-intercept of the back 
extrapolate elimination 
line Cp’ 
exponents of 
biexponential 
equation 
(first-order rate 
constants) 
distribution phase ??
min-1 or hrs-1 
slope of the distribution 
line (determine from line 
Cp - Cp’) 
elimination phase ?? slope of the elimination line 
first-order mi-
cro rate con-
stants 
transfer rate constant from 
the peripheral to the central 
compartment 
K21 
(A ? ? +  B ? ?)
(A +  B)  
elimination rate constant from 
the central compartment K10 
(? ? ?)
???
 
transfer rate constant from 
the central to the peripheral 
compartment 
K12 (? + ?)?  (K?? + ???) 
distribution 
half-life time required for the concen-
tration of a drug to reach half 
of its starting value 
?1/2 ? 
min or hrs 
ln(2)
?  
elimination 
half-life ?1/2 ?   
ln(2)
?  
area under the 
curve 
integral of the plasma drug 
concentration vs time curve 
(bioavailability in plasma) 
AUC ??????? ?-1 
?
? +
?
? 
systemic 
clearance 
volume of plasma purified 
from a drug per unit of time CL ????rs
-1?kg 
??
???  ?? ?? ? ? 
volume of the 
central com-
partment  
volume in which a drug dis-
tributes after i.v. injection at 
time zero 
VC  
?????-1 
??
(A +  B) 
volume of dis-
tribution in the 
?-phase 
volume in which a drug dis-
tributes during the elimination 
phase 
VD 
??
?  ?? 
??
??? ? ?  
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